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This thesis entitled ‘Early prediction of preeclampsia’ has been composed by me, 
Ranjit Akolekar, and the work in this thesis is my own. This research project was 
composed by me with advice from my supervisors, Dr Sarah Stock, Professor Andrew 
Calder and Professor Kypros Nicolaides.  I liaised with the National Ethics Committee 
to ensure the project was ethically approved and worked closely with the Research and 
Development Department to keep study documents and site-file up to date with 
relevant paperwork and substantial amendments whenever necessary. I liaised with the 
Human Tissue Authority to ensure that storage of serum and plasma samples was 
according to their recommendations and guidelines. I was responsible for ensuring that 
research samples were stored appropriately in -80°C freezers and for maintaining a 
database for stored research samples throughout the study period. I contributed to the 
process of obtaining pregnancy outcomes and ensured that the outcome measures were 
accurately coded in the research database by reviewing obstetric records of women 
reported as having hypertensive disorders of pregnancy. I carried out the statistical 
analysis for the studies in this thesis, conducted literature searches for reviews of 
published studies and wrote and composed this thesis. This work has not been 














Preeclampsia (PE) is a major cause of perinatal and maternal morbidity and mortality. 
In the United Kingdom, the National Institute for Clinical Excellence (NICE) has 
issued guidelines on routine antenatal care recommending that at the booking visit a 
woman’s level of risk for PE should be determined and the subsequent intensity of 
antenatal care should be based on this risk assessment. This method relies on a risk 
scoring system derived from maternal characteristics and medical history; the 
performance of screening by this method is poor with detection of less than 50% of 
cases of preterm-PE and term-PE.  
 
The objective of this thesis is to develop a method for the estimation of the patient-
specific risk for PE by combining the a priori risk based on maternal characteristics 
and medical history with the results of biophysical and biochemical markers obtained 
at 11-13 weeks’ gestation. Such early identification of high-risk pregnancies could 
lead to the use of pharmacological interventions, such as low-dose aspirin, which could 
prevent the development of the disease.  
 
The data for the thesis were derived from two types of studies: First, prospective 
screening in 65,771 singleton pregnancies, which provided data for maternal factors 
and serum pregnancy associated plasma protein-A (PAPP-A). In an unselected 
sequential process we also measured uterine artery pulsatility index (PI) in 45,885 of 
these pregnancies, mean arterial pressure (MAP) in 35,215 cases and placental growth 
factor (PLGF) in 14,252 cases. Second, cases-control studies for evaluating the ten 
most promising biochemical markers identified from search of the literature; for these 
studies we used stored serum or plasma samples obtained during screening and 
measured PLGF, Activin-A, Inhibin-A, placental protein-13 (PP13), P-selectin, 
Pentraxin-3 (PTX-3), soluble Endoglin (sEng), Plasminogen activator inhibitor-2 
(PAI-2), Angiopoietin-2 (Ang-2) and soluble fms-like tyrosine kinase-1 (s-Flt-1). 
 





A competing risk model was developed which is based on Bayes theorem and 
combines the prior risk from maternal factors with the distribution of biomarkers to 
derive patient-specific risk for PE at different stages in pregnancy. The prior risk was 
derived by multiple regression analysis of maternal factors in the screening study. The 
distribution of biophysical and biochemical markers was derived from both the 
screening study and the case-control studies. 
 
The prior risk increased with advancing maternal age, increasing weight, was higher 
in women of Afro-Caribbean and South-Asian racial origin, those with a previous 
pregnancy with PE, conception by in vitro fertilization and medical history of chronic 
hypertension, type 1 diabetes mellitus and systemic lupus erythematosus (SLE) or anti-
phospholipid syndrome (APS). The estimated detection rate (DR) of PE requiring 
delivery at <34, <37 weeks’ gestation and all PE, at false positive rate (FPR) of 10%, 
in screening by maternal factors were 51, 43 and 40%, respectively. The addition of 
biochemical markers to maternal factors, including maternal serum PLGF and PAPP-
A, improved the performance of screening with respective DRs of 74, 56 and 41%. 
Similarly, addition of biophysical markers to maternal factors, including uterine artery 
PI and MAP, improved the performance of screening with respective DRs of 90, 72 
and 57%. The combination of maternal factors with all the above biophysical and 
biochemical markers improved the respective DRs to 96, 77 and 54%. 
 
The findings of these studies demonstrate that a combination of maternal factors, 
biophysical and biochemical markers can effectively identify women at high-risk of 
developing PE.  








Preeclampsia (PE), defined as high blood pressure and proteinuria developing during 
the second half of pregnancy, is a major cause of serious risk to the life and health of 
mothers and babies. In the United Kingdom, there are national recommendations to 
suggest that a woman’s risk of developing PE should be determined by recording 
maternal characteristics and medical history to enable planning of her antenatal care. 
However, this method identifies only a minority of pregnancies that develop PE.  
 
This thesis aims to develop a new method of screening for PE during the third month 
of pregnancy that will identify majority of women that will develop PE. The rationale 
for such early identification of high-risk pregnancies is that treatment at this stage, 
with drugs such as low-dose aspirin, can potentially prevent the development of the 
disease. 
 
We searched the literature to identify various metabolites that can be measured in 
maternal blood and have been reported to have altered levels in pregnancies that 
develop PE (biochemical markers). We also found from previous studies that the 
resistance to blood flow from the mother to the uterus and the blood pressure of women 
that develop PE are higher than in normal pregnancies.   
 
We measured the level of the ten most promising biochemical markers in stored blood 
obtained from women in the third month of pregnancy and compared the values 
between those that subsequently developed PE and those with normal pregnancies. 
This series of studies led to the conclusion that six of the ten biochemical markers 
would be potentially useful in identifying high-risk pregnancies. 
 
We also conducted a large prospective study in 65,771 pregnancies which included 
1,426 (2.4%) that developed PE. In this study, we measured the blood flow to the 
uterus in 45,885 cases and the blood pressure in 35,215 cases. The study found that 





the maternal factors which place a woman at an increased risk for developing PE are 
advancing maternal age, increasing weight, Afro-Caribbean and Asian racial origin, 
previous pregnancy with PE, conception by in vitro fertilization and medical history 
of chronic hypertension, type 1 diabetes mellitus and systemic lupus erythematosus or 
anti-phospholipid syndrome. We also found that the resistance to blood flow from the 
mother to the uterus and the blood pressure of women that develop PE are higher than 
in normal pregnancies.   
 
We developed a mathematical method of combining the information from maternal 
factors, resistance to blood flow to the uterus, blood pressure and biochemical markers 
measured during the third month of pregnancy. This new method could predict 96% 
of pregnancies that develop severe PE requiring delivery before the 34th week of 
pregnancy, 77% of those with PE requiring delivery before 37 weeks and 54% of all 
cases that develop PE at any stage in pregnancy. This method is by far superior to 
previous methods that relied only on maternal factors. 
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uterine artery pulsatility index (PI), mean arterial pressure (MAP), serum pregnancy 
associated plasma protein-A (PAPP-A) and serum placental growth factor (PLGF) 
according to Caucasian and Afro-Caribbean racial origin and obstetric history.  
 







AUROC: Area Under Receiver Operating Characteristic Curves 
ACOG: American College of Obstetricians and Gynaecologists 
Ang-2:  Angiopoeitin-2 
BMI:   Body Mass Index 
BP:   Blood Pressure 
CI:   Confidence Interval 
CRL:   Crown-Rump Length 
CV:   Coefficient of Variation 
DELFIA:  Dissociation-Enhanced Lanthanide Fluorescent Immunoassay 
DR:   Detection Rate 
ELISA:  Enzyme-Linked Immunosorbent Assay 
FPR:   False Positive Rate 
GH:   Gestational Hypertension 
hCG:   Human Chorionic Gonadotropin 
IQR:  Interquartile Range 
ISSHP:  International Society for Study of Hypertension in Pregnancy 
IVF:  In-vitro Fertilisation 
LMWH:  Low Molecular Weight Heparin 
MAP:   Mean Arterial Pressure 
MoM:  Multiple of Median 
NT:   Nuchal Translucency 
NICE:  National Institute of Clinical Excellence 
OR:   Odds Ratio 
PAPP-A:  Pregnancy Associated Plasma Protein-A 
PAI-2:  Plasminogen Activator Inhibitor-2 
PE:   Preeclampsia 
PI:   Pulsatility Index 
PlGF:   Placental Growth Factor 
PP13:   Placental Protein 13






PTX-3:  Pentraxin-3 
RCT:   Randomized Controlled Trial 
RR:   Relative Risk 
SD:   Standard Deviation 
sEng:   Soluble Endoglin 
sFlt-1:  Soluble fms-like Tyrosine Kinase-1 
TGF-β1:  Transforming Growth Factor-β1 
UK:   United Kingdom 
VEGF:  Vascular Endothelial Growth Factor 
WHO:  World Health Organisation 
 
 































Preeclampsia (PE) complicates around 2-5% of pregnancies and is an important cause 
of maternal and perinatal morbidity and mortality (World Health Organization, 2005; 
Confidential Enquiry into Maternal and Child Health Perinatal Mortality, 2009).  
 
The aetiology of PE is quite heterogeneous but it is mainly characterised by impaired 
trophoblastic invasion, as documented by the findings of histological studies of the 
uterine arteries (Khong et al., 1986; Pijnenborg et al., 1991; Lyall, 2002). The diameter 
of spiral arteries in a normal pregnancy is greatly increased and the vascular smooth 
muscle is replaced by trophoblast cells. This process, which is controlled by genetic 
and immunological factors, is deficient in PE (Wilson et al., 2003), which results in 
increased impedance and decreased vascular capacitance in the uteroplacental 
circulation (Sagol et al., 1999). 
 
The hallmark of PE is demonstration of high blood pressure (BP) and significant 
proteinuria during the second trimester of pregnancy. At the booking visit early in 
pregnancy, a detailed maternal history is obtained to identify risk factors for PE along 
with measurement of BP at the initial visit and later during subsequent antenatal visits, 
which constitutes the basis of screening for PE throughout pregnancy. There is 
evidence from studies that the main diagnostic feature of PE, which is raised BP, can 
be observed as early as in the first-trimester of pregnancy, well before the clinical onset 
of the disease (Moutquin et al., 1985; Higgins et al., 1997, Poon et al., 2008a). 
 
The use of Doppler ultrasound allows non-invasive assessment of utero-placental 
circulation. In normal pregnancies, impedance to flow in the uterine arteries decreases 
with gestation, but in pregnancies destined to develop PE this impedance is increased 
(Martin et al., 2001; Papageorghiou et al., 2002; Placensia et al., 2007). The finding 
that impaired placental perfusion, reflected in increased uterine artery pulsatility index 
(PI), is associated with the development of PE is compatible with the hypothesis that 
PE is the consequence of impaired placentation and the results of previous first and 





second-trimester Doppler studies as well as histological studies of the maternal spiral 
arteries (Olofsson et al., 1993; Martin et al., 2001; Papageorghiou et al., 2002; 
Plasencia et al., 2007).  
 
A large number of biochemical markers have been investigated for the prediction of 
PE. Many such markers represent measurable manifestations of impaired placentation 
due to inadequate trophoblastic invasion of the maternal spiral arteries and reduced 
placental perfusion leading to placental ischemia related damage with the release of 
inflammatory factors, platelet activation, endothelial dysfunction, maternal renal 
dysfunction, or abnormal oxidative stress (De Wolf et al., 1975; Khong et al., 1986; 
Redman 1991; Meekins et al., 1994a; Pijnenborg 1996). 
 
 
1.2 DEFINITION OF PREECLAMPSIA 
 
PE is defined as development of hypertension and proteinuria in a previously 
normotensive woman. However, there is lack of consensus regarding the precise 
definition of PE as although hypertension and proteinuria are considered easy to 
measure, both are fraught with methodological problems. The traditional method of 
non-invasive BP monitoring is the use of mercury sphygmomanometers, but there are 
concerns regarding the clinical performance and safety of these instruments (Mion and 
Pierin, 1998; Markandu et al., 2000). In addition, other sources of error which 
undermine clinical performance of this method are poor calibration, inappropriate cuff 
size, threshold avoidance and rounding up of values (Perry et al., 1991). In the last few 
years, there is a move away from use of mercury sphygmomanometers, largely for 
occupational health and safety reasons, which has led to the automated devices being 
used more commonly.  
 
There is also a growing recognition of potential inaccuracies in measurement of 
proteinuria. The dipstick analysis of a random urine sample has a poor correlation with 
24-hour urine sample in the diagnosis of significant proteinuria and this leads to 





inaccuracies not just in the measurement of proteinuria but also in the diagnosis of PE 
(Meyer et al., 1994). 
 
There are several definitions for diagnosis of PE which have been reported in 
published literature and proposed by various professional bodies but the accepted 
definition of PE is that of the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) (Davey and MacGillivray, 1988; Brown et al., 2001, Tranquilli et 
al., 2014). A summary of various definitions proposed is mentioned in Table 1.1. 
 













Systolic/Diastolic Diastolic Diastolic Diastolic Either 
     
Threshold 90 mmHg x 2  
or 
110 mmHg x 1 










     
Increment No No 25 mmHg No 
     
Proteinuria Yes Yes No Yes 
     
Baseline Normotensive 
< 20 weeks 
Normotensive 
< 20 weeks 
<90mmHg 
< 20 weeks 
Normotensive 
< 20 weeks 
     
Endorsed by ISSHP   ACOG 
 
ISSHP - International Society for the Study of Hypertension in Pregnancy 
WHO - World Health Organization 
NHBPEPWG - National High Blood Pressure Education Program Working Group Report on 
High Blood Pressure in Pregnancy 
ACOG - American College of Obstetrics and Gynecology 
 






1.2.1 ISSHP Diagnostic criteria 
 
The ISSHP recognised that one of the major reasons for lack of consensus and 
controversies was whether or not proteinuria should be an essential part of diagnosis 
of PE. They recommended that a broad definition, at times not including proteinuria, 
could be applied for the clinical definition of PE whilst the inclusion of proteinuria 
would ensure more specificity around the diagnosis when reporting clinical criteria for 
patients enrolled in scientific research (Tranquilli et al., 2014).  
 
For the purposes of this research, the ISSHP classification of hypertensive disorders 
of pregnancy was chosen as it represents a consensus view of an appropriate definition 
for research use. The ISSHP revised its classification of hypertensive disorders in 
pregnancy as follows: 
 
Table 1.2 The revised ISSHP classification of hypertensive disorders in pregnancy. 
 
Revised ISSHP classification (2013) for hypertensive disorders in pregnancy 
1 Chronic hypertension 
2 Gestational hypertension 
3 Preeclampsia – de novo or superimposed on chronic hypertension 





Hypertension is diagnosed as systolic BP of > 140 mm Hg or diastolic BP > 90 mm 
Hg. BP should be ideally measured by instruments validated for use in pregnancy 
either automated, liquid-crystal or mercury sphygmomanometer. Regardless of the 
method used, the BP should be measured at least twice. 
 








Chronic hypertension is hypertension ideally predating the pregnancy. As many 
women will not have their BP measured close to pregnancy, in practice the diagnosis 
of hypertension in the first trimester is considered diagnostic of chronic hypertension.  
 
Gestational hypertension and preeclampsia 
 
New onset of hypertension after 20 weeks’ gestation is characteristic of gestational 
hypertension and PE. The diagnosis of PE is made by hypertension and the co-
existence of one or more of the following conditions: 
 
Proteinuria 
The presence of significant proteinuria defined as presence of > 300 mg/day protein in 
a 24-hour urine sample or urine protein/creatinine ratio of > 30 mg/mmol. 
 
Maternal organ dysfunction 
This is characterised by: 
- Renal insufficiency: characterised by serum creatinine levels of > 90 mol/L or 
1.02 mg/dL 
- Liver involvement: characterised by elevated transaminases with levels at least 
twice the upper limit of normal range with or without right upper quadrant or 
epigastric abdominal pain 
- Neurological complications: characterised by hyperreflexia accompanied by 
clonus; severe headache accompanied by persistent visual scotoma; blindness, 
stroke or eclampsia 
- Haematological complications: characterised by platelet count below 150,000/dL 
 
Utero-placental dysfunction 
This is characterised by presence of fetal growth restriction. 






Gestational hypertension is diagnosed when hypertension develops de novo after 20 
weeks’ gestation and is not accompanied by any of the above features. PE 
superimposed on chronic hypertension is diagnosed when chronic hypertension is 
accompanied by one or more of the above features.  
 
Table 1.3 The revised ISSHP definition of preeclampsia (2014). 
 
Hypertension developing after 20 weeks co-existing with new onset of one or 
more of the following features 
1 Proteinuria 
2 Maternal organ dysfunction 
- Renal insufficiency 
- Liver involvement  
- Neurological complications 
- Haematological complications 
3 Utero-placental insufficiency  
- Fetal growth restriction 
 
 
White coat hypertension 
 
This is characterised by hypertension diagnosed in clinical setting but with normal BP 
measurements in home setting. This diagnosis is confirmed by taking repeated BP 




This is defined as finding of a significant proteinuria as defined above without 
accompanying hypertension or primary renal disease. 
 





1.3 PATHOGENESIS OF PREECLAMPSIA 
 
The exact pathogenesis of PE is not clear but it is thought to be the consequence of 
impaired trophoblastic invasion of the placenta eventually leading to endothelial 
dysfunction which accounts for its clinical signs and symptoms.  
 
The placenta develops primarily from the trophoblasts, which then differentiates into 
two cell types, the cytotrophoblasts and syncytiotrophoblasts. The cytotrophoblasts are 
precursors of all trophoblast cells whereas the syncytiotrophoblasts are responsible for 
the invasion into the decidua, and in particular, into the maternal spiral arteries. There 
are two waves of trophoblastic invasion, one in early pregnancy and the second later 
in pregnancy, around 14 to 16 weeks’ gestation (Robillard 2002). The invasion of the 
syncytiotrophoblasts into the spiral arteries results in converting these muscular high-
resistance arteries into wide low-resistance vessels, thereby increasing the blood flow 
available to the developing fetus and placenta (Brosens et al., 1972). 
 
 
Figure 1.1 Impaired trophoblastic proliferation of spiral arteries in preeclampsia. 
(Reprinted by permission from Nature Publishing group; Macmillan Publishers Ltd: 
[Nat Rev Immunol] (Moffett-King, A et al., 2002). 





In PE, trophoblastic invasion and subsequent remodeling of the spiral arteries, 
especially during the second wave of invasion, is deficient, resulting in spiral artery 
diameters that are only about 40% as wide as those in a normal pregnancy. The result 
is placental ischemia and poor placental perfusion in women who will eventually 
develop the clinical signs of PE (Wilson et al., 2003). 
 
The main factors which are thought to play an important role in aetiology and 
pathogenesis of PE are genetic factors, immunological maladaptation, placental 




Figure 1.2 Pathogenesis of preeclampsia (Reprinted by permission from Nature 
Publishing group; Macmillan Publishers Ltd: [Nat Med] (Parikh and Karumanchi, 
2008). 






1.3.1 Genetic factors 
 
PE is thought to have a genetic bias as there is evidence that there is familial clustering 
for PE and in women with a positive family history, the risk of subsequent PE is 
increased about three times compared to those without such a family history 
(Arngrimsson et al., 1990; Cincotta and Brennecke, 1998; Duckitt and Harrington 
2005). The analysis of pedigree charts suggests that one or more genes or their alleles 
may act as “preeclampsia susceptibility gene” and such candidate genes may include 
those that are involved in regulation of BP and those that play an important role in 
modifying placental function. The proposed genetic models mainly include either a 
single recessive gene or a single dominant gene (Cooper and Liston, 1979; Chesley 
and Cooper, 1986). There are many reported associations between PE and 
polymorphisms of genes such as angiotensinogen, tumour necrosis factor- (TNF-), 
factor V Leiden and the 5,10-methylenetetrahydrofolate reductase genes (Morgan et 
al., 1999; Lachmeijer et al., 2001; Bendetto et al., 2002; Heiskanen et al., 2002). 
 
In a recent systematic review of literature and meta-analysis (Human Genome 
Epidemiology Review [HuGE review]), the authors examined the association between 
maternal genotype and severe PE according to functional gene groups (immune, cell-
signalling, metabolic, thrombophilic and vasoactive). They examined 57 studies which 
evaluated 50 genotypes in 5,049 cases and 16,989 controls and reported that a high-
risk for severe PE was noted with coagulation factor V gene (proaccelerin, labile 
factor) polymorphism rs6025, coagulation factor II (thrombin) gene mutation 
G20210A, leptin receptor gene (LEPR) polymorphism rs1137100 and the 
thrombophilic gene group. The authors reported that although there appears to be a 
role for thrombophilia genes in severe PE, there is insufficient evidence to establish a 
causal relationship and further studies will need to be carried out to examine the 
thrombophilia genes and their polymorphisms (Fong et al., 2014). In another meta-
analysis, the authors specifically examined the relationship between the risk of PE and 
the two thrombophilia single-neucleotide polymorphisms (SNPs), the factor V 
G1691A SNP and prothrombin G20210A SNP. They examined 37 studies with 5,048 





patients with PE and 6,796 controls and reported that both these polymorphisms are 
associated with increased risk of all types of PE, including severe PE. In this meta-
analysis, the presence of a prothrombin 20210A polymorphism was associated with a 
2-fold increased risk for PE and an approximately 3-fold increase for severe PE (Wang 
et al., 2014).  
 
Although, there are associations between these gene polymorphisms and the risk for 
PE, there is a need for further larger studies as the results from these meta-analyses 
may be affected by heterogeneity between studies and a potential for bias from poor-
quality genotyping, inconsistent definition of phenotype and publication bias (Fong et 
al., 2014; Wang et al., 2014). 
 
 
1.3.2 Immunological factors 
 
The placental structure takes its origin from fetal tissues and it has both maternal and 
paternal derived antigens. During a normal pregnancy, the mother is tolerant of foreign 
fetal antigens and mounts a modified immune response to allow acceptance of the 
semi-allogenic fetus. There is evidence from studies that in PE, there is activation of a 
broad continuum of immune cells to induce immunity towards the fetus and placenta, 
rather than immune tolerance (Dekker and Robillard 2005; Robillard et al., 2007; 
Laresgoiti-Servitje 2013). What is uncertain is whether this immune maladaptation 
precedes the abnormal implantation of placenta and endothelial dysfunction or follows 
it (Djurisic and Hviid 2014). 
 
There is evidence from epidemiological observations that support an immunological 
cause for PE, which may be due to an abnormal and heightened maternal immune 
response to paternally derived antigens on the trophoblast. This hypothesis is 
supported by the epidemiological observations that, firstly, PE is more common in a 
first pregnancy, secondly, the risk of PE decreases after the first pregnancy due to the 
protection from repeated exposure to specific antigens from the same partner, thirdly, 





changing partners for a subsequent pregnancy increases the risk of PE which suggests 
that primipaternity is important (Robillard et al.,1999; Li and Wi, 2000). Additional 
evidence to support the hypothesis is that both artificial donor insemination and oocyte 
donation lead to an increased risk in PE (Smith et al., 1997a; Wilson et al., 2003). 
 
Human Leukocyte Antigens (HLA) 
 
There are two classes of human leukocyte antigens (HLA): class I and II. The class 
HLA Ia antigens (A, B and C) and HLA II (DR, DQ and DP) are important for antigen 
presentation and therefore in organ transplantation and autoimmunity. The HLA Ib (E, 
F and G) genes on the other hand are primarily expressed in the extravillous 
trophoblast cells lining the placenta and by syncytiotrophoblast cells (Ishitani et al., 
2003; Bhalla et al., 2006). HLA-G is believed to be involved in modulating immune 
responses in the context of vascular remodeling during pregnancy as well as in 
dampening potentially harmful immune attacks raised against the semi-allogeneic 
fetus (Djurisic and Hviid 2014). Soluble HLA-G (sHLA-G) in the maternal circulation 
is predominantly produced and shed from trophoblast cells during pregnancy (Kovats 
et al., 1990).  
 
The association between HLA-G and PE is supported by findings from 
immunohistochemistry and in situ hybridisation studies on placental samples from 
pregnancies with PE which demonstrate a reduced expression of HLA-G compared to 
normotensive pregnancies (Hara et al., 1996; Goldman-Wohl et al., 2000). There is 
evidence that circulating levels of sHLA-G are reduced in women with PE compared 
to normotensive women (Hackmon et al., 2007; Darmochwal-Kolarz et al., 2012) and 
that these altered levels are also noted prior to clinical onset of PE (Yie et al., 2005). 
Although, these studies suggest a possible role for HLA-G in PE but these data are 
based on small case-control studies and further studies are needed to establish a precise 
role in the pathogenesis of PE (Djurisic and Hviid 2014). 
 
 





NK cells, T-cells and B-cells 
 
Natural killer (NK) cells are a part of the innate immune response to foreign antigens. 
They are present in the peripheral blood and form 5% of leukocyte population (pNK) 
cells whereas a unique subset of cytokine producing decidual NK cells (dNK) are 
identified in the placenta during the pregnancy. These dNK cells secrete vascular 
endothelial growth factor (VGEF), placental growth factor (PlGF), interleukin-8 (IL-
8) and IFN-inducible protein-10 (IP-10) (Hanna et al., 2006). These findings raise the 
possibility for a role for NK cells in PE but the evidence from studies is controversial 
with some studies showing a difference in PE and controls (Molvarec et al., 2010) but 
others not demonstrating any significant difference (Toldi et al., 2008).  
 
There is some evidence that the release of cytokines from the Th1 subset of T-
lymphocytes such as interleukin-1 (IL-1), IL-2 and interferon- (IFN-) is increased in 
PE whereas the production of Th2 cytokines such as IL-5 and IL-10 is decreased 
(Verlohren et al., 2009). The presence of low IL-10 levels can be associated with 
development of PE as IL-10 protects the fetus from rejection during a normal 
pregnancy via activation of HLA-G expression at the fetal-maternal interface and 
lower levels may lead to immune maladaptation and eventually to PE (Hennessy et al., 
1999; Moreau et al., 1999).  
 
The B-cells, which produce immunoglobulins, have been implicated in the 
pathogenesis of PE through the identification a population of B-cells which produce 
autoantibodies against type I angiotensin II receptor (AT1) (Wallukat et al., 1999; 
Jensen et al., 2012). These autoantibodies can activate AT1 in endothelial cells, 
vascular smooth muscle and mesangial cells eventually leading to renal disease 
characterised by hypertension and proteinuria, prothrombotic and anti-angiogenic state 









1.3.3 Placental factors 
 
The placenta is the main factor responsible for development of PE. The support for 
this hypothesis is from observations that the risk of PE is increased with placental mass 
being higher in multiple pregnancies, molar pregnancies and hydrops fetalis. In normal 
pregnancy, the trophoblastic cells – mainly the syncytiotrophoblast – invade the spiral 
arteries which become high-capacity low resistance uteroplacental vessels with a 
dilated tortuous lumen, complete absence of muscular and elastic tissue and no 
continuous endothelial lining. The development of PE is thought to be result of 
placental disease at two different stages: the first stage is the process that results from 
impaired trophoblastic proliferation which affects the spiral arteries resulting in 
deficient placental perfusion and the second stage involves the effects of placental 
ischaemia on both fetus and mother. 
 
Placentation in normal pregnancy 
 
The placenta is formed from cells derived from the fetus – the trophoblasts. There are 
two types of trophoblastic cells: the cytotrophoblasts, which are the precursors to all 
subsequent trophoblast cells and the syncytiotrophoblasts, which are responsible for 
the invasion into the decidua, and particularly, the maternal spiral arteries. At an early 
stage of pregnancy, approximately 5 weeks of gestation, the cytotrophoblasts 
differentiate from the villous Langerhans type to the invasive extravillous type and 
break through the syncytiotrophoblasts to invade the maternal spiral arteries resulting 
in what is called as the endovascular invasion.  
 
These invasive trophoblastic cells then migrate into the decidua and through into the 
myometrium underlying the placental bed, a process which is termed as the interstitial 
invasion. The interstitial cytotrophoblasts are initially focused near the spiral arteries, 
but after about 8 weeks of gestation, the cytotophoblasts are more broadly distributed 
and invade the inner third of the myometrium (Pijnenborg et al., 1991).  





There is evidence suggesting that priming of the spiral artery for subsequent invasion 
by endovascular trophoblast may be initiated by perivascular interstitial trophoblasts 
which cause degenerative changes in the vessel wall structure (Kam et al., 1999). The 
endovascular trophoblastic cells appear inside the lumen of the decidual spiral arteries 
from around 4 weeks of gestation, migrating towards the proximal part of the vessel 
(Pijnenborg et al., 1991). These trophoblastic cells then replace the endothelium and 
invade the walls of the intradecidual portion of the spiral vessels, destroying the elastic 
and muscular layers of the vessel wall. As a result of this trophoblastic invasion, the 
narrow-diameter high resistance spiral arteries become wide-diameter, high-flow, low 
resistance, funnel-shaped, uteroplacental arteries. The diameter of the spiral arteries 
increases considerably thus allowing a ten-fold increase in uterine blood flow to meet 
the requirements of the fetus. This process, as alluded to before, is thought to occur in 
two different stages: the initial stage is the first wave of trophoblastic invasion which 
involves the decidual portion of the spiral arteries and starts at 8 weeks, whereas the 
next stage is the second wave of trophoblastic invasion which involves the myometrial 
segments of the spiral arteries and occurs at 14-24 weeks of gestation (Lyall, 2002). 
 
Placentation in preeclampsia 
 
The dominant feature in PE is failure of endovascular and interstitial invasion of the 
placenta that is a prerequisite for normal placentation (Khong et al., 1986). The 
sequence of vascular modifications of the spiral arteries that are a hallmark of 
development of an effective uteroplacental circulation, do not occur as in the normal 
pregnancies. Although there is trophoblastic invasion of spiral arteries in PE, but this 
process is impaired and largely deficient being limited to the decidual part of the 
vessels without extending into the myometrial segments of the spiral arteries (Brosens 
et al., 1972; Gerretsen et al., 1981; Meekins et al., 1994a).   
 
The other characteristic histological feature of PE is endothelial dysfunction which is 
evidenced by finding of acute atherosis (Sheppard and Bonnar, 1981). This 
histological change is principally characterised by fibrinoid necrosis, lipid-laden 





macrophage infiltration of the damaged vessel wall and a perivascular mononuclear 
cellular infiltrate (Pijnenborg et al., 1991). There is increased deposition of lipoprotein 
within the walls of these arteries (Meekins et al., 1994b) and there is evidence of both 
microthrombi within the vessels and macroscopic placental infarction (Salafia et al., 
1995). This finding of acute atherosis is not unique to PE but is also noted in other 
pregnancy complications such as pregnancies with recurrent miscarriages, fetal growth 
restriction and antiphospholipid syndrome. There is a degree of overlap and impaired 
trophoblastic proliferation as well as acute atherosis is noted in pregnancies with fetal 
growth restriction with or without PE (Frusca et al., 1989). 
 
There is an association between the severity of histological changes in spiral arteries, 
the impedance to blood flow in uterine arteries and the severity of PE. There is 
evidence from histological studies of the placenta that there is a good relationship 
between uterine artery Doppler and placental bed biopsies with higher resistance 
values of PI more related to advanced histological changes (Olofsson et al., 1993; 
Meekins et al., 1994a; Sagol et al., 1999). The severity of histological changes and 
abnormal uterine artery values are also reflected in clinical severity of disease by an 
earlier clinical onset of the disease. There appears to be an inverse relationship between 
the severity of histological and Doppler changes and the clinical onset of PE with 
studies demonstrating that the likelihood of clinical diagnosis of PE before 32 weeks’ 
gestation increases with progressive impairment of the uteroplacental circulation 
(Ghidini et al., 1997). There is further evidence from clinical and histological studies 
which demonstrate that early onset disease is more likely to be associated with 
abnormal villous and vascular morphology while in late onset disease the placental 
morphology and histology is not dissimilar to those of normotensive pregnancies 
(Moldenhauer et al., 2003; Egbor et al., 2006). 
 
There appears to be considerable overlap in the degree of placental vascular lesions 
between normal and PE pregnancies (Ghidini et al., 1997). On the other hand, there is 
evidence from some studies that there can be a significant degree of uteroplacental 
vascular pathology with normal uterine artery Doppler flow even in normal 





pregnancies (Aardema et al., 2001). These studies imply that defective placentation is 
not universally present in all cases of PE and equally well, it is not unique to PE 
(Pijnenborg et al., 1991; Meekins et al., 1994a). There is considerable variation in the 
spectrum of histological changes in pregnancies with or without PE. Some 
investigators have demonstrated through studies that trophoblastic invasion within a 
vessel wall can be variable and that physiological change can be present in the whole 
circumference or restricted to one segment only in the same patient. Hence, the 
spectrum of changes in the spiral arteries may not necessarily correlate to the degree 
of severity of the clinical disease (Pijnenborg et al., 1991).   
 
In summary, there is evidence that impaired trophoblastic proliferation is present in 
pregnancies with PE. There is a significant correlation between histological and 
Doppler findings in pregnancies with PE with more severe changes associated with 
high uterine artery PI, significant histological findings and an earlier onset of the 
clinical disease. However, there is also evidence that in some pregnancies with PE, 
there is normal placentation whilst on the other hand, there are some normal 
pregnancies which show evidence of impaired trophoblastic proliferation. Therefore, 
it may be that inadequate trophoblast invasion is a predisposing factor, with the 




1.3.4 Endothelial dysfunction 
 
Endothelial cell activation has been suggested as a dominant feature of PE. This is 
underlined by the increased vascular resistance which is a key feature of the disease. 
It is suggested that impaired trophoblastic proliferation leads to placental 
hypoxia/ischemia which in turn results in oxidative stress, intravascular inflammation 
and endothelial cell activation (Redman and Sargent 2003; Myatt and Webster 2009). 
There is evidence that impaired placentation and the resulting placental hypoxia can 
lead to intravascular inflammation and consequent activation or repression of 





endothelial cell function (Redman, 1991; Gervasi et al., 2001; Redman and Sargent, 
2003; Myatt and Webster, 2009; Saito and Nakashima, 2014).  
 
The resulting endothelial dysfunction leads to a series of changes which include 
alterations in level of angiogenic and anti-angiogenic proteins such as vascular 
endothelial growth factor (VEGF) and soluble VEGF receptor-1 also called as soluble 
fms-like tyrosine kinase-1 (sFlt-1). The altered concentration of these proteins further 
enhances the endothelial dysfunction established by intravascular inflammation 
(Luttun et al., 2002; Maynard et al., 2003; López-Novoa, 2007; Widmer et al., 2007; 
Zhou et al., 2011; Murphy et al., 2013). 
 
VEGF is a pro-angiogenic protein released by many cell types including the 
cytotrophoblast and it is involved in promoting angiogenesis and vasculogenesis. The 
VEGF protein is transcribed from the VEGF gene which is located on chromosome 6, 
which also encodes for various isoforms of VEGF including placental growth factor 
(PlGF) (Romero et al., 2008b; Cheng et al., 2013). These angiogenic factors exert their 
role in endothelial cells by mediating increased vascular permeability, which includes 
angiogenesis, vasculogenesis and growth of endothelial cells (Yamazaki et al., 2006; 
Maharaj et al., 2008).  
 
The sFlt-1 protein is primarily produced by the syncytiotrophoblast and is produced 
by alternative splicing of the Flt-1 gene which results in a truncated protein which 
cannot bind to PlGF or VEGF inside the cells but attaches to the transmembrane 
receptors thus acting as an antagonist to of PlGF and VEGF and preventing these 
angiogenic factors from interacting with their receptors (Maynard et al., 2003; Levine 
et al., 2004; Romero et al., 2008b; Tache et al., 2011).  The sFlt-1 exerts anti-
angiogenic effects by inhibiting biological activity of VEGF and PlGF (Kendall and 
Thomas, 1993). VEGF is important for maintaining endothelial function in fenestrated 
endothelium especially and in brain, liver and renal glomeruli (Esser et al., 1998). The 
higher levels of sFlt-1 also counteract vasodilatory effects of nitric oxide induced by 





VEGF thereby leading to hypertension (Maynard et al., 2003). In addition, sFlt-1 can 
induce proteinuria by blocking effects of VEGF (Eremina et al., 2003).  
 
A second anti-angiogenic factor implicated in the pathogenesis of PE is soluble 
endoglin (sEng), a surface receptor of transforming growth factor-β1 (TGF- β1), which 
induces growth and proliferation of endothelial cells (Venkatesha et al., 2006). The 
sEng protein has anti-angiogenic properties since it prevents binding of TGF- β1 to its 
receptors on endothelial cells this compromising its function and leading to 
impairment in production of nitric oxide (Levine et al., 2006). There is evidence from 
animal studies that increased expression of sEng in mice leads to increased vascular 
permeability and hypertension. If in addition to sEng, there was also increased 
expression of sFlt-1, then it led to severe vascular damage, nephrotic syndrome, 
proteinuria and growth restriction (Venkatesha et al., 2006).  
 
Endothelial cell dysfunction leads to vasospasm and platelet activation and there is 
evidence to support an important role for platelet dysfunction and thrombocytopaenia 
prior to development of hypertension (Romero et al., 1988). There are studies 
reporting abnormalities in platelet size, platelet life span, and increased production of 
thromboxane by platelets in pregnancies with PE (Kenny et al., 2009). There are 
abnormalities in the levels of prostacyclin and thromboxane A2. Prostacyclin causes 
vasodilatation and inhibits platelet aggregation whereas thromboxane A2 leads to 
vasoconstriction and platelet aggregation (Romero et al., 1988). The evidence for a 
central role for platelet activation in PE is supported by studies which suggest that 
there is reduction in levels of a metabolite of prostacyclin in maternal blood and urine 
in pregnancies with PE (Bussolino et al., 1980). This is supported by increased 
production of thromboxane A2 compared to prostacyclin from placentae in 
pregnancies with PE (Walsh, 1985). This altered balance between these proteins along 
with platelet activation results in platelet aggregation and formation of thrombi in the 
microcirculation of different organs, which is a major contributor to pathogenesis of 
PE (Romero and Duffy, 1980). 
 






1.3.5 Oxidative stress 
 
The production of reactive oxygen species (ROS) leads to oxidative stress when the 
inherent anti-oxidant mechanisms in tissues are overwhelmed. In pregnancies with PE, 
impaired placentation leads to the sequence of placental hypoxia and reperfusion 
induced damage leading to increased production of ROS which in turn further 
contributes to oxidative stress (Burton and Jauniaux, 2011). There is evidence that 
placental anti-oxidant mechanisms are impaired in pregnancies with PE as evidenced 
by decreased levels of superoxide dismutase and glutathione peroxidase compared 
with normal pregnancies (Vaughan and Walsh, 2002). In summary, impaired 
placentation leads to hypoxia and reperfusion injury which lead to oxidative stress and 
release of proinflammatory cytokines and trophoblast debris in the circulation thus 
contributing to the pathophysiology of PE (Cindrova-Davies et al., 2007). 
 
There appear to be some similarities between PE and atherosclerosis with some 
investigators suggesting that events that lead to development of atherosclerosis may 
also contribute towards the pathophysiology of PE. There is evidence that altered and 
abnormal lipid metabolism along with oxidative stress results in changes in endothelial 
function leading to atherosclerosis (Witztum, 1994). Similarly, hypoxia at the 
maternal-fetal interface due to reduced placental perfusion results in the generation of 
free radicals, which in turn leads to oxidative damage to the vascular endothelium. The 
main mechanism of damage is suggested to be generation of ROS which interact with 
circulating lipids to form stable lipid peroxidation products which are capable of 
damaging endothelial cell structures.  
 
Dyslipidaemia in pregnancies complicated by PE can lead to the accumulation of very 
low density lipoproteins (VLDL), which are easily oxidised to form highly reactive 
oxidised LDL. These oxidised LDL alter the membrane protein and phospholipids and 
increase the expression of signalling molecules which recruit monocytes. The 
membrane damage by oxidised LDL alters endothelial function while monocytes take 





up oxidised LDL to form foam cells and eventually the fatty streak characteristic of 
atherosclerosis (Roberts and Cooper, 2001). In PE, the reduced reserve in net anti-
oxidant activity leads to further damage by these oxygen free radicals. 
 
 




The traditional method for early detection and diagnosis of PE is to undertake serial 
measurements of BP and assessment of proteinuria during regular scheduled antenatal 
visits but unfortunately this approach is not useful for early prediction or identification 
of a high-risk group that are likely to develop PE. Although recognition of risk factors 
can be useful in clinical practice, it cannot be used reliably for screening and prediction 
of PE (Wallenburg, 2001). However, in the UK the National Institute for Clinical 
Excellence (NICE, 2008) has issued guidelines for antenatal care which recommend 
that at the booking visit, a woman’s level of risk for PE, based on factors in her history, 
should be determined and the subsequent intensity of antenatal care should be based 
on this assessment of risk (Table 1.4).  
 
There is however, no available data on the performance of such a recommended 
screening strategy which treats each of the risk factors, such as age of 40 years or older, 
nulliparity, body mass index (BMI) of 30 Kg/m2 or above, family history or personal 
history of PE and pre-existing vascular disease, as separate screening tests with 
additive detection and false positive rates.  
 
This approach of screening for PE is likely to result in classifying a large number of 
pregnant women as screen-positive and therefore in need of more frequent antenatal 
monitoring, which undermines the purpose of screening and creates a substantial strain 
on the healthcare system. 
 






Table 1.4 National Institute for Clinical Excellence recommendations on screening for 
preeclampsia. 
 
NICE recommendations on Screening for preeclampsia 
At the booking appointment, the following risk factors for PE should be 
determined: 
- Age 40 years or older 
- Nulliparity 
- Pregnancy interval of more than 10 years 
- Family history of PE 
- Previous history of PE 
- Body Mass Index of 30 Kg/m2 or above 
- Pre-existing vascular disease such as hypertension 
- Pre-existing renal disease 
- Multiple pregnancy 
More frequent blood pressure measurements should be considered for pregnant 
women with above risk factors 
 
 
The main factors in maternal demographic characteristics and obstetric history which 
contribute towards the background risk for PE are discussed below. There are several 
observational, cohort and case studies with few studies quantifying the actual impact 
of an individual risk factor towards development of PE.  
 
 




There is evidence from a considerable number of studies which suggest that there is 
an increase in the risk of PE with increasing maternal age. Previous studies, which 





dichotomised maternal age with cut-offs at either 35 or 40 years, have shown a 
doubling of the risk of developing PE (Bianco et al., 1996; Lawoyin and Ani, 1996; 
Lee et al., 2000; Chen et al., 2000). Data from US shows that the risk for PE appears 
to increase more abruptly after the mid-30s (Saftlas et al., 1990) and similarly reported 
in a study by Mittendorf et al., (1996) which shows that the risk for PE increases by 
30-40% for every additional year of age past 34 years. In a study which demonstrated 
the association of advanced maternal age with PE, the authors reported that the 
increase in risk of PE was significantly higher in mothers older than 40 years compared 
to younger mothers and this association remained statistically significant regardless of 
adjustment for parity (Ziadeh and Yahaya, 2001). The association of advanced 
maternal age with PE may be related to the underlying progressive vascular endothelial 
damage associated with aging (Naeye, 1983; Eisenberg and Schenker 1997). 
 
These results were consistent with results of a systematic review in which the authors 
reported that maternal age above 40 years is associated with doubling in risk of PE 
(Duckitt and Harrington 2005). The association of PE with maternal age is also 
reported in a large study which examined the risk factors for PE in a multivariate 
approach, thus accounting for confounding effects and interactions, and reported that 
the risk for late onset PE increases by 4% every year over the age of 32 years (Poon et 
al., 2010).  In a large prospective observational cohort study of more than 75,000 
singleton pregnancies examining the association of maternal age with adverse 
pregnancy outcomes, the authors reported that the risk of PE was significantly higher 
in women with advanced maternal age more than 40 years. Compared to younger 
women, the risk of developing early-PE was higher than late-PE. They reported that 
even after adjusting for other maternal characteristics, maternal age of 35-39 years and 





The relationship between women in their first pregnancy and risk of PE is reported 
widely. A systematic review of controlled studies showed that nulliparity increases the 





likelihood of PE by a factor of about three (Duckitt and Harrington, 2005). Similar 
results were reported by Luo et al., (2007) in a systematic review of 26 studies 
reporting that the summary crude odds ratio was 2.42 for risk of PE among primiparous 
vs multiparous women. They further reported that this elevated risk for PE remained 
even after adjusting for other risk factors such as maternal age, race and body mass 
index and the summary adjusted odds ratio was 2.71 (Luo et al., 2007). 
 
Women with a previous pregnancy, albeit a miscarriage appears to provide some 
degree of reduction in risk for PE (Dekker et al., 1998). An explanation for this 
association between nulliparity and risk of PE is provided by the immune 
maladaptation hypothesis which states that the fetal-placental unit contains paternal 
antigens are antigenic to the nulliparous mother who mounts an abnormal immune 
response resulting in manifestations of PE (Dekker, 1999). This hypothesis is 
supported by observations that suggest that multiparity reduces the risk of PE and that 
this protective effect is lost with change of partner (Robillard et al., 1993). Another 
support for immune maladaptation hypothesis in explaining the association of 
nulliparity and PE is the finding that in multiparous women conceived by donor 
insemination, the risk of PE is increased (Need et al., 1983). There are studies 
suggesting that regular sperm exposure over a prolonged period prior to conceiving 
may result in the mother’s immune system being exposed to paternal antigens and 
therefore affording some protection against PE in nulliparous mothers (Marti and 
Herrmann 1977; Dekker 2002; Dekker and Robillard, 2005). Although the immune 
maladaptation theory is a proposed hypothesis to explain the increased risk but the 
evidence for this from biological studies is not strong (Luo et al., 2007). There are 
however, recent studies which suggest that differences in angiogenic factor profile or 
reactivity to insulin resistance may explain the primiparity-associated PE risk (Wolf et 
al., 2002 and 2005). There is evidence that women in their first pregnancies had a 
significantly increased level of anti-angiogenic factor sFlt-1 compared to women in 
their second pregnancies and this difference persisted despite adjusting for other 
confounding factors which are associated with PE (Wolf et al., 2005). In summary, 





there is an increased risk for PE associated with nulliparity but further research into 
the mechanisms for this need to be carried out. 
 
Change of partner  
 
There is evidence from some studies that the risk of PE in a second pregnancy is lower 
only if the mother's partner remains the same. The basis for this association is that the 
risk may be reduced with repeated maternal exposure or adaptation to specific foreign 
antigens of the partner, while a new partner presents with new antigens that results in 
a risk of PE that is similar to that of a first pregnancy (Robillard et al., 1993; Trupin et 
al., 1996). However, it is likely that the increased risk of PE associated with a change 




In a large study examining 550,000 women who had two or more singleton deliveries 
including 200,000 women who had three or more singleton deliveries, the authors 
demonstrated that an association between the risk of PE and interval is more significant 
than the association between the risk and a change of partner, with the risk in a second 
or third pregnancy directly related to the time elapsed since the previous delivery 
(Skjaerven et al., 2002). In addition, when the inter-pregnancy interval is 10 years or 
more the risk of PE is about the same as that in nulliparous women. After adjustment 
for the presence or absence of a change of partner, maternal age and year of delivery, 
the probability of PE is increased by a factor of 1.12 for each year increase in the inter-
pregnancy interval. Similar results were reported by another study where the authors 
stratified the analysis in mothers with a subsequent pregnancy according to whether 
they had previous PE or not. In women without previous PE, the risk of subsequent 
PE increased with increasing time interval between deliveries regardless of change in 
paternity for the second pregnancy. Whereas in women with a previous PE, there was 
no significant difference in the risk of PE according to time interval between deliveries 
in women with same or new paternity pregnancies (Trogstad et al., 2001). Additional 
evidence for the importance of the inter-pregnancy interval derives from a cross-





sectional study which reported a significant increase in the risk of PE in women with 
inter-pregnancy intervals of more than 59 months compared with those with intervals 
of 18-23 months (Conde-Agudelo et al., 2000). 
 
Parous women with history of previous preeclampsia 
 
There is evidence from observational studies that a previous history of PE increases 
the risk of developing PE in future pregnancies. Women who have PE in a first 
pregnancy are seven to ten times more likely to develop PE in a second pregnancy 
(Campbell et al., 1985; Sibai et al., 1986; Lie et al., 1998; Lee et al., 2000; Mostello 
et al., 2002; Duckitt and Harrington, 2005), whilst women with PE in their second 
pregnancy are also seven times more likely to have had a history of PE in their first 
pregnancy than women in their second pregnancy who do not develop PE (Eskenazi 
et al., 1991; Stone et al., 1994).  
 
There are varying reports in the literature with regard to quantifying such recurrence 
risks. In an individual patient data meta-analysis examining the recurrence of 
hypertensive disorders in pregnancy, the authors reported their results based on data 
from 94 studies including more than 99,000 pregnancies. The recurrence rate for all 
hypertensive disorders for pregnancy was 20.7% and in particular was 13.8% for PE 
and 8.6% for GH. The authors further reported that there was an inverse relationship 
between the gestational age at delivery in the first pregnancy and the risk of PE in a 
subsequent pregnancy (van Oostwaard et al., 2015).    
 
There are studies which provide results separately for early onset and late onset PE 
and it was demonstrated that previous history of PE increases twice as much the risk 
for early-PE (< 32 weeks) as opposed to late-PE (Odegard et al., 2000). There are other 
studies reporting their results on the recurrence risk for a subsequent early-PE (< 34 
weeks) given a previous history of early onset-PE in the index pregnancy but the 
recurrence risks range from 5 to 17% (van Rijn et al., 2006; Langenveld et al., 2010). 
In a systematic review examining the risks of early delivery at < 34 weeks following 





early-onset PE in an index pregnancy, the authors reported results from 11 studies 
including 2377 women and found that the pooled recurrence risk for recurrence of 
early disease is in the region of 8%. (Langenveld et al., 2011). 
 
Assisted reproductive technologies 
 
There are several studies which report that use of ART double the risk for PE (Maman 
et al., 1998; Jackson et al., 2004; Shevell et al., 2005; Lambert-Messerlian et al., 2006; 
Trogstad et al., 2009). It is unclear whether either IVF and ovulation induction equally 
influence the risk of PE or they have different contributions. In a large observational 
study, the authors showed that it is IVF but not ovulation induction that increases the 
risk for PE (Shevell et al., 2005) and one smaller case-control study reported that both 
techniques increase the likelihood of developing hypertension in pregnancy (Maman 
et al., 1998). In a conflicting report form another study, the authors reported that it is 
ovulation induction rather than IVF that increases the risk of PE by 2-fold (Trogstad 
et al., 2009). 
 
In a large prospective observational cohort study, the authors examined more than 
40,000 pregnancies including 634 that conceived after IVF and 682 that conceived 
following ovulation induction and reported that the risk of PE was significantly 
increased in those conceived following IVF but not ovulation induction. The 
unadjusted odds ratio for risk of PE was 1.76. They further reported that when the risk 
was examined separately for early and late PE, after adjusting for maternal 
characteristics, there was a significant increase in the risk for early-PE (OR 3.28) but 
not for late-PE. These results raise the possibility that IVF, independent of maternal 
characteristics, somehow contributes to the process of impaired trophoblastic 
proliferation that is a hallmark of early and severe disease (Chaveeva et al., 2011).  
 
In another cohort study of 47,088 pregnancies following assisted reproductive 
technology, the authors reported that the risk of PE was higher in IVF pregnancies 
compared to those conceived spontaneously and in addition, the risk was higher in 





frozen-thawed cycles compare to fresh cycle pregnancies (Opdahl et al., 2015). 
Similarly, when the risk of PE was compared between women having autologous 
ovum IVG with those having donor oocyte IVF, there was an increased risk in those 
that had the donor IVF (Simeone et al., 2016). There is some evidence from IVF 
pregnancies with ovum donation that there is impaired autophagy of extravillous 
trophoblast and immunological changes in decidua basalis which may induce 
impairment in spiral artery remodelling and contribute to subsequent development of 
PE (Nakabayashi et al., 2015). This was supported from a systematic review of 19 
studies including more than 86,000 pregnancies which reported that the risk of PE is 
higher in oocyte donation IVF cycles compared to other methods of assisted 




Obesity is an important risk factor for developing PE. The results from many of the 
previously published studies, which treated BMI as a binary variable showed an 
overall doubling to quadrupling of the risk of PE with an increase in pre-pregnancy or 
booking BMI (Eskenazi et al., 1991; Stone et al., 1994; Mittendorf et al., 1996; Conde-
Agudelo and Belizán, 2000; Mostello et al., 2002; Duckitt and Harrington, 2005). In a 
Norwegian population-based study, the authors reported that a high pre-pregnancy 
BMI is not an independent risk factor for early-PE but it increases the risk of late-PE 
by two-fold (Odegard et al., 2000). 
 
In a large prospective observational cohort study of more than 45,000 singleton 
pregnancies examining the association of maternal BMI with pregnancy 
complications, the authors reported that the risk of PE increased with increasing 
maternal BMI in spite of adjustment for other maternal characteristics known to be 
associated with risk of PE. Although the risk for total PE was increased but univariate 
analysis demonstrated a higher risk for late disease compared to early disease 
(Syngelaki et al., 2011a). In another cohort study examining the association between 
maternal BMI and risk of severe PE, the authors reported that there was no significant 





difference between the 4 BMI categories with regard to risk of severe PE but in those 
that are overweight, obese or morbidly obese, the risk of severe late-onset PE is 
increased (Durst et al., 2015). 
 
The mechanisms linking obesity with increased risk of PE may be explained by effect 
of metabolic factors in obese mothers which impact on various stages of pathogenesis 
of PE such as cytotrophoblast migration and placental ischaemia, release of soluble 
factors in maternal circulation and impact on endothelial cell dysfunction (Spradley et 
al., 2015). There is direct and indirect evidence from studies to suggest that obesity 
related metabolic factors may lead to impaired spiral artery remodelling.  
 
There are studies reporting that the maternal serum level of PlGF examined in early 
second trimester is lower in obese pregnant women compared to their lean counterparts 
(Ghosh et al., 2013). This is consistent with observations that obese women have 
reduced placental vascularity characterized by villi having large diameters and low 
numbers of capillaries (Dubova et al., 2011). Similarly, there is evidence that maternal 
serum levels of sFlt-1 and leptin in an obese hypertensive pregnancy were greater than 
those in obese normotensive pregnancy in early and late pregnancy (Mise et al., 1998; 
Hendler et al., 2005; Masuyama et al., 2012; Straughen et al., 2013).  
 
Another biomarker for obesity that is altered in pregnancies with PE is adiponectin. 
There is evidence that maternal serum levels of adiponectin in the first trimester are 
significantly higher in women who subsequently develop early-PE than in women who 
develop late-PE or those who remain normotensive. The authors report that 
adiponectin levels are however not related to biophysical and biomarker of impaired 
placentation such as uterine artery PI and serum PAPP-A and these altered levels may 












There is considerable evidence in the literature which suggests that ethnic or racial 
origin is an important predictor of PE. One small series (Eskenazi et al., 1991) has 
demonstrated that African race is associated with a 12-fold increase in the risk of PE 
while larger studies have reported a 20-50% increase in the risk (Mittendorf et al., 
1996; Sibai et al., 1997; Knuist et al.,1998; Mostello et al.,2002; Caughey et al., 2005). 
 
The risk for PE is higher not only in women of Afro-Caribbean Race but also women 
of South Asian racial origin. These differences in risks for PE are also supported by 
evidence from metabolic profile of non-pregnant women which suggests susceptibility 
to cardiovascular disease. In both Afro-Caribbean and South Asian women, the risk 
for chronic hypertension and cardiovascular disease is increased but in particular, 
Afro-Caribbean women are more prone to stroke and renal failure whereas South 
Asian women are more at high risk of coronary heart disease (Cappuccio 1997a; 
Cappuccio et al., 1997b; Ramraj and Chellapa 2008). Another retrospective cohort 
study including 67,746 pregnancies examining the risk of developing PE reported that 
in East Asian women of Chinese descent the risk of PE is significantly lower compared 
to Caucasian women and the possible factors associated with this may be difference in 
BMI and lifestyle factors such as length of cohabitation with partner (Xiao et al., 
2014). Similar findings were also reported in Hispanic women where the risk for PE 
among Hispanic-black women was significantly increased compared to non-Hispanic 
White women (Ghosh et al., 2014). 
 
In a large prospective observational cohort study of more than 79,000 singleton 
pregnancies examining the association of maternal racial origin with pregnancy 
outcomes, the authors reported that the risk of PE was significantly higher in women 
of Afro-Caribbean and South Asian racial origin compared to Caucasian women. This 
increase in risk remained significant even after adjusting for other maternal 
characteristics known to be associated with a risk for PE. In fact, after chronic 





hypertension, Afro-Caribbean race was the second highest risk factor associated with 
risk for developing PE with an OR of 2.60 (Khalil et al., 2013b).  
 
Family history of preeclampsia 
 
The risk of PE is also shown to be increased by a factor of 3-4 times when there is a 
history of PE in the family i.e. mother or sister (Arngrimsson et al., 1990; Cincotta and 
Brennecke, 1998). In a study investigating the risk of PE in 94 families spanning over 
at least 3 generations, the authors reported that the prevalence of PE is higher in in 
daughters-in-law (23% vs 10%) (Arngrimsson et al., 1990). There are other reports 
which have also reported that a family history of PE in a mother, sister or both triples 




There is evidence from case-control and observational studies that in women who 
smoke, the risk of PE is lower (Conde-Agudelo et al., 1999). In a systematic review 
of 28 cohort and 7 case-control studies including more than 800,000 women, the 
authors reported that cigarette smoking in pregnancy is associated with an overall 30% 
reduction in the risk of PE (Conde-Agudelo et al., 1999). There was an inverse dose-
response relationship with the risk for PE decreasing as the number of cigarettes 
smoked increased. Similarly, a meta-analysis of 9 cohort studies reported that smokers 
of less than 10 cigarettes per day and 10 or more cigarettes per day had 20% and 30% 
reductions respectively in the risk of PE.  
 
Pre-existing medical conditions 
 
There are some medical conditions that predispose a mother to developing PE. These 
include a history of type I diabetes mellitus, chronic hypertension, renal disease, 
autoimmune diseases and anti-phospholipid syndrome. These reported risks for PE in 
cohort and case-control studies were analysed in a systematic review by Duckitt and 





Harrington (2005) and they reported summary relative risks for PE given these pre-
existing medical conditions (Table 1.5).  
 
Diabetes mellitus 
The likelihood of PE is more than triple if type I diabetes is mellitus present before 
pregnancy (Garner et al., 1990; Ros et al., 1998; Lee et al., 2000). 
 
Chronic hypertension 
Pre-existing hypertension has been shown to double the risk for PE, after controlling 
for other maternal characteristics, (Conde-Agudelo et al., 2000). 
 
Table 1.5. Relative risks of pre-existing medical conditions for the development of 





N RR (95% CI) 
Type 1 diabetes mellitus Cohort 56,968 3.56 (2.54-4.99) 
Hypertension  
Systolic  > 130 mm Hg vs 
< 130 mm Hg at booking 
Cohort 906 2.37 (1.78-3.15) 
Diastolic  > 80 mm Hg vs 
< 80 mm Hg at booking 
Cohort 907 1.38 (1.01-1.87) 




760 6.12 (0.35-108.35) 
 
RR = relative risk; CI = confidence interval 
 
Autoimmune disease  
A matched case-control study by Stamilio et al. (2000) has found that women who 
developed PE were six times more likely to have an autoimmune disease. The presence 
of antiphospholipid antibodies (anti-cardiolipin antibodies or lupus anticoagulant or 
both) has been observed to significantly increase the risk of developing PE in both 





cohort and case-control studies (Branch et al., 1989; Sletnes et al., 1992; Pattison et 
al., 1993; Yasuda et al., 1995; Dreyfus et al., 2001). 
 
1.4.3 Biophysical markers 
 
Uterine artery Doppler 
 
The examination of impedance to flow in the uterine arteries has been shown to 
correlate with not only histological studies but also clinical severity of PE. There is 
evidence from studies that suggest that screening based on uterine artery Doppler in 
not only the second but also the first trimester of pregnancy is effective.  
 
Doppler ultrasound provides a non-invasive method for the assessment of the 
uteroplacental circulation. Several studies using colour Doppler imaging of the distal 
branches of uterine arteries demonstrate a significant decrease in resistance in the 
spiral arteries with advancing gestation during the first-trimester which is in keeping 
with physiological changes (Carbillon et al., 2001).  There is an initial fall in the 
impedance to flow until 24-26 weeks of gestation due to the effects of trophoblastic 
invasion of the spiral arteries and their conversion from narrow muscular vessels to 
low resistance wide non-muscular channels (Campbell et al., 1983). The continuing 
fall in impedance may be due to hormonal effect in pregnancy on the elasticity of 
arterial walls.  
 
The observation of abnormal uteroplacental flow velocity waveforms, as a result of 
persistent high impedance to flow in the uterine arteries, constitutes indirect evidence 
of abnormal placentation. Previous histological findings from placental bed biopsies 
of pregnancies affected by PE have shown good correlation with high resistance in 
uterine artery Doppler waveforms (Olofsson et al., 1993). Cross-sectional studies in 
pregnancies with PE have shown that impedance to flow in the uterine arteries is 
increased due to an inability to convert maternal placental arteries into low resistance 
vessels (Aardema et al., 2001). 






Second-trimester uterine artery Doppler 
 
The assessment of uterine artery has evolved from a blind technique, using continuous 
wave Doppler (Hanretty et al., 1989) to real-time ultrasound in order to positively 
identify the vessels (Bower et al., 1993a,b). The correct vessel is identified using 
pulsed wave Doppler and distinguishes uterine artery blood flow from adjacent high 
resistance internal iliac vessels and lower resistance arcuate arteries. The use of colour 
flow along with pulsed wave Doppler makes it easier to identify the vessels of interest 




Figure 1.3. Transabdominal technique in obtaining uterine artery waveform at the 
crossover with iliac artery. 
 
 
Transabdominally, the uterine artery can be identified by holding the transducer in the 
longitudinal axis and lateral to the uterus. In that position the scan shows the 
bifurcation of the common iliac artery into external and internal iliac arteries and there 
is apparent cross-over of the uterine artery and the external iliac artery (Figure 1.3).  





Transvaginally, the ultrasound probe is placed into the lateral fornices and the uterine 
artery is identified at the level of the internal cervical os (Figure 1.4). The Doppler gate 










Figure 1.5.  Pulsed wave signals of uterine artery blood flow (a) normal waveform: 
note the systolic unslope is less steep with an abundance of end-diastolic flow velocity 
(arrow); (b) abnormal waveform suggesting impaired placentation: note the steep 
systolic upslope with an early diastolic notch (yellow arrow) and reduced end-diastolic 
flow velocity (white arrow). 





The pulsed Doppler is applied to obtain flow velocity waveform and when 3 consistent 
waveforms are obtained, the image is frozen and the pulsatility indices are obtained by 
automatically or manually tracing these waveforms.  
 
The indices derived from the flow velocity waveforms are described below. The 
possible range of the resistance index is between 0 and 1 and that of the pulsatility 
index is greater than 0.  
 
Resistance index = (Peak systolic velocity - minimum diastolic velocity) 
                                Peak systolic velocity 
 
Pulsatility index = (Peak systolic velocity - minimum diastolic velocity) 
             Mean velocity 
 
The normal waveform of uterine artery at 22-23 weeks’ gestation where the 
placentation is complete, the systolic upslope is less steep, with an abundance of 
diastolic flow velocity (Figure 1.5). In contrast, the high resistance waveform is 
characterised by steep systolic upslope with an early diastolic notch and reduced end 
diastolic flow velocity (Figure 1.5). Albaiges et al. (2003) compared velocity and 
impedance indices irrespective of notch status in a high-risk population defined by an 
increased uterine artery impedance > 95th centile or the presence of bilateral notches 
at a follow-up assessment from 24 weeks of gestation. The study concluded that uterine 
artery mean impedance indices perform better than velocity indices in the prediction 
of adverse pregnancy outcomes irrespective of notch status. Quantitative uterine artery 
indices provide a more objective method of calculating individual risk for adverse 
outcome and remove the subjectivity of an operator-dependent assessment of a notch. 
 
Some studies further examined the association of abnormal Doppler findings with the 
severity of PE and they have shown that uterine artery Doppler is better in predicting 
more severe disease. Harrington et al. (1996) have found that bilateral notching at 24 
weeks of gestation identified 55% of women who later developed PE and 81% with 





PE requiring delivery before 35 weeks of gestation. Similarly, Kurdi et al. (1998) have 
found that bilateral notches and a mean resistance index of greater than 0.55 identified 
62% of women who later developed PE and 88% with PE requiring delivery before 37 
weeks while Albaiges et al. (2000) have shown that the detection rates of increased PI 
or bilateral notches in predicting all PE and early onset PE (delivery before 34 weeks) 
were 45% and 90%, respectively. 
 
First trimester uterine artery Doppler 
 
There is evidence from studies conducted in the 1990s that there is a good correlation 
between first and second trimester uterine artery Doppler measurements. The 
hypothesis for these studies was that since the trophoblastic proliferation starts in the 
first trimester then the development of uteroplacental circulation in the second 
trimester is not a random event but a consequence of events in first trimester. These 
studies initially demonstrated that the impedance to flow in the uterine arteries 
increases with gestational age from 10 to 22 weeks and that the impedance to flow in 
uteroplacental circulation in second trimester depends on values in first trimester 
(Jurkovic et al., 1991; Kaminipetros et al., 1991). The feasibility, methodology and 
reproducibility of first trimester uterine artery Doppler measurements has been 
reported more than a decade ago (Martin et al., 2001).  
 
As with other biomarkers, the values of uterine artery Doppler should be adjusted for 
characteristics that affect the measurements in unaffected pregnancies. These 
relationships were examined in a study of more than 6,500 pregnancies in which the 
authors reported that uterine artery PI decreased with gestational age and maternal 
BMI and was higher in women of Afro-caribbean racial origin, in nulliparous women 
and in those parous women with a previous history of PE (Plasencia et al., 2007). The 
studies examining the value of screening for PE by combination of maternal factors 
and uterine artery Doppler demonstrated that effective screening can be provided for 
PE, in particular early-PE, at a DR of about 80% for a FPR of 10% (Plasencia et al., 
2007; Poon et al., 2009b). The relationship between first and second trimester uterine 
artery Dopplers and the change in PI between two trimesters in prediction of PI was 





examined in a study of 3,107 pregnancies and the authors reported that the decrease in 
impedance to flow in uterine arteries between 12 and 23 weeks is steeper in 
pregnancies with a normal outcome than in those developing PE and therefore the rate 
of change in uterine artery PI between the two trimesters improves the performance of 
screening and this information can be used to follow-up women with high PI at 12 




The mainstay of early detection, prediction and diagnosis of hypertension in pregnancy 
is accurate measurement of BP. There is considerable evidence from studies 
suggesting that raised BP in women destined to develop PE can be observed as early 
as in the first-trimester of pregnancy (Moutquin et al., 1985; Higgins et al., 1997; Poon 
et al., 2008 and 2011a). The limitation of using booking BP for early prediction of PE 
is that it is difficult to distinguish undiagnosed pre-existing hypertension from those 
without as the booking measurement may the first health screen performed in young 
women. This limitation makes one-off BP assessment a difficult screening tool for PE 
in retrospective studies. Careful prospective evaluation of booking BP using 
standardised measurements may be of value.  
 
A systematic review examined the value of using BP to predict PE using data from 
more than 60,000 women including 3,300 cases with PE and concluded that MAP is 
significantly better at predicting PE than systolic or diastolic BP but regardless, the 
measurement of BP is not useful in prediction of PE (Cnossen et al., 2008). However, 
there was considerable heterogeneity between studies in this review with major 
differences in study design, sample size, differences in use of machines used to 
measure BP, mixture of high-risk and low-risk populations and major differences in 
the DR between studies.  
 
In a large prospective screening study of more than 9,000 pregnancies at 11-13 weeks’ 
gestation, the authors examined the performance of systolic BP, diastolic BP and MAP 





in screening for hypertensive disorders of pregnancy using validated automated 
devices. They reported that although systolic BP, diastolic BP and MAP were all 
increased in women who subsequently developed PE. The best performance of 
screening was provided by MAP and the DR of early-PE at a FPR of 10% increased 
from 47% based on maternal factors alone to 76% based on a combination of maternal 
factors and MAP (Poon et al., 2011a). 
 
Accurate measurement of MAP requires the adherence to a strict protocol (Poon et al., 
2012). First, the women should be in the sitting position with their arms supported at 
the level of the heart, second, a small (22 cm), normal (22 to 32 cm) or large (33 to 42 
cm) adult cuff should be used depending on the mid-arm circumference, third, 
validated automated devices should be used, fourth, after rest for five minutes, two 
recordings of blood pressure should be made in both arms simultaneously and the final 
MAP calculated as the average of all four measurements.  
 
 
1.4.4 Biochemical markers 
 
A large number of biochemical markers have been put forward for the prediction of 
PE. Many such markers represent measurable manifestations of impaired placentation 
due to inadequate trophoblastic invasion of the maternal spiral arteries. The reduced 
placental perfusion is though to lead to placental ischaemia with consequent release of 
inflammatory factors, platelet activation, endothelial dysfunction, maternal renal 
dysfunction or abnormal oxidative stress. The majority of studies have examined these 
markers during established disease and in the second trimester. 
 
In biochemical testing it is necessary to make adjustments in the measured maternal 
serum metabolite concentration to correct for certain maternal and pregnancy 
characteristics as well as the machine and reagents used for the assays and is then 
expressed in a multiple of the expected median (MoM) of the normal (Kagan et al., 
2008a).  






Pregnancy associated plasma protein-A 
 
Maternal serum pregnancy associated plasma protein-A (PAPP-A) is a well-
established biochemical marker for the effective screening for trisomies 21, 18 and 13 
in combination with maternal age, fetal nuchal translucency thickness (NT) and 
maternal serum free ß-human chorionic gonadotrohpin (ß-hCG) at 11-13 weeks of 
gestation. All three trisomies are associated with increased maternal age, increased 
fetal NT and decreased maternal serum PAPP-A, but in trisomy 21 serum free ß-hCG 
is increased whereas in trisomies 18 and 13 this is decreased. In unaffected pregnancies 
the median free ß-hCG and PAPP-A is 1.0 MoM.  In trisomy 21 pregnancies the 
median free ß-hCG is 2.0 MoM and the median PAPP-A is 0.5 MoM whereas in 
trisomy 18 the respective values are 0.2 MoM and 0.2 MoM and in trisomy 13 they 
are 0.5 MoM and 0.3 MoM (Kagan et al., 2008b, Nicolaides, 2011). 
 
However, measurement of PAPP-A is not an effective method of screening for PE 
because only 8-23% of affected cases have serum levels below the 5th centile, which 
is about 0.4 MoM. Nevertheless, in the management of individual patients found 
coincidentally during first-trimester screening for trisomies to have a low levels of 
PAPP-A, their obstetrician should be aware of the increased risk for PE.  At the 5th 
centile of normal for PAPP-A the reported odds ratios for PE varied between 1.5 and 
4.6. Although a low PAPP-A in itself is not a strong indicator of PE, it has shown a 
significant improvement in detection by combining first-trimester PAPP-A 
measurement with second-trimester uterine artery Doppler velocimetry (Spencer et al., 
2005, 2007). This had led to the recommendation that the observation of a low first-
trimester PAPP-A MoM in euploid pregnancies should be followed up further with 
22- 24 weeks Doppler measurement to assess the risk of PE. 
 
In established disease, there are reports suggesting that the maternal serum PAPP-A 
level is increased (Bersinger et al., 2003; Bersinger and Odegard, 2004; Deveci et al., 
2009). In chromosomally normal pregnancies there is evidence that low maternal 





serum PAPP-A in the first- and second-trimesters is associated with increased risk for 
subsequent development of PE (Table 1.6).  
 
Table 1.6. Summary of studies of pregnancy associated plasma protein-A in the 




Screening for preeclampsia 
N (%) 





Ong et al., 2000 5,297 135 (2.6) 5th centile (-) 11.1 2.1 
Yaron et al., 2002 1,622 27 (1.7) 15th centile (0.50) 22.2 1.7 
Smith et al., 2002 8,839 331 (3.7) 5th centile (-) 10.6 2.3 
Dugoff et al., 2004 33,395 764 (2.3) 5th centile (0.42) 7.9 1.5 
Spencer et al., 2005 4,390 64 (1.5) 5th centile (0.42) 14.1 2.8 
Pilalis et al., 2007 878 13 (1.5) 5th centile (0.41) 23.1 4.6 
Spencer et al., 2007 47,770 222 (0.5) 5th centile (0.42) 14.6 3.7 
 
PAPP-A = pregnancy associated plasma protein-A; MoM = multiple of median; DR = 
detection rate; OR = odds ratio; RR = relative risk. 
 
 
PAPP-A is a syncytiotrophoblast-derived metalloproteinase which enhances the 
mitogenic function of the insulin-like growth factors by cleaving the complex formed 
between such growth factors and their binding proteins (Bonno et al., 1994; Lawrence 
et al., 1999). The insulin-like growth factor system is believed to play an important 
role in placental growth and development, it is therefore not surprising that low serum 
PAPP-A is associated with a higher incidence of PE. 
 
Placental growth factor 
 
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor 
(VEGF) sub-family. It is a glycosylated dimeric glycoprotein and it binds to VEGF 
receptor-1 to facilitate its actions on angiogenesis. PlGF is synthesised in villous and 
extravillous cytotrophoblast and has both vasculogenetic and angiogenetic functions. 
It is believed to contribute a change in angiogenesis from a branching to a non-





branching phenotype controlling the expansion of the capillary network. Its 
angiogenetic abilities have been speculated to play a role in normal pregnancy and 
changes in the levels of PlGF or its inhibitory receptor have been implicated in the 
development of PE (Maynard et al., 2003; Ahmad and Ahmed, 2004; Levine et al., 
2004; Stepan et al., 2007a). PE is associated with reduced placental production of PlGF 
and several studies reported that during the clinical phase of PE the maternal serum 
PlGF concentration is reduced (Table 1.7).   
 
Table 1.7. Studies comparing maternal serum concentration of placental growth factor 











Studies during established preeclampsia 
Torry et al., 1998 36 30 40.7 30 132.6 <0.0001 
Reuvekamp et al., 1999 34 28 54.1 28 497.9 < 0.0001 
Livingston et al., 2001 37 22 125.2 22 449 0.003 
Taylor et al., 2003 35 31 75.6 31 308 0.001 




































Teixiera et al., 2008 33-35 32 30 9 490 =0.0001 
 
* Early onset preeclampsia, † Late onset preeclampsia 
 
There is also evidence that reduced levels of serum PLGF are apparent during the 
second and even first trimester of pregnancy and several weeks before the clinical 
onset of the disease (Table 1.8). 
 
Previous studies demonstrated that prediction of PE can be improved by combining 
the second-trimester uterine artery Doppler findings with maternal serum 
concentration of PlGF (Espinoza et al., 2007) and the anti-angiogenic protein soluble 
fms-like tyrosine kinase 1 (sFlt-1; Stepan et al., 2007). Although in pregnancies 





developing PE reduced levels of PlGF are evident from the first-trimester, significant 
increase in levels of sFlt-1 become apparent only about five weeks before the onset of 
PE (Levine et al., 2004). The authors examined serum levels of PlGF at various time 
points in pregnancy beginning from as early as first trimester to the development of 
PE. The PlGF concentrations steadily increased with gestational age, with levels 
peaking at 29-32 weeks’ gestation and decreasing thereafter. In women with PE, the 
levels follow a similar pattern but were significantly lower than in controls from as 
early as 12-13 weeks of gestation (Levine et al., 2004). 
 
Table 1.8. Studies comparing maternal serum concentration of placental growth factor 










Studies in second-trimester before onset of preeclampsia 












Livingston et al., 2001 11-20 22 98.8 22 56.3 NS 

















Pollioti et al., 2003 16-19 20 61.3 60 122.4 <0.001 
Krauss et al., 2004 22-29 44 286 177 441 0.024 





















Studies in first-trimester before onset of preeclampsia 
Tidwell et al., 2001 5-15 14 20.1 25 58.5 <0.0001 





Thadani et al., 2004 11-14 40 23 80 63 <0.01 
Smith et al., 2007 11-14 309  937   











* Early onset preeclampsia, † Late onset preeclampsia 
 






Placental protein 13 
 
Placental protein 13 (PP13) is a 32-kDa dimer protein and a member of a group of 
proteins that are highly expressed in the placenta (Than et al., 1999, 2004). It is 
believed that it has a role in placental implantation and maternal artery remodelling 
(Burger et al., 2004). Early studies suggest that maternal serum level of PP13 during  
the first-trimester is lower in women with PE requiring early delivery, compared to the 
level of PP13 in normotensive pregnancies (Nicolaides et al., 2006; Chafetz et al., 
2007; Spencer et al., 2007; Romero et al., 2008b; Huppertz et al., 2008; Gonen et al., 
2008; Khalil et al., 2009). There is evidence from studies in the first-trimester of 
pregnancy that the maternal serum concentration of PP13 is reduced in women who 
subsequently develop PE (Table 1.9). However, the number of PE cases in these 
studies varied from 4 to 88, and the reported levels of PP13 in PE cases ranged from 
0.07 MoM to 0.69 MoM. 
 
 
Table 1.9 Studies reporting on the association between maternal serum placental 













Nicolaides et al., 2006  11-14 10 0.07 423 1.00 < 0.001 
Chafetz et al., 2007 9-12 47 0.20 290 1.00 < 0.01 
Spencer et al., 2007 11-14 88 0.69 446 1.00 < 0.001 
Romero et al., 2008a 8-13 50 0.59 250 1.00 < 0.001 
Huppertz et al., 2008 5-10 4 0.12 41 1.00 <0.005 
Gonen et al., 2008 6-10 20 0.30 1178 1.01 <0.001 
Khalil et al., 2009 11-14 42 0.40 210 1.00 < 0.001 
 
GA= gestational age; MoM=Multiple of the unaffected median 
 
 








Inhibin A is a dimeric glycoprotein hormone produced by many tissues but in normal 
pregnancy the main source of circulating inhibin A is the placenta (Florio et al., 2001; 
Muttukrishna et al., 1997a; Petraglia, 1997). Several studies have reported that in 
patients with established PE there is a 1.5- to 8.5-fold increase in the maternal plasma 
inhibin A concentration (Muttukrishna et al., 1997b; Silver et al., 1999; Gratacos et 
al., 2000; Zeeman et al., 2002; Florio et al., 2002; Bersinger et al., 2003; Hanisch et 
al., 2004; Hamar et al., 2006; Paiwattananupant and Phupong, 2008) (Table 1.9). 
There is also evidence that increased levels of inhibin A precede the clinical onset of 
PE and may be evident from the first trimester of pregnancy (Cuckle et al., 1998; Raty 
et al., 1999; Sebire et al., 2000; Grobman and Wang, 2000; D’Anna et al., 2002; 
Davidson et al., 2003; Florio et al., 2003; Ay et al., 2005; Wald et al., 2006; Spencer 
et al., 2006; Kim et al., 2006; Zwahlen et al., 2007; Kang et al., 2008; Spencer et al., 
2008a) (Table 1.10). 
 
The exact function of inhibin A in pregnancy is uncertain but there is evidence that 
inhibin A has autocrine and paracrine roles in the placenta thereby affecting 
trophoblastic function (Muttukrishna et al., 1997b; Petraglia, 1997). The mechanism 
of increased maternal plasma levels of inhibin A in pregnancies destined to develop 
PE is uncertain. Immunohistochemical studies have localized inhibin A to the 
syncytiotrophoblast layer (McCluggage et al., 1998) and it was postulated that the 
increased plasma levels in PE may be the consequence of reactive hyperplasia of the 
cytotrophoblast cells leading to increased production or due to functional alterations 
in syncytiotrophoblast giving rise to increased leakage of placental proteins into the 
maternal circulation (Aquilina et al., 1999). There is evidence that in established PE 
the increased plasma levels may be secondary to increased placental m-RNA 
production (Silver et al., 2002). In contrast, in vitro studies demonstrated that in 
placental explants low oxygen tension and hypoxia down regulate the expression of 
the inhibin A gene (Manuelpillai et al., 2003). 







Table 1.10 Studies reporting on the association between maternal serum inhibin A 







n Inhibin A  n Inhibin A 
During preeclampsia  
       
Muttukrishna et al., 1997b 25-33 20 3.05 ng/mL† 20 0.36 ng/mL <0.001 
Silver et al., 1999 25-42 60 2.6 MoM 60 1.00 MoM <0.0001 
Gratacos et al., 2000 30-37 20 2.18 ng/mL† 60 0.50 ng/mL <0.001 
Keelan et al., 2002 30-38 22 15.1 ng/mL‡ 22 5.3 ng/mL <0.001 
Zeeman et al., 2002 34-40 77 1806.3 pg/ml‡ 83 936.0 pg/ml <0.001 
Florio et al., 2002 25-38 21 2.46 MoM 42 1.00 MoM <0.001 
Bersinger et al., 2003 25-39 19 3080 pg/mL† 19 1510 pg/mL <0.01 
Hanisch et al., 2004 29-35 21 1325.5 pg/ml† 11 346.1 pg/ml <0.05 
Hamar et al., 2006 26-38 31 1863.7 pg/ml† 16 572.6 pg/ml <0.05 
Paiwattananupant et al., 2008 33-39 30 1229.7 pg/ml† 30 839.1 pg/ml <0.01 
       
Before preeclampsia  
       
Cuckle et al., 1998 13 –18 28 2.01 MoM 701 1.00 MoM <0.001 
Raty et al., 1999 12-20 22 1.09 U/ml† 7 0.85 U/ml NS 
Sebire et al., 2000 10-14 9 233 pg/ml‡ 759 167 pg/ml <0.05 
Grobman et al., 2000 14 –28 12 700.0 pg/mL† 24 613.0 pg/mL NS 
D’Anna et al., 2002 15-18 20 1.43 MoM 40 1.03 MoM NS 
Davidson et al., 2003 15-20 39 206 pg/ml‡ 155 188 pg/mL NS 
Florio et al., 2003 24 18 131.2 pg/ml† 40 91.9 pg/ml <0.05 
Ay et al., 2005 16-18 14 3.36 MoM 164 0.99 MoM <0.001 
Wald et al., 2006 15-20 96 1.39 MoM 480 1.00 MoM <0.05 
Spencer et al., 2006 22-24 24 2.03 MoM 144 1.05 MoM <0.001 
Kim et al., 2006 14-23 40 414 pg/ml‡ 80 280 pg/ml <0.001 
Zwahlen et al., 2007 11-13 52 0.46 mg/ml‡ 104 0.28 mg/ml <0.05 
Kang et al., 2008 10-21 32 1.73 MoM 3044 1.00 MoM <0.001 
Spencer et al., 2008 11-14 64 1.24 MoM 240 1.00 MoM <0.001 
 
† = mean values, ‡ = median values, MoM = multiple of median 








Similar to inhibin A, activin A is a glycoprotein hormone produced by many tissues 
but in normal pregnancy the main source is the placenta (Florio et al., 2001; 
Muttukrishna et al., 1997a; Petraglia, 1997). Several studies have reported that in 
patients with PE there is a 2- to 9-fold increase in the maternal serum activin A 
concentration (Petraglia et al., 1995; Muttukrishna et al., 1997b; Silver et al., 1999; 
D’Antona et al., 2000; Yair et al., 2001; Manuelpillai et al., 2003; Keelan et al., 2002; 
Florio et al., 2002; Bersinger et al., 2003; Diesch et al., 2006). There is also evidence 
that increased levels of activin A precede the clinical onset of PE and may be evident 
from the first-trimester of pregnancy (Grobman and Wang, 2000; Davidson et al., 
2003; Florio et al., 2003; Ong et al., 2004; Ay et al., 2005; Madazli et al., 2005; 
Spencer et al., 2006; Banzola et al., 2007; Spencer et al., 2008a).  
 
The role of activin A in the pathogenesis of PE is uncertain. However, there is evidence 
that activin A promotes trophoblastic invasion in early pregnancy (Bearfield et al., 
2005), and the reported increased maternal serum activin A level in patients with PE 
may reflect a placental compensatory mechanism to promote trophoblastic invasion in 
cases where this process is impaired (Muttukrishna et al., 2006). Secretion of activin 
A by cytotrophoblasts in vitro is stimulated by the pro-inflammatory cytokine TNF 
(Mohan et al., 2001). There is also evidence that in addition to the placenta another 
source for the increased circulating activin A levels in PE are peripheral mononuclear 
cells and endothelium activated by pro-inflammatory cytokines such as TNF- 
(Tannetta et al., 2003). 
 
Previous studies reporting the maternal serum levels of Activin A in women with 
established PE reported contradictory results (Table 1.11). Studies examining the 
potential performance of serum Activin A in screening for PE are limited to second 
trimester of pregnancy. 
 






Table 1.11. Studies reporting on the association between maternal serum activin A 
concentration and preeclampsia. 
 
 
Author Gestation (w) 
Preeclampsia Controls 
P value 
n Activin A n Activin A 
During preeclampsia  
       
Petraglia et al., 1997 29.0 (25-34) 16 57.4 10 9.2 <0.01 
Muttukrishna et al., 1997b 29.2 (25-33) 20 38.1 20 4.0 <0.001 
Silver et al., 1999 35.5 (25-42) 60 3.0* 60 1.0* <0.0001 
D’Antona et al., 2000 32.0 (26-39) 16 4.6 38 1.0* <0.001 
Yair et al., 2001 36.3 (32-40) 20 445.7 20 133.1 <0.0001 
Manuelpillai et al., 2001 34.0 (29-40) 23 3.5* 62 1.0* <0.0001 
Keelan et al., 2002 34.9 (30-38) 22 33.4 22 8.0 <0.001 
Florio et al., 2002 31.0 (25-38) 21 2.1* 42 1.0 * <0.001 
Bersinger et al., 2003 31.6 (25-39) 19 32.4 19 3.8 <0.001 
Diesch et al., 2006 35.0 (29 -41) 34 12.1 44 7.1 <0.001 
       
Before preeclampsia  
       
Grobman et al., 2000 21.7 (14 –28) 12 11.3 24 11.1 NS 
Davidson et al., 2003 16.6 (15-20) 39 1.6 155 1.4 NS 
Florio et al., 2003 24 18 2.7 40 1.8 <0.05 
Ong et al., 2004 12.0 (11-13) 
13
1 
1.5* 494 1.0* <0.001 
Ay et al., 2005 17.0 (16-18) 14 12.3* 164 1.0* <0.001 
Madazli et al., 2005 23.6 (21-26) 14 26.5 108 8.6 <0.001 
Spencer et al., 2006 23.0 (22-24) 24 2.1* 144 1.0* <0.001 
Banzola et al.,  2007 13.2 (11-15) 56 1.8* 168 1.0* <0.001 
Spencer et al., 2008a 12.0 (11-13) 64 1.2* 240 1.0* <0.05 
 
All values are in ng/mL unless indicated * = multiple of the median (MoM) 








P-selectin is an adhesion molecule found in platelets. In inflammatory and 
thrombogenic conditions, the molecule is expressed on the cell membrane and initiates 
interactions between endothelial cells leukocytes and platelets (Stenberg et al., 1985; 
Larsen et al., 1989; Johnston et al., 1990; Hamburger et al., 1990; Geng et al., 1990). 
Platelet activation occurs in normal pregnancy (Holmes et al., 2002; Gerbasi et al., 
1990), but this is exaggerated in PE which is characterised by platelet aggregation, 
vasoconstriction and endothelial injury (Nisell et al., 1998; McCarthy et al., 1993; 
Whigham, 1978; Holthe et al., 2004; Norris et al., 1994). The maternal plasma 
concentration of P-selectin, a marker for platelet activation, is increased during 
established PE and there is also evidence that this elevation may be evident from the 
first-trimester of pregnancy (Halim et al., 1996; Heyl et al., 1999; Aksoy et al., 2002; 
Chaiworapongsa et al., 2002; Chavarria et al., 2008; Banzola et al., 2007; Bosio et al., 
2001) (Table 1.12). 
 
Table 1.12 Studies reporting on the association between maternal plasma or serum P-








n P-selectin n P-selectin 
During preeclampsia 
Halim et al., 1996 33-40 30 901.3 ng/ml 10 174 ng/ml <0.001 
Heyl et al., 1999 26-40 38 3.26 ng/ml 20 3.99 ng/ml NS 
Aksoy et al., 2000 28-36 28 28.2 ng/mL 65 18.9 ng/mL <0.001 
Chaiworapongsa et al, 2002 23-40 55 119.5 ng/ml 100 92.6 ng/ml <0.001 
Chavarria et al., 2008 32-40 75 101.0 ng/ml 125 80.0 ng/ml <0.05 
       
Before preeclampsia 
Banzola et al., 2007 11-15 56 2.49 MoM 168 1.00 MoM <0.001 
Bosio et al., 2001 10-14 20 85.5 ng/ml 26 31.6 ng/ml  <0.001 
Chavarria et al., 2008 20 75 91.2 ng/ml 125 82.5 ng/ml  <0.05 
  








Innate defence mechanisms against pathogens and damaged tissues consist of a 
cellular and a humoral arm. Pentraxins (PTX), a superfamily of proteins highly 
conserved during evolution, are an essential component of the humoral immune system 
(Garlanda et al., 2005). There are two types of PTXs. The short ones, such as C-
reactive proteins, which are produced by the liver and the long ones, such as PTX3, 
which is expressed by many cells including vascular endothelial cells, monocytes, 
macrophages and fibroblasts (Garlanda et al., 2005). Plasma levels of PTX3 are 
increased in shock, sepsis and vascular disorders such as myocardial infarction and 
small vessel vasculitis (Muller et al., 2001; Peri et al., 2000; Fazzini et al., 2001). A 
suggested role for PTX3 is binding to dying or apoptotic cells and their constituents, 
thereby limiting their immunogenicity and reducing the risk of autoimmunity (Rovere 
et al., 2000; Baruah et al., 2006; Manfredi et al., 2008). Apoptosis is a normal event 
during pregnancy (Huppertz and Kingdom, 2004; Smith et al., 1997b) and PTX3 may 
play a role in preventing maternal alloimmunisation against the fetus (Rovere-Querini 
et al., 2006). Two studies have reported that in patients with PE, there is a six to nine-
fold increase in maternal plasma levels of PTX3 (Rovere-Querini et al., 2006; Cetin et 
al., 2006). 
 
Plasminogen activator inhibitor-2 
 
Plasminogen activators (PA) and plasminogen activator inhibitors (PAIs) are proteins 
which are crucial for maintaining hemostatic balance by preventing the deposition of 
excess fibrin. Fibrinolysis is activated by conversion of plasminogen to plasmin which 
depends on an intricate balance between PA and PAIs. There are two major types of 
PAIs, the PAI-1 which is primarily synthesized by endothelial cells and PAI-2 which 
is mainly produced by the trophoblast and found only in the plasma of pregnant women 
(Asted et al., 1986; Kruithof et al., 1995; Norris 2003; Bremme 2003).  Longitudinal 
studies in pregnant women reported that the maternal plasma concentration of PAI-2 





increases with gestational age until term and then declines to undetectable levels six 
weeks after delivery (Kruithof et al., 1987; Halligan et al., 1994; Coolman et al., 
2006). 
 
There is evidence that established PE is associated with activation of platelets and 
coagulation cascade with up-regulation of intravascular coagulation (O’Riordan and 
Higgins 2003). This increase in fibrin and thrombus deposition is accompanied by 
reduced levels of PAI-2 in maternal blood (Table 1.13). The possible explanation for 
these reduced levels in maternal circulation is due to decreased production by a 
hypoxic placenta. There is some suggestion that in addition to its role in the 
coagulation cascade, PAI-2 is involved in trophoblastic invasion and therefore may 
play a role in the pathogenesis of PE (Asted et al., 1998; Clausen et al., 2002).  
 
Table 1.13. Studies reporting on the association between maternal plasma 














Estelles et al.,., 1989 28-40 13 186.3 24 269.3 <0.05 
Reith et al., 1993 29-39 11 105.3 11 187.1 <0.001 
Koh et al., 1993 25-38 14 58.4 14 105.2 <0.001 
Halligan et al., 1994 33-40 12 48.5 32 183.5 <0.001 
Lindoff et al., 1994 34-40 36 172.1 40 212.0 NS 
He et al., 1995 30-35 19 74.0* 22 156.0* <0.05 
Nakashima et al., 1996 28-40 18 96.7 22 169.7 <0.001 
Schjetlein et al., 1999 24-42 200 120.0* 97 158.0* <0.0005 
Roes et al., 2002 30-33 42 51.0* 18 80.0* <0.01 
Tanjung et al., 2005 31-40 40 146.8 27 219.5 <0.01 
Sartori et al., 2008 31-36 35 36.9 68 62.8 <0.01 
Before preeclampsia 
Halligan et al., 1994 9-16 4 13.3 32 20.5 NS 
Clausen et al., 2002 17-19 71 78.8* 71 67.6* 0.002 
 
The values of PAI-2 are mean except those indicated by * which are medians 







Angiopoietins are angiogenic proteins produced by the villous trophoblast and they 
are thought to play an important role in placental vascular development (Charnock-
Jones et al., 2004; Seval et al., 2008). There are three stages in the vascular 
development of the placenta; firstly, vasculogenesis which refers to formation of a 
primitive vascular network from endothelial progenitor cells, secondly, branching 
angiogenesis and thirdly, non-branching angiogenesis both of which involve the 
formation of new blood vessels from already existing ones (Geva et al., 2002; 
Yancopoulos et al., 2000; Carmeliet et al., 2000). The angiopoietins act on the second 
and third stages: angiopoietin-1 (Ang-1) causes endothelial maturation and vascular 
stabilization, whereas angiopoietin-2 (Ang-2) acts as an antagonist of Ang-1 thereby 
leading to further angiogenesis (Zhang et al., 2001; Suri et al., 1996; Maisonpierre et 
al., 1997).  
 
There is evidence from studies that in women with PE the serum levels of Ang-2 are 
significantly lower than in controls (Hirokoshi et al., 2005; Nadar et al., 2005) but it 
is uncertain whether the reduced levels of this protein in PE is a consequence of the 
disease or whether the decrease precedes the clinical onset of PE and is a reflection of 
the involvement of this growth factor in the pathogenesis of the disease. 
 
Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 
 
VEGF is a pro-angiogenic protein released by many cell types including the 
cytotrophoblast and it is involved in promoting angiogenesis and vasculogenesis. The 
VEGF protein is transcribed from the VEGF gene which is located on chromosome 6, 
which also encodes for various isoforms of VEGF including placental growth factor 
(PlGF) (Romero et al., 2008b; Cheng et al., 2013). These angiogenic factors exert their 
role in endothelial cells by mediating increased vascular permeability, which includes 
angiogenesis, vasculogenesis and growth of endothelial cells (Yamazaki et al., 2006; 
Maharaj et al., 2008). The soluble form of VEGF receptor-1 (VEGFR-1) (sFlt-1) is 





primarily produced by the syncytiotrophoblast and is produced by alternative splicing 
of the Flt-1 gene which results in a truncated protein which cannot bind to PlGF or 
VEGF inside the cells but attaches to the transmembrane receptors thus acting as an 
antagonist to of PlGF and VEGF and preventing these angiogenic factors from 
interacting with their receptors (Maynard et al 2003; Levine et al., 2004; Romero et 
al., 2008b; Tache et al., 2011).  The sFlt-1 exerts anti-angiogenic effects by inhibiting 
biological activity of VEGF and PlGF (Kendall and Thomas, 1993). VEGF is 
important for maintaining endothelial function in fenestrated endothelium especially 
and in brain, liver and renal glomeruli (Esser et al., 1998). The higher levels of sFlt-1 
also counteract vasodilatory effects of nitric oxide induced by VEGF thereby leading 
to hypertension (Maynard et al., 2003). In addition, sFlt-1 can induce proteinuria by 
blocking effects of VEGF (Eremina et al., 2003). In pregnancies with PE the maternal 
plasma or serum concentration of free-VEGF and PlGF is decreased whereas the 
concentration of sFlt-1 is increased (Tables 1.14 and 1.15). 
 
Table 1.14. Studies reporting the median maternal circulating free vascular endothelial 
growth factor (VEGF) concentration (pg/mL) in patients during or before 







n VEGF n VEGF 
During preeclampsia 
Lyall et al., 1997 26-40 34 2.3 34 12.9 <0.001 
Reuvekamp et al., 1999 28-40 30 0.3* 30 18.3* <0.001 
Livingston et al., 2000 27-40 21 6.4* 21 18.7* <0.001 
Maynard et al., 2003 29-40 21 4.1 11 14.0 <0.05 
Levine et al., 2004 37-41 21 6.7 26 9.9 <0.05 
Muy-Rivera et al., 2005 35-39 131 10.9 175 13.6 NS 
Buhimschi et al., 2006 23-40 42 0.1 13 1.6 <0.001 
Lee et al., 2007 29-40 20 21.3 20 134.0 <0.001 
Before preeclampsia 
Polliotti et al., 2003 14-21 20 2.6 60 6.0 <0.001 
Levine et al., 2004 21-32 6 5.1 102 12.8 <0.05 
 
Values in * indicate mean values 
 





Table 1.15 Studies reporting the median maternal plasma soluble fms-like tyrosine 
kinase-1 (sFlt-1) concentration (pg/mL) in patients during or before preeclampsia 








n sFlt-1 n sFlt-1 
During preeclampsia 
Tsatsaris et al., 2003 30-38 19 2690 31 120 <0.001 
Levine et al., 2004 29-41 23 4382 23 1643 <0.001 
Staff et al., 2005 24-40 32 9932 38 3417 <0.001 
Shibata et al., 2005 28-40 22 5221 24 1857 <0.001 
Buhimschi et al., 2006 23-40 42 2026 13 434 <0.001 
Masuyama et al., 2007 33-40 30 5666* 30 1204* <0.01 
Stepan et al., 2007a 20-37 18 8388 15 2602 <0.01 
Salahuddin et al., 2007 28-40 19 74700* 20 16600* <0.01 
Lee et al., 2007 29-40 20 1935* 20 298* <0.001 
De Vivo et al., 2008 31-40 52 44870 52 12560 <0.001 
Woolcock et al., 2008 25-41 18 3130 18 470 <0.001 
Kim et al., 2009 23-40 62 2755* 62 554* <0.001 
Reddy et al., 2009 37-41 10 10100 10 4900 <0.05 
       
Before preeclampsia 
Levine et al., 2004 8-12 21  20  NS 
Thadani et al., 2004 7-12 40 1048 80 973 NS 
Park et al., 2005 16-23 32 730 128 441 <0.05 
Kim et al., 2007 14-23 46 3861 100 2353 <0.001 
Rana et al., 2007 11-13 39 3500* 147 3000* NS 
Vatten et al., 2007 4-12 154 135* 392 166* <0.01 
Erez et al., 2008 6-15 56 1405 201 1788 <0.05 
Baumann et al., 2008 11-13 46 1764* 92 1537* <0.05 
Lim et al., 2008 14-21 40 4945* 100 2788* <0.001 
 
Values in * indicate mean values 
 
 





There are studies reporting that maternal serum concentrations of sFlt-1 is altered in 
PE and that this precedes the clinical onset of the disease (Table 1.14). However, there 
is contradictory evidence concerning first-trimester maternal circulating levels of sFlt-
1 in pregnancies that subsequently develop PE with some studies reporting an increase 
(Baumann et al., 2008) and others a decrease (Erez et al., 2008; Vatten et al., 2007) or 
no difference (Levine et al., 2004; Rana et al., 2007; Thadani et al., 2004) from normal. 
The maternal circulating levels of free-VEGF are also decreased prior to the clinical 
onset of PE (Levine et al., 2004; Polliotti et al., 2003) but there are no reports 




Another anti-angiogenic factor implicated in the pathogenesis of PE is soluble 
endoglin (sEng), a surface receptor of transforming growth factor-β1 (TGF- β1), which 
induces growth and proliferation of endothelial cells (Venkatesha et al., 2006). The 
sEng protein has anti-angiogenic properties since it prevents binding of TGF- β1 to its 
receptors on endothelial cells this compromising its function and leading to 
impairment in production of nitric oxide (Levine et al., 2006). There is evidence from 
animal studies that increased expression of sEng in mice leads to increased vascular 
permeability and hypertension. In combination with sFlt-1, the increased levels of 
sEng lead to severe vascular damage, nephrotic syndrome, proteinuria and growth 
restriction (Venkatesha et al., 2006).  
 
Several studies have reported that in women with established clinical disease, the 
concentration of sEng in maternal blood is increased (Table 1.16). However, there is 
contradictory evidence whether this increase precedes the clinical onset of disease or 
is merely a manifestation of disease rather than a cause and whether these alterations 
are detectable from first trimester of pregnancy (Rana et al., 2007; Erez et al., 2008; 
Bauman et al., 2008; Lim et al., 2009). 
 
 





Table 1.16. Studies reporting on the association between maternal plasma soluble 







n sEng n sEng 
During preeclampsia 
Stepan et al., 2007 20-37 18 57.1 15 5.3 <0.001 
Masuyama et al., 20071 33-40 30 60.9 30 11.2 <0.01 
Jeyabalan et al., 2008 34-39 10 39.1 10 17.5 0.001 
De Vivo et al., 2008 31-40 52 28.2* 52 14.8* <0.01 
Kim et al., 2009 28-40 62 74.5 62 17.2 <0.0001 
Reddy et al., 2009 35-41 10 188.0* 10 52.2* <0.0001 
       
Before preeclampsia 
Rana et al., 2007 17-20 39 6.4 147 5.2 <0.01 
Rana et al., 2007 11-14 39 6.9 147 6.6 NS 
De Vivo et al., 2008 24-28 52 14.6* 52 9.1* <0.001 
Erez et al., 2008 21-24 56 7.1* 201 5.9* <0.05 
Erez et al., 2008 9-14 56 7.7* 201 7.2* NS 
Baumann et al., 2008 11-14 46 5.5 92 4.8 <0.01 
Lim et al., 2009 14-19 60 10.5 124 3.9 <0.001 
 




1.5 PREVENTION OF PREECLAMPSIA 
 
The term ‘primary prevention’ describes preventing the occurrence of a disease.  The 
identification and manipulation of recognised risk factors might allow primary 
prevention. PE is a multi-system disorder of complex aetiology. There are several 
agents that have been used in an effort to prevent the disease and reduce its incidence 
such as dietary supplementation and pharmacological treatment aimed at interfering 
with the mechanisms that cause vasoconstriction, loss of vascular pressor 
refractoriness, platelet and endothelial activation and reduction of perfusion in PE. 
 







The hypothesis linking the use of calcium for prevention of PE comes from 
observations and studies reporting that women who had a high calcium intake in their 
diet had a lower incidence of PE (Hamlin 1962; Belizan et al., 1988; Villar et al., 
1993). In the prevention of PE this is the most extensively researched dietary 
supplement. Low calcium intake may cause high BP by stimulating either parathyroid 
hormone or renin release, thereby increasing intracellular calcium in vascular smooth 
muscle and leading to vasoconstriction, hence high BP (Belizan et al., 1988). Calcium 
supplementation may reduce parathyroid hormone release and intracellular calcium 
thus reducing smooth muscle contractility.  There is some evidence suggesting that 
calcium supplementation affects utero-placental blood flow by lowering the resistance 
in uterine and umbilical vasculature (Caroli et al., 2010). 
 
A recent systematic review of randomised controlled trials comparing calcium 
administration vs placebo in preventing the occurrence of PE examined data from 14 
studies including 15,730 women and reported that calcium supplementation of > 
1g/day was associated with a reduction in risk of PE (RR 0.45, 95% CI 0.31 to 0.65), 
particularly for women with low-calcium diets (RR 0.36, 95% CI 0.20 to 0.65). 
However, the authors commented that these data should be interpreted with caution as 
there was a possibility of small-study effect or publication bias. This was also evident 
from the significant amount of heterogeneity between studies with I2 values of between 
70-80%. This limited evidence needs to be confirmed in larger, good quality trials 




There is evidence from both animal and human studies which support a role for folic 
acid in prevention of PE (Wen et al., 2008a and 2008b). The proposed mechanisms to 
explain the beneficial effect of folic acid in PE include a direct role in placental growth 
and development, through the effect of folic acid on lowering blood homocysteine 





levels and lastly through the effect of folic acid in improving endothelial function. 
Hyperhomocysteinemia is a risk factor for PE and it is hypothesized that folic acid 
may have a role in prevention by reducing the levels of homocysteine (Lindblad et al., 
2005; Guven et al., 2009). In addition, increased levels of homocysteine are suggested 
to lead to endothelial activation and folic acid may mitigate this endothelial 
dysfunction thereby contributing to preventing the development of PE (Powers et al., 
1998).  
 
There is data from 4 retrospective cohort studies which examined the effect of folic 
acid in prevention of PE which suggest that regular use of folic acid supplementation 
reduces the risk of PE (Hernandez-Diaz et al., 2002; Bodnar et al., 2006; Wen et al., 
2008a; Catov et al., 2009). There are two other studies which failed to find a protective 
effect of folic acid supplementation (Timmermans et al., 2011; Li et al., 2013). Based 
on these data, a systematic review reported that the OR for reduction in risk of PE as 
being 0.14 (95% CI = 0.06–0.31), showing a strong protective effect of folic acid 
supplementation (Wen et al., 2013). An RCT is being carried out to examine the 
effectiveness of folic acid in a study entitled, The Effect of Folic Acid Supplementation 
in Pregnancy on Preeclampsia: the Folic Acid Clinical Trial (FACT) aims to recruit 
3,656 high risk women to evaluate a new prevention strategy for PE: supplementation 
of folic acid throughout pregnancy. Pregnant women with increased risk of developing 
PE presenting to a trial participating center between 8 and 16 weeks of gestation will 
be randomized in a 1:1 ratio to folic acid 4.0 mg or placebo (Wen et al., 2013).  
 
1.5.3 Anti-oxidants  
 
There is evidence linking oxidative stress in the pathophysiology of PE and therefore, 
there have been studies which have examined whether administration of anti-oxidants, 
which reduce the production of ROS and thereby oxidative stress, can be useful in 
prevention of PE (Vaughan and Walsh, 2002). Anti-oxidants are important in 
maintaining cellular integrity in normal pregnancy by inhibiting peroxidation reactions 
and thus protecting enzymes, proteins and cells from destruction by peroxides 





(Rumbold et al., 2006). The studies that have investigated the role of anti-oxidants in 
the prevention of PE have mostly involved the use of vitamins C and E. Vitamin C 
(ascorbic acid) scavenges free radicals in the aqueous phase, and the lipid soluble 
vitamin E (-tocopherol) acts in vivo to prevent the formation of lipid peroxides and 
thus, protect cell membranes (Rumbold et al., 2006). The use of vitamin supplements 
may reduce oxidative stress by preventing endothelial damage and the subsequent 
development of PE. In a recent meta-analysis of seven studies including 5,969 women, 
the authors concluded that concomitant supplementation with vitamins C and E does 
not prevent PE in women at risk (pooled RR: 0.79; 95% CI 0.58-1.08), but does 
increase the rate of babies born with a low birth weight (pooled RR: 1.13; 95% CI of 
1.00-1.27) (Rahmi et al., 2009). 
 
There are some reports suggesting that the use of magnesium supplements in 
pregnancy can potentially reduce the incidence of PE. (Conradt et al., 1984). However, 
a Cochrane review of two randomised trials (474 patients) showed no apparent effect 
of magnesium treatment on the risk of PE or GH (Makrides and Crowther, 2001). 
Another anti-oxidant, which has been investigated in regard to prevention of PE is 
Zinc, which is an essential trace element required in many metabolic pathways. There 
appears to be a decrease in maternal and umbilical plasma zinc concentrations in PE 
when compared to normal pregnancy (Bassiouni et al., 1979). It has been suggested 
that this is due to zinc and oestrogen competing for common binding sites on plasma 
proteins (Adeniyi, 1987). Bassiouni et al. (1979) suggested that low plasma zinc 
concentrations in PE may be a sign of zinc deficiency and recommended maintenance 
of adequate dietary zinc nutrition during pregnancy. However, two randomised 
controlled trials involving 1,288 patients failed to show any significant benefit 




There has been interest in the use of low molecular weight heparin (LMWH) alone or 
in combination with an anti-platelet drug for prevention of hypertensive disorders in 





pregnancy especially in women with known thrombophilic tendencies or a previous 
history of PE, but trials had been too small for reliable conclusions (Duley et al., 
2006a; 2006b; Walker et al., 2006). There is however accumulating evidence, albeit 
based on smaller studies, for a role for LMWH as a potential pharmacological therapy 
for preventing PE. Two systematic reviews summarizing the published literature 
concluded that heparin significantly reduces the recurrence of PE and was associated 
with reductions in perinatal mortality, preterm birth, and infant birth weight <10th 
percentile in high-risk women (Dodd et al., 2013; Rodger et al., 2014). There is limited 
evidence from a meta-analysis suggesting that use of LMWH in addition to aspirin in 
women with a history of PE compared to aspirin alone was associated with a 
significant reduction in PE (RR 0.54, 95% CI 0.31 to 0.92) (Roberge et al., 2015). 
 
Although, the exact mechanism underlying the potential benefit of using LMWH in 
preventing PE is not known but it may be attributable to an anti-coagulant action of 
heparin within the placenta although none of the studies examining the role of LMWH 
included placental examination as part of the study methods or protocols. An 
alternative explanation is that LMWH exerts direct vascular actions in the maternal 
compartment to reverse the placenta-mediated systemic vascular dysfunction 
characteristic of PE (McLaughlin et al., 2015). LMWH also significantly lowered 
systolic and diastolic blood pressure and reduced resistance indices in the uterine 
arteries, suggesting that LMWH can potentially ‘normalize’ maternal blood pressure 
and uteroplacental blood flow (Mello et al., 2005). There is some evidence for a 
potential role of LMWH in prevent development of severe PE in high-risk women but 
large high quality RCTs are necessary to substantiate the results of smaller studies and 




The majority of interest and evidence in prevention of PE is based on use of Aspirin 
(acetylsalicylic acid). There have been studies reporting the potential for Aspririn in 
prevention of PE since the 80s. The basis for recommending low dose aspirin in the 





prevention of PE is that Aspirin through its actions on prostaglandin pathways 
modifies the imbalance between thromboxane A2 and prostacyclin, which is altered in 
PE and contributes to the vasospasm and coagulation abnormalities. Wallenburg et al., 
(1991) proposed that in normal pregnancy the levels of prostacyclin increase, therefore 
causing a reduced maternal response to angiotensin II and other vasopressors and by 
extension a reduction in systemic vascular resistance. In PE, eicosanoid synthesis is 
greatly altered with relatively low prostacyclin levels, high thromboxane A2 levels and 
a low prostacyclin to thromboxane A2 ratio in the maternal and fetal circulation. This 
imbalance causes the pressor effects of angiotensin II and catecholamines to be 
ineffectively opposed, resulting in the clinical syndrome of PE (Chavarria et al., 2003). 
Low dose aspirin treatment in pregnancy inhibits biosynthesis of platelet thromboxane 
A2 with little effect on vascular prostacyclin production, thus altering the balance of 
the prostacyclin and preventing development of PE (Sibai et al., 2005). 
 
The enzyme cyclo-oxygenase plays a central role in the production of both 
prostacyclin and thromboxane A2. Aspirin inhibits endothelial cyclo-oxygenase 
(Dekker and Sibai, 2001) and this process is irreversible in platelets, where the enzyme 
is inhibited for their entire life-span. In contrast, the enzyme is re-synthesised in 
endothelial cells and prostacyclin production is re-established relatively rapidly. This 
selective inhibition of cyclo-oxygenase and the resulting alteration in the prostacyclin 
to thromboxane A2 ratio in the placenta forms the basis of using aspirin to prevent or 
delay the onset of PE.  
 
There are early reports suggesting that low dose aspirin in high-risk women does 
reduce the prevalence of fetal growth restriction and PE (Beaufils et al., 1985; 
Wallenburg et al., 1986). However, a series of subsequent large randomised studies 
showed no effect in preventing these complications (Italian Study of Aspirin in 
Pregnancy, 1993; CLASP Collaborative Group, 1994). A meta-analysis by Duley et 
al., (2001) assessed the effectiveness and safety of anti-platelet drugs (mainly aspirin) 
for the prevention of PE. This study, which examined more than 30,000 women from 
39 trials, concluded that the use of an anti-platelet agent was associated with a 15% 





reduction in the risk of PE (32 trials; 29,331 women; pooled RR 0.85) with an 8% 
reduction in the risk of preterm birth before 37 weeks and a 14% reduction in the risk 
of fetal or neonatal for women allocated to low dose aspirin. The PARIS (Perinatal 
Antiplatelet Review of International Studies) collaborative group (2005) meta-
analysed individual patient data from 32,217 women from 31 randomised trials of anti-
platelets for the prevention of PE. The relative risk of developing PE, of delivering 
before 34 weeks and of having a pregnancy with a serious adverse outcome was 0.90. 
There was no significant effect on the risk of death of the fetus or baby, having a small 
for gestational age infant or bleeding events for either the women or their babies. Thus 
the findings were similar to those of Duley et al. (2004) in that there was a moderate 
but consistent reduction in the relative risk of PE (Askie et al., 2007). 
 
A number of randomised studies have examined the value of prophylactic aspirin in 
women with increased impedance to flow in the uterine arteries. A meta-analysis 
examining nine randomised controlled trials with a total of 1,317 women, assessed the 
influence of gestational age at the time of administration of low dose aspirin on the 
incidence of PE in women at increased risk, on the basis of abnormal uterine artery 
Doppler and demonstrated that aspirin treatment commenced in early gestation was 
associated with a greater reduction in the incidence of PE than treatment started in late 
gestation: < 16 weeks of gestation resulted in a RR of 0.48 (95% CI 0.33-0.68), at 17-
19 weeks RR 0.55 (95% CI 0.17-1.76), and at > 20 weeks RR 0.82 (95% CI 0.62-1.09) 
(Bujold et al., 2009).  
 
The authors further examined specifically the effect of early administration of aspirin 
before 16 weeks and reported that Aspirin was particularly effective in preventing 
early disease requiring delivery before term, rather than at term (RR 0.11, 95% CI 
0.04–0.33 vs RR 0.98, 95% CI 0.42–2.33) and in severe, rather than mild PE (RR 0.22, 
95% CI 0.08–0.57 vs RR 0.81, 95% CI 0.33–1.96) (Roberge et al., 2012a and 2012b). 
They also suggested that not only PE but there was a 50% reduction in risk of FGR 
and 60% reduction in risk of perinatal death if treatment was commenced before 16 
weeks rather than thereafter (Roberge et al., 2013; Bujold et al., 2014).  







1.6 OBJECTIVES OF THE THESIS 
 
 To examine the maternal serum or plasma levels of a series of biochemical 
markers thought to be involved in placentation or in the cascade of events leading 
from impaired placentation to the development of the clinical symptoms of the 
PE at 11-13 weeks’ gestation and determine which markers are significantly 
altered in women who subsequently develop PE 
 
 To examine the performance of screening for early, intermediate and late-PE by 
a combination of the a priori risk, derived from maternal factors, in combination 
with various biochemical markers and biophysical markers including uterine 
artery Doppler and MAP. 
 
 To investigate the performance of screening for PE based on a survival time 
model which treats gestation at delivery as a continuous variable and using Bayes 




                                       
 
   


























2.1 STUDY POPULATION 
 
This was a prospective screening study for hypertensive disorders in women attending 
their routine first hospital visit in pregnancy at King’s College Hospital, Medway 
Maritime Hospital and University College Hospital between March 2006 and 
September 2010. In this visit, which is held at 11+0-13+6 weeks’ gestation, all women 
have an ultrasound scan to confirm gestational age from the measurement of the fetal 
CRL, to diagnose any major fetal abnormalities and to measure fetal nuchal 
translucency (NT) thickness and maternal serum free ß-hCG and PAPP-A as part of 
screening for chromosomal abnormalities (Snijders et al., 1998; Kagan et al., 2008b).  
 
All women attending for this visit were invited to participate in the research study 
entitled ‘Early Prediction of Pregnancy Complications’, which was approved by the 
Ethics Committee (REC reference number: 02-03-033, R&D reference number: 
03WH06) (Section 2.2). We obtained a written informed consent from women 
agreeing to participate in the study and in these women we recorded maternal 
characteristics and medical history, measured the uterine artery pulsatility index (PI) 
by transabdominal colour Doppler and mean arterial pressure (MAP) by automated 
devices and stored plasma and serum at -80C for subsequent biochemical analysis. 
 
The inclusion criteria for this study were singleton pregnancies delivering a 
phenotypically normal livebirth or stillbirth at or after 24 weeks of gestation. We 
excluded pregnancies with major fetal abnormalities and those ending in termination, 
miscarriage or fetal death before 24 weeks.  
 
The studies presented in the following chapters are based on case-control studies 
investigating the biochemical markers for early prediction of PE (Chapter 3) and 
studies based on data collected as a part of the prospective screening study for 
hypertensive disorders (Chapter 4 and 5). 






2.1.1 Case-control studies 
 
The case-control studies involved measurement of maternal serum or plasma 
concentration of PLGF, Activin-A, Inhibin-A, PP13, P-selectin, Pentraxin-3, sEng, 
Plasminogen activator inhibitor-2, Angiopoietin-2 and soluble fms-like tyrosine 
kinase-1 at 11-13 weeks’ gestation in pregnancies complicated by PE and unaffected 
controls. These were nested case-control studies drawn from the larger prospective 
screening study on the basis of availability of stored samples from pregnancies that 
developed early and late-PE. Each case was matched with controls that had blood 
collected and stored on the same day and delivered a phenotypically normal neonate 
appropriate for gestational age at term and did not develop any pregnancy 
complications. None of the samples were previously thawed and refrozen. 
 
2.1.2  Screening studies 
 
Prediction of preeclampsia from maternal factors, biophysical and biochemical 
markers 
 
In the first screening study, described in Chapter 4, we prospectively screened 36,743 
singleton pregnancies. We excluded 3,141 cases because they had missing outcome 
data (n=2,005) or the pregnancies resulted in miscarriage, termination or the birth of 
babies with major defects (n=1,136). In the remaining 33,602 cases there were 752 
(2.2%) that developed PE and 32,850 that were unaffected by PE. 
 
The measurements of maternal serum PAPP-A were available in all cases. Uterine 
artery PI was available in 21,673 of the 32,850 pregnancies, including 583 (2.7%) that 
developed PE and MAP was available in 13,946 of the 32,850 pregnancies, including 
431 (3.0%) that developed PE. The maternal characteristics and history in each PE 
group and the unaffected pregnancies in the screening population and in the subgroups 

















(n=32,850) (n=112) (n=187) (n=453) 
Maternal age in years, median (IQR) 32.3 (27.9-36.0)  31.3 (25.7-36.2) 32.1 (28.1-36.8) 31.3 (27.2-36.3) 
Maternal weight in kg, median (IQR) 65.0 (59.0-75.0) 72.0 (63.0-85.0)* 70.0 (61.0-85.0)* 72.0 (63.3-85.0)* 
Fetal Crown-Rump Length in mm, median (IQR) 64.0 (59.2-69.5) 64.9 (58.1-72.1) 62.5 (57.4-68.2) 63.1 (58.9-69.4) 
Racial origin     
   Caucasian, n (%) 23,765 (72.3) 47 (42.0) 90 (48.1) 247 (54.5) 
   African, n (%) 6,051 (18.4) 53 (47.3)* 75 (40.1)* 165 (36.4)* 
   South Asian, n (%) 1,430 (4.4) 8 (7.1) 14 (7.5) 20 (4.4) 
   East Asian, n (%) 651 (2.0) 0 2 (1.1) 10 (2.2) 
   Mixed, n (%) 953 (2.9) 4 (3.6) 6 (3.2) 11 (2.4) 
Parity     
   Nulliparous, n (%) 15,698 (47.8) 65 (58.0) 104 (55.6) 291 (64.2)* 
   Parous with no previous preeclampsia, n (%) 16,196 (49.3) 27 (24.1)* 55 (29.4)* 105 (23.2)* 
   Parous with previous preeclampsia, n (%) 956 (2.9) 20 (17.9)* 28 (15.0)* 57 (12.6)* 
Cigarette smoker, n (%) 2,695 (8.2) 2 (1.8) 12 (6.4) 29 (6.4) 
Family history of preeclampsia, (n, %) 1,480 (4.5) 13 (11.6)* 17 (9.1)* 34 (7.5)* 
Conception     
   Spontaneous, n (%) 31,618 (96.2) 104 (92.9) 174 (93.0) 435 (96.0) 
   Assisted, n (%) 1,232 (3.8) 8 (7.1) 13 (7.0) 18 (4.0) 
History of chronic hypertension, n (%) 322 (1.0) 15 (13.4)* 18 (9.6)* 29 (6.4)* 
History of pre-existing diabetes, n (%) 245 (0.7) 3 (2.7) 8 (4.3)* 2 (0.4) 
 
Comparison between each outcome group and unaffected controls (χ2 - test and Fisher’s exact test for categorical variables and Mann-
Whitney test with post hoc Bonferroni correction for continuous variables): * Critical significance level p < 0.0167.  







































(n=21,090) (n=86) (n=143) (n=354) 
Maternal age in years, median (IQR) 32.1 (27.7 (35.9) 31.4 (25.5-36.4) 32.0 (28.0-36.8) 31.6 (27.3-36.4) 
Maternal weight in kg, median (IQR) 65.0 (59.0-75.0) 73.5 (63.0-85.0)* 70.0 (61.0-86.0)* 73.0 (64.0-86.0)* 
Fetal Crown-Rump Length in mm, median (IQR) 63.9 (58.9-69.3) 65.0 (57.9-71.4) 62.7 (57.0-69.0) 63.4 (58.9-69.9) 
Racial origin     
   Caucasian, n (%) 13,889 (65.9) 31 (36.0) 57 (39.9) 166 (46.9) 
   African, n (%) 5,164 (24.5) 43 (50.0)* 66 (46.2)* 157 (44.4)* 
   South Asian, n (%) 929 (4.4) 8 (9.3) 12 (8.4) 14 (4.0) 
   East Asian, n (%) 417 (2.0) 0 2 (1.4) 7 (2.0) 
   Mixed, n (%) 691 (3.3) 4 (4.7) 6 (4.2) 10 (2.8) 
Parity     
   Nulliparous, n (%) 10,221 (48.5) 46 (53.5) 76 (53.1) 220 (62.1)* 
   Parous with no previous preeclampsia, n (%) 10,276 (48.7) 21 (24.4)* 46 (32.2)* 83 (23.4)* 
   Parous with previous preeclampsia, n (%) 593 (2.8) 19 (22.1)* 21 (14.7)* 51 (14.4)* 
Cigarette smoker, n (%) 1,696 (8.0) 1 (1.2) 11 (7.7) 21 (5.9) 
Family history of preeclampsia, (n, %) 886 (4.2) 12 (14.0)* 14 (9.8)* 25 (7.1)* 
Conception     
   Spontaneous, n (%) 20,235 (95.9) 80 (93.0) 132 (92.3) 338 (95.5) 
   Assisted, n (%) 855 (4.1) 6 (7.0) 11 (7.7) 16 (4.5) 
History of chronic hypertension, n (%) 229 (1.1) 14 (16.3)* 13 (9.1)* 26 (7.3)* 
History of pre-existing diabetes, n (%) 158 (0.7) 3 (3.5) 6 (4.2)* 2 (0.6) 
 
Comparison between each outcome group and unaffected controls (χ2 - test and Fisher’s exact test for categorical variables and Mann-
Whitney test with post hoc Bonferroni correction for continuous variables): * Critical significance level p < 0.0167. 







































(n=13,515) (n=69) (n=111) (n=251) 
Maternal age in years, median (IQR) 32.1 (27.7-35.7) 30.1 (25.4-36.3) 32.4 (28.8-37.0) 31.7 (27.3-36.6) 
Maternal weight in kg, median (IQR) 65.0 (59.0-75.0) 75.0 (63.0-86.0)* 70.0 (61.0-85.0)* 74.0 (64.0-87.0)* 
Fetal Crown-Rump Length in mm, median (IQR) 63.3 (58.5-68.6) 63.5 (56.4-71.2) 62.0 (56.9-67.9) 62.1 (58.5-68.9) 
Racial origin     
   Caucasian, n (%) 8,925 (66.0) 24 (34.8) 48 (43.2) 123 (49.0) 
   African, n (%) 3,243 (24.0) 34 (49.3)* 46 (41.4)* 107 (42.6)* 
   South Asian, n (%) 618 (4.6) 7 (10.1) 10 (9.0) 10 (4.0) 
   East Asian, n (%) 253 (1.9) 0 1 (0.9) 4 (1.6) 
   Mixed, n (%) 476 (3.5) 4 (5.8) 6 (5.4) 7 (2.8) 
Parity     
   Nulliparous, n (%) 6,680 (49.0) 37 (53.6) 59 (53.2) 155 (61.8)* 
   Parous with no previous preeclampsia, n (%) 6,649 (47.9) 18 (26.1)* 36 (32.4)* 60 (23.9)* 
   Parous with previous preeclampsia, n (%) 366 (2.7) 14 (20.3)* 16 (14.4)* 36 (14.3)* 
Cigarette smoker, n (%) 1,110 (8.2) 1 (1.4) 8 (7.2) 17 (6.8) 
Family history of preeclampsia, (n, %) 551 (4.1) 10 (14.5)* 10 (9.0)* 19 (7.6)* 
Conception     
   Spontaneous, n (%) 13,073 (96.7) 64 (92.8) 103 (92.8) 237 (94.4) 
   Assisted, n (%) 442 (3.3) 5 (7.2) 8 (7.2) 14 (5.6) 
History of chronic hypertension, n (%) 143 (1.1) 12 (17.4)* 11 (9.9)* 18 (7.2)* 
History of pre-existing diabetes, n (%) 107 (0.8) 2 (2.9) 4 (3.6)* 2 (0.8) 
 
Comparison between each outcome group and unaffected controls (χ2 - test and Fisher’s exact test for categorical variables and Mann-
Whitney test with post hoc Bonferroni correction for continuous variables): * Critical significance level p < 0.0167.




























Competing risks model in early screening for PE by biophysical and biochemical 
markers 
 
In the second screening study, described in Chapter 5, we prospectively screened 
65,771 singleton pregnancies (Table 2.4). We excluded 6,887 cases because they had 
missing outcome data (n=2,133), the pregnancies resulted in miscarriage, termination 
or the birth of babies with major defects (n=1,586) or the birth of SGA neonates in the 
absence of PE (n=3,168). In the remaining 58,884 cases there were 1,426 (2.4%) that 
developed PE and 57,458 that were unaffected by PE.  
 
 







Maternal age in years, median (IQR) 31.3 (26.7-35.2) 31.2 (26.4-36.2) 
Maternal weight in kg, median (IQR) 65.0 (58.8-75.0) 72.0 (62.0-85.0)* 
Fetal CRL in mm, median (IQR) 63.4 (58.4-69.0) 62.9 (58.3-68.6) 
Racial origin   
   Caucasian, n (%) 47,025 (76.3) 865 (58.4) 
   Afro-Caribbean, n (%) 8,860 (14.4) 478 (32.3)* 
   South Asian, n (%) 2,872 (4.7) 81 (5.5) 
   East Asian, n (%) 1,415 (2.3) 26 (1.8) 
   Mixed, n (%) 1,434 (2.3) 32 (2.2) 
Parity   
   Nulliparous, n (%) 29,680 (48.2) 910 (61.4) 
   Parous with no previous PE, n (%) 30,343 (49.3) 373 (25.2)* 
   Parous with previous PE, n (%) 1,583 (2.6) 199 (13.4)* 
Cigarette smoker, n (%) 6,419 (10.4) 117 (7.9)* 
Family history of PE, (n, %) 2,512 (4.1) 126 (8.5)* 
Conception   
   Spontaneous, n (%) 59,351 (96.3) 1,400 (94.5) 
   Assisted, n (%) 2,255 (3.7) 82 (5.5)* 
History of chronic hypertension, n (%) 550 (0.9) 142 (9.6)* 
History of type 1 DM, n (%) 253 (0.4) 15 (1.0)* 
History of type 2 DM, n (%) 160 (0.3) 13 (0.9)* 
History of SLE or APS 106 (0.2) 7 (0.4)* 
  * Significance value p<0.05 
The measurements of maternal serum PAPP-A were available in all cases. Uterine 
artery PI was available in 45,885 of the 58,884 pregnancies, including 1,245 (2.7%) 
that developed PE, MAP was available in 35,215 of the 58,884 pregnancies, including 





979 (2.8%) that developed PE and serum PLGF was available in 14,252 of the 58,884 
pregnancies, including 385 (2.7%) that developed PE. 
 
In the PE group, compared to unaffected pregnancies, there was a higher mean 
maternal weight and prevalence of Afro-Caribbean racial origin, family and personal 
history of PE, chronic hypertension, diabetes mellitus and systemic lupus 
erythematosus or anti-phospholipid syndrome and a lower prevalence of cigarette 
smokers. 
 
2.2 ETHICAL COMMITTEE APPROVAL 
 
The study entitled Early Prediction of Pregnancy Complications, was approved by the 
King’s College Hospital Ethics Committee (Ref: 02-03-033, R & D reference number 
03WH06). The patients received an information leaflet outlining the details of the 
research study (Table 2.5) and a written informed consent (Table 2.6) was obtained 
from the women agreeing to participate in the study. 
 
2.3 BIOCHEMICAL MARKERS 
 
2.3.1 Placental growth factor 
 
Duplicate serum sample of 100 µl was used to measure PlGF concentration by a 
quantitative enzyme linked immunoassay (ELISA) technique using Quantikine® 
human PlGF immunoassay (R&D systems Europe Ltd., Abingdon, UK). The assays 
were performed on an automated ELISA processor (Dade-Behring BEP 2000, 
Liederbach, Germany). Absorbance readings were taken on a VICTOR3 plate reader 
(PerkinElmer Life and Analytical Sciences, Turku, Finland) and PlGF concentrations 
were determined using MultiCalc software (PerkinElmer Life and Analytical Sciences, 
Turku, Finland). The lower limit of detection of the assay was 7 pg/mL and the 
between-batch imprecision was 8.3% at a PlGF concentration of 48 pg/mL, 5.6% at 
342 pg/mL and 5.1% at 722 pg/mL. Samples whose coefficient of variation of the 
duplicates exceeded 15% were reanalysed. 






Table 2.5 Patient information sheet for the study. 
 
    
PATIENT INFORMATION SHEET 
 
Research Study: Early prediction of pregnancy complications 
 
 
We would like to invite you to take part in a research study. Before you decide 
whether to do so it is important for you to understand why the research is being 
done and what it will involve.  Please take time to read this leaflet. Ask us if there 
is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part. Thank you for reading this. 
 
What is the purpose of the study? 
 
We are looking for new ways through scientific research to improve the care of 
pregnant women and their unborn babies. As part of this work, we are inviting all 
women that attend for the 11-13 weeks scan to participate in a large study on 
preeclampsia (high blood pressure of pregnancy) and fetal growth restriction (poor 
fetal growth). 
 
Preeclampsia and fetal growth restriction are two important complications of 
pregnancy which can have serious implications for mother and baby. These 
problems can affect any pregnant woman, irrespective of previous healthy 
pregnancies and irrespective of how healthy the mother is. 
 
Our aim is to try and identify the women who are at high risk of developing these 
problems and to do so as early in pregnancy as possible. 
 
Why have I been chosen? 
 
All pregnant women attending for the 11-13 weeks scan are welcome to take part 
in this study.  
 
Do I have to take part? 
 
It is up to you to decide whether you would like to take part. If you decide to take 
part you will be given this information sheet to keep and will be asked to sign a 
consent form. Once you have decided to take part you are still free to withdraw at 
any time without giving any reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 






What will happen to me if I take part?  
 
The study consists of three components which are done at the time of the 11-13 
week scan: 
 
1. Maternal blood markers 
This involves us saving some of the blood that we take from you as part of the test 
to determine the risk for Down’s syndrome. Since new tests may become available 
in the future we feel it would be prudent to store some of your blood and urine 
sample for future studies. 
 
2. Measurement of blood flow from the mother to the placenta 
During your visit we will use ultrasound to examine your baby. We will also use 
ultrasound to look at the vessels that supply blood to the uterus and the placenta. 
This extra scan takes a couple of minutes to do. It is not uncomfortable and does 
not carry any risks to you or your baby. 
 
3. Blood pressure measurement 
During your visit we will measure your blood pressure. Usually this measurement 
is taken from your left arm. We are trying to find out if it is better to use the reading 
from the left or the right arm or the average one from both arms. We would take 
blood pressure measurements from both of your arms simultaneously.  
 
What are the possible benefits of taking part? 
If we find that you have high blood pressure we will arrange for any follow up tests 
and monitoring that would be necessary. This will have a direct benefit for you. In 
addition, the information we get from the study may help us to help you and/or 
other women in the future.   
 
What are the possible disadvantages and risks of taking part? 
The blood pressure measurement may also be uncomfortable because of the 
inflation of the cuffs. If you find this examination intolerable please let us know, 
we will stop immediately. 
 
Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept 
confidential.  
 
What if I want to complain? 
If you have a concern about any aspect of this study, you can ask to speak with one 
of the researchers who will do their best to answer your questions.  By agreeing to 
take part in the study you do not lose any legal rights.  If you remain unhappy and 
wish to complain formally, you can do this through the NHS Complaints Procedure.  
Details can be obtained from the hospital (Contact: Mr Tim Hiles on 0207 346 
3983).  






Table 2.6 Consent form for the study. 
 
 
              CONSENT FORM 
 
Research Study: Early prediction of pregnancy complications 
 
We are requesting your permission to participate in the research study that 
essentially involves the following: 
 
1. Maternal blood analysis 
2. Measurement of blood flow to the placenta 
3. Measurement of blood pressure 
We hope that you find it worthwhile to take part in this study. If you should decide 
to participate, please sign the consent below. We would ask you to sign three copies 
of this form, one for your own records, one for our research, and one for your 
medical notes. Thank you. 
 
1. I confirm that I have read and understand the information sheet for the 
above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary, and that I am free to 
withdraw at any time, without affecting my medical care or legal rights. 
 
 I agree / disagree to have a sample of my blood taken for current testing and 
storage for future tests 
 I agree / disagree to the measurement of flow in the uterine arteries 
 I agree / disagree to the measurement of my blood pressure. 
 
ID number: ………………………..Date: ………………………………… 
Patient's name: ……………………Patient’s signature: …………………… 




What will happen to the results of the research study? 
It is hoped that the results will be published in medical journals and perhaps also 
in the press. You may request a copy of any published documents in relation to 
the study. You will not be identified in any of these reports.  
 
Who is organising and funding the research?  
This research is carried out by the team of Professor Kypros Nicolaides and it is 
funded by the Fetal Medicine Foundation (Registered charity: 1037116).  
 






2.3.2  Activin-A 
 
Duplicate serum samples of 75µl were used to measure total Activin A concentration 
by a solid phase sandwich ELISA (Enzyme Linked Immunoadsorbent Assay) using 
Oxford Bio-Innovation total Activin A immunoassay kits (Oxford Bio-Innovation 
Limited, Oxfordshire, UK). The lower limit of detection of the assay was 0.078 ng/mL 
and the between-batch imprecision was 15.8% at Activin A concentration of 1.13 
ng/mL, 8.3% at 1.79 ng/mL and 12.3% at 3.85 ng/mL. All samples were analysed in 
duplicate and those with a coefficient of variation exceeding 15% were reanalysed.  
 
2.3.3  Inhibin-A 
 
Duplicate plasma samples of 50 µl were used to measure inhibin A concentration by a 
quantitative enzyme linked immunoassay (ELISA) technique using DSL-10-28100 
inhibin A immunoassay (Diagnostic systems laboratories, Inc. Webster, Texas, USA). 
The assays were performed on an automated ELISA processor (Dade-Behring BEP 
2000, Liederbach, Germany). Absorbance readings were taken on a VICTOR3 plate 
reader (PerkinElmer Life and Analytical Sciences, Turku, Finland) and inhibin-A 
concentrations were determined using MultiCalc software (PerkinElmer Life and 
Analytical Sciences, Turku, Finland). The lower limit of detection of the assay was 1.0 
pg/mL and the between-batch imprecision was 15.4% at an inhibin-A concentration of 
94.5 pg/mL and 8.2% at 361.0 pg/mL. All samples were analysed in duplicate and 
those with a coefficient of variation exceeding 10% were reanalysed. 
 
2.3.4 Placental protein-13 
 
DELFIA® (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) research 
reagents (Perkin Elmer Life and Analytical Sciences, Turku, Finland) were used to 
measure PP13 in maternal serum samples (25 µl/well in duplicate). The concentration 
of PP13 measured was directly proportional to the fluorescence measured on time-
resolved fluorometer at 615 nm. The coefficient of variation (CV) was 4.1% at a PP13 





concentration of 16.6 pg/ml, 2.0% at 60.4 pg/ml and 2.7% at 136.2 pg/ml. Samples 




Duplicate plasma sample of 100 µl was used to measure P-selectin concentration by a 
quantitative enzyme linked immunoassay (ELISA) technique using human soluble P-
selectin/CD62P immunoassay (R & D Systems Europe, Ltd., Abingdon, United 
kingdom). The assays were performed on an automated ELISA processor (Dade-
Behring BEP 2000, Liederbach, Germany). Absorbance readings were taken on a 
VICTOR3 plate reader (PerkinElmer Life and Analytical Sciences, Turku, Finland) 
and P-selectin concentrations were determined using MultiCalc software (PerkinElmer 
Life and Analytical Sciences, Turku, Finland). The lower limit of detection of the assay 
was 0.5 ng/mL and the between-batch coefficient of variation (CV) was 12.3% at a P-
selectin concentration of 383.0 ng/mL, 11.9% at 212.0 pg/mL and 14.9% at 21.3 ng/ml. 
All samples were analysed in duplicate and those with a coefficient of variation 




Duplicate plasma samples were analysed using a PTX3 enzyme-linked 
immunosorbent assay (ELISA) kit (R & D Systems Europe Ltd, Abingdon, United 
Kingdom). The assay was performed according to the manufacturer’s instructions. 
Sample pre-treatment was performed manually. The ELISA assay was performed on 
an automated ELISA processor (Dade-Behring BEP 2000, Liederbach, Germany). 
Substrate and Stop reagents were added manually. Absorbance readings were taken on 
a VICTOR3 plate reader (PerkinElmer Life and Analytical Sciences, Turku, Finland). 
The concentrations of PTX3 were determined using MultiCalc software (PerkinElmer 
Life and Analytical Sciences, Turku, Finland). The lower limit of detection of the assay 
was 0.025 ng/mL and the between-batch imprecision was 8.4% at PTX3 concentration 
of 0.9 ng/mL, 8.3% at 3.4 ng/mL and 5.6% at 9.0 ng/mL. All samples were analysed 





in duplicate and those with a large coefficient of variation (more than 20% for values 
of less than 1 ng/mL and more than 15% for values of 1 ng/mL or more) were 
reanalysed. 
 
2.3.7 Soluble endoglin 
 
Plasma sEng was measured by enzyme linked immunoassay (ELISA) technique using 
DuoSet® human sENG (R&D Systems Europe Ltd., Abington, UK) according to 
manufacturer’s instructions. The lower limit of detection of the assays was 5 pg/mL. 
Samples whose coefficient of variation of the duplicates exceeded 15% were 
reanalysed.  
 
2.3.8 Plasminogen Activator Inhibitor-2 
 
Maternal plasma samples diluted 1:10 were analysed in duplicate using a DELFIA® 
(Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) PAI-2 sandwich 
immunoassay using a monoclonal antibody and a goat polyclonal antibody against 
human PAI-2 (Omnio AB, Sweden). Assays were performed manually using a 2-step 
protocol. Fluorescence readings were measured on a VICTOR2D plate reader 
(PerkinElmer Life and Analytical Sciences, Turku, Finland). The concentrations of 
PAI-2 were determined using MultiCalc software (PerkinElmer Life and Analytical 
Sciences, Turku, Finland). The between-batch coefficient of variation was less than 
5% in all the samples analysed. The investigators were blinded to the pregnancy 




Duplicate serum samples of 50 µL were analysed using a DELFIA® (Dissociation-
Enhanced Lanthanide Fluorescent Immunoassay) Ang-2 sandwich immunoassay 
(PerkinElmer Life and Analytical Sciences, Turku, Finland) using a two-step protocol. 
The analysis was done using two monoclonal anti-human angiopoietin antibodies (R 





& D Systems, Minnesota, USA; catalogue number MAB098 and MAB0983). Firstly, 
standards and samples (50µL/well) in duplicates were added to the wells followed by 
assay buffer (150µL/well) and then incubated at room temperature for 2 hours. The 
plate was then washed four times and then DELFIA Enhancement solution 
(200µl/well) was dispensed. Fluorescence readings were measured on a VICTOR2D 
plate reader (PerkinElmer Life and Analytical Sciences, Turku, Finland). The 
concentrations of Ang-2 were determined using MultiCalc software (PerkinElmer Life 
and Analytical Sciences, Turku, Finland). The between-batch coefficient of variation 
was less than 5 % in all the samples analysed. 
 
2.3.10 Soluble fms-like tyrosine kinase-1 
 
Plasma sFlt-1 was measured by enzyme linked immunoassay (ELISA) technique using 
DuoSet® human sFlt-1 (R&D Systems Europe Ltd., Abington,UK). The lower limit 
of detection of the assays was 15 pg/mL for sFlt-1. Samples whose duplicate values 
differed by more than 15% were analysed. 
 
2.4 BIOPHYSICAL MARKERS 
 
2.4.1  Blood pressure 
 
The blood pressure (BP) was taken by validated automated devices (3BTO-A2, 
Microlife, Taipei, Taiwan; Reinders et al., 2005) that were calibrated before and at 
regular intervals during the study (every 1,000 inflations). The recordings were made 
by doctors who had received appropriate training on the use of these machines. Women 
were allowed to rest for 5 minutes and the BP measurements were taken in a quiet 
room with temperature of between 20°C and 24°C. The women were in the seating 
position, with their arms supported at the level of the heart and either a small (< 22 
cm), normal (22-32 cm) or large (33-42 cm) adult cuff was used depending on the mid-
arm circumference (Pickering et al., 2005; Poon et al., 2012).  
 





The BP was measured in both arms simultaneously (Figure 2.1) and two recordings 
were made in both arms (National Heart Foundation of Australia, 2004). The final 
MAP was calculated as the average of all 4 measurements from both arms along with 
its measurements of systolic BP and diastolic BP for the subsequent analysis of results 




Figure 2.1 Measurement of blood pressure. 
 
2.4.2  Uterine artery Doppler 
 
For the measurement of uterine artery pulsatility index (PI) by transabdominal 
ultrasound, a sagittal section of the uterus was obtained and the cervical canal and 
internal cervical os were identified. Subsequently, the transducer was gently tilted 
from side to side and colour flow mapping was used to identify each uterine artery 
along the side of the cervix and uterus at the level of the internal os (Figure 2.2; 
Plasencia et al., 2007).  
 






Pulsed wave Doppler was used with the sampling gate set at 2 mm to cover the whole 
vessel and care was taken to ensure that the angle of insonation was less than 30º. 
When three similar consecutive waveforms were obtained, the uterine artery PI was 
measured from the left and right arteries (Figure 2.3). All operators who participated 
in the study had obtained the Fetal Medicine Foundation Certificate of competence in 
obstetric Doppler imaging (http://www.fetalmedicine.com). The results of the Doppler 
studies were not given to the women or their doctors and did not influence the 





Figure 2.2 The uterine artery as demonstrated by colour flow mapping along the side 





Figure 2.3 Uterine artery Doppler waveform. 





2.5 RECORDING OF INFORMATION 
 
Women were asked to complete a questionnaire on age, racial origin (Caucasian, 
African, South Asian, East Asian and Mixed), cigarette smoking during pregnancy 
(yes or no), method of conception (spontaneous or assisted conception by either 
ovulation induction alone or in-vitro fertilisation), medical history (including chronic 
hypertension, diabetes mellitus, anti-phospholipid syndrome, thrombophilia, and 
sickle cell disease), medication (including anti-hypertensive, anti-depressant, anti-
epileptic, aspirin, steroids, beta-mimetics, insulin, and thyroxine), parity (parous, 
nulliparous with no previous pregnancies, nulliparous with miscarriage or termination 
before 24 weeks), previous pregnancy with PE (yes or no) and family history of PE 
(mother, sister or both). The questionnaire was then reviewed by a doctor together with 
the patient. 
 
The following measurements were made:   
 Maternal weight and height were measured and the body mass index (BMI) was 
calculated in Kg/m2, 
 Stabilised measurement  of systolic BP, diastolic BP and MAP, 
 Uterine artery PI of the two arteries 
 
 
2.6 OUTCOME MEASURES 
 
The definitions of PE and GH were those of the International Society for the Study of 
Hypertension in Pregnancy (Davey and MacGillivray, 1988). In GH the diastolic BP 
should be 90 mmHg or more on at least two occasions four hours apart developing 
after 20 weeks of gestation in previously normotensive women in the absence of 
significant proteinuria and in PE there should be GH with proteinuria of 300 mg or 
more in 24 hours or two readings of at least ++ on dipstick analysis of midstream or 
catheter urine specimens if no 24-hour collection is available.  
 





In PE superimposed on chronic hypertension significant proteinuria (as defined above) 
should develop after 20 weeks of gestation in women with known chronic hypertension 
(history of hypertension before conception or the presence of hypertension at the 
booking visit before 20 weeks of gestation in the absence of trophoblastic disease). 
 
The obstetric records of all women with pre-existing or pregnancy associated 
hypertension were examined to determine if the condition was chronic hypertension, 
PE or GH. Similarly, for quality control we examined the records of 500 randomly 
selected cases without pregnancy associated hypertension.  
 
 
2.7 STATISTICAL ANALYSIS 
 
2.7.1  Case-control studies 
 
Continuous data were presented as median and IQR and categorical data as n (%). 
Comparison between the outcome groups was by χ2-test or Fisher’s exact test for 
categorical variables and Mann Whitney-U test for continuous variables. A p value of 
p<0.05 was considered significant. Where necessary post hoc correction for 
significance level was done with either Bonferroni correction or Dunn’s test. 
 
In case of each biochemical marker, the following steps were taken. First, the 
distribution of the biochemical marker was made Gaussian after logarithmic 
transformation (PLGF, Activin-A, Inhibin-A, PP-13, P-Selectin, PTX-3, sEng, PAI-2  
and Ang-2). In case of sFlt-1, the distribution of was transformed using the equation: 
Y= log10(sFlt-1 – k) to approximate a Gaussian distribution. Distributions were 
confirmed to be Gaussian using Kolmogorov-Smirnov test, histograms or probability 
plots. Second, multivariate regression analysis was used to determine which of the 
factors amongst the maternal characteristics and gestation were significant predictors 
of the log10 transformed biochemical marker in the unaffected group. Then the 
distribution of log10 transformed biochemical marker expressed as MoM of the 
unaffected group, were determined in the PE group. The measured uterine artery PI 





and PAPP-A were converted into MoM after adjustment for maternal characteristics 
(Poon et al., 2009b; Kagan et al., 2008a). Third, non-parametric testing using either 
Mann-Whitney test with post hoc Bonferroni correction or Kruskall-Wallis test with 
post hoc Dunn’s procedure was used to compare median MoM of biochemical marker 
between the outcome groups. Fourth, regression analysis was used to determine the 
significance of association between log10 transformed biochemical marker and log10 
uterine artery MoM and log10 PAPP-A MoM in the outcome groups. Fifth, logistic 
regression analysis was used to determine if the log10 transformed maternal factor-
derived a priori risks, log10 transformed biochemical marker, log10 PAPP-A MoM and 
log10 uterine artery MoM had a significant contribution in predicting PE. The detection 
and false positive rates were calculated as the respective proportions of PE (detection 
rate) and unaffected pregnancies (false positive rate) with MoM values above given 
cut-offs. The performance of screening was determined by receiver operating 
characteristic (ROC) curves analysis. 
 
The statistical software package SPSS 16.0 (SPSS Inc.,Chicago, IL), Medcalc for 
windows, version 9.6.2.0 (MedCalc Software, Mariakerke, Belgium) and XLSTAT-
Pro 2008 (Addinsoft, USA) were used for data analyses. 
 
2.7.2 Screening studies 
 
Prediction of PE from maternal factors, biophysical and biochemical markers 
 
Comparison between the early, intermediate and late PE groups with the unaffected 
pregnancies was by χ2-test or Fisher’s exact test for categorical variables and Mann 
Whitney-U test for continuous variables, both with post-hoc Bonferroni correction 
(critical statistical significance p<0.0167). 
 
The following steps were used to develop a model for predicting early, intermediate 
and late PE based on maternal characteristics. First, the association of continuous 
variables, such as maternal age, weight and height, with PE was assessed to determine 





if this was linear or non-linear. Second, univariate analysis was performed to examine 
the individual variables contributing significantly to early, intermediate and late PE by 
assessing their odds ratios (ORs) and 95% confidence intervals. Third, logistic 
regression analysis with backward stepwise elimination of variables was used to 
develop the model. Fourth, to assess the predictive accuracy of our model we 
calculated the shrinkage factor using the equation [χ2 – (df-1)]/ χ2 where χ2 is the model 
chi-square derived from the log-likelihood statistic and df is the degree of freedom. 
This shrinkage factor was then applied to all the parameters in the model to adjust for 
over fitting. Fifth, the patient-specific risk for early, intermediate and late PE was 
calculated from the formula: odds / (1+odds), where odds= eY and Y was derived from 
the logistic regression analysis. The distribution of risks was then used to calculate 
detection and false positive rates at different risk cut-offs and the performance of 
screening was determined by receiver operating characteristic (ROC) curves analysis. 
 
The following steps were used to develop a model for predicting early, intermediate 
and late PE based on the combination of maternal characteristics and biophysical and 
biochemical markers. First, the measured serum PAPP-A and free ß-hCG were 
converted to multiples of the expected normal median (MoM) corrected for fetal CRL, 
maternal age, weight, smoking, parity, racial origin and method of conception as 
previously described (Kagan et al., 2008a). Second, the values of uterine artery PI, 
MAP, PLGF, PP13, inhibin-A, activin-A, sEng, PTX3 and P-selectin were log 
transformed to make their distribution Gaussian. Third, in the unaffected pregnancies 
multiple regression analysis was used to determine which of the factors amongst the 
maternal characteristics and fetal CRL were significant predictors of each marker. In 
each case of PE and unaffected pregnancies the measurements were converted into a 
multiple of the normal median (MoM) and the MoM values in different groups were 
compared. Fourth, Guassian distributions of markers in early, intermediate, late-PE 
and unaffected pregnancies were fitted. These fitted distributions define the likelihood 
ratios for the screening tests that can be combined with the a priori maternal 
characteristics-derived risk to produce a posteriori risk. Fifth, the maternal factors-
related a priori risks and log10MoM values of the biophysical and biochemical markers 





were simulated for 500,000 pregnancies for each group of early, intermediate and late 
PE and 500,000 unaffected pregnancies. The maternal factors-related a priori risks for 
each of the PE groups were multiplied by the likelihood ratios of the biophysical and 
biochemical markers to derive the a posteriori risks in the simulated samples of 
500,000 PE and 500,000 unaffected pregnancies. Fifth, the a priori and a posteriori 
risks in each of the PE groups and unaffected pregnancies were used to calculate the 
detection rates at fixed false positive rates of 5% and 10%. The large size of the 
simulated population was chosen to ensure that the error resulting from simulation was 
negligble. The process of sampling with replacement from the screening data of PE 
and unaffected pregnancies ensured that the modelled screening performance reflects 
the screening population.  
 
The statistical software package SPSS 16.0 (SPSS Inc.,Chicago, IL) was used for data 
analyses. Monte-Carlo simulations were programmed in R (The R Foundation for 
Statistical Computing, R version 2.11.0, ISBN 3-900051-070-0, http://www.r-
project.org). 
 
Competing risks model in early screening for PE by biophysical and biochemical 
markers 
 
This model for early screening for PE was based on a survival time model for the time 
of delivery for PE.  Bayes theorem was used to combine the prior information from 
maternal characteristics with biomarker multiple of the median (MoM) values. We 
used a competing risk model (Kalbfleisch and Prentice 2002). In this model it is 
assumed that if the pregnancy was to continue indefinitely all women would have 
developed PE and in this respect there is a competition between delivery before or 
after development of PE. We applied a model to represent the distribution of 
gestational age at delivery with PE. In pregnancies at low risk for PE the gestational 
age distribution is shifted to the right with the implication that in most pregnancies 
delivery will actually occur before the development of PE. In pregnancies at high-risk 
for PE the gestational age distribution is shifted to the left with the implication that in 
many pregnancies delivery will actually occur after the development of PE. Given 





maternal characteristics and biomarker levels the risk of PE occurring at or before a 
specified gestational age was given by the area under the distribution curve.   
 
The distribution of gestational age at delivery with PE was defined by two 
components: firstly, the prior distribution based on maternal characteristics and 
secondly, the distribution of MoM biomarker values with gestational age in 
pregnancies affected by PE. Although such model fitting was complicated because of 
the censoring in situations when delivery occurred before PE, fitting regression models 
to censored data was carried out routinely with standard statistical software.  
 
The values of uterine artery PI, MAP, PAPP-A and PLGF were log10 transformed to 
make their distribution Gaussian. Each measured value in the unaffected and PE 
pregnancies was expressed as a multiple of the normal median (MoM) after adjustment 
for those characteristics found to provide a substantial contribution to the log 
transformed value (Wright et al., 2010 and 2012; Pandya et al., 2012). In each case of 
PE the measurements were converted into a MoM and regression analysis was used to 
determine the relationship between log10 MoM values with getational age at delivery. 
 
In the estimation of performance of screening the values of uterine artery PI, MAP, 
PAPP-A and PLGF in the whole screened population were simulated based on the 
mean and SD of the log10 transformed marker values in the unaffected and PE 
pregnancies. In the PE group the mean and SD values used for simulation were specific 
for each gestational week at delivery, which were estimated from the regression 
analysis of the log10 MoM values of available data with getational age at delivery. 
 
                                       
















BIOCHEMICAL MARKERS IN EARLY 
PREDICTION OF PREECLAMPSIA











A large number of maternal blood markers have been put forward for the prediction of 
PE (Chapter 1.4.4). Many such markers represent measurable manifestations of 
impaired placentation-related placental ischaemia and damage with subsequent release 
of inflammatory factors, platelet activation, endothelial dysfunction, maternal renal 
dysfunction or abnormal oxidative stress. The majority of studies have examined these 
markers either during established PE or in the second trimester before the clinical onset 
of the disease. However, there is some contradictory evidence that some markers may 




The objectives of the studies in this chapter are firstly, to investigate whether the 
maternal serum or plasma levels of a series of biochemical markers are altered in 
women who subsequently develop PE, secondly, to examine the association between 
these biochemical markers and established markers of placental dysfunction such as 
uterine artery PI and maternal serum PAPP-A and thirdly, to estimate the performance 





The studies investigating the levels of maternal serum or plasma biochemical markers 
were nested case-control studies drawn from a larger prospective observational study 
at 11-13 weeks’ gestation for early prediction of pregnancy complications. The 
description of study population (Section 2.1), data collection (Section 2.5) and 
outcome measures (Section 2.6) are outlined in Chapter 2. 






We searched our database to identify cases that developed early and late PE with 
available stored samples. Each case was matched with controls that did not develop 
any pregnancy complication and had blood collected and stored on the same day. All 
sample analyses were in duplicate and in those where the CV exceeded 15%, the 
samples were reanalysed. Detailed description of biochemical (Section 2.3) and 





3.3.1 Placental growth factor 
 
Serum PLGF was measured in 127 cases and 609 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between PLGF MoMs and serum PAPP-A MoM and uterine artery PI 
MoM in cases and controls were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 PLGF 
MoM with log10 PAPP-A MoM and log10 uterine artery PI MoM. Multivariate logistic 
regression analysis was used to determine factors providing a significant contribution 
in prediction of early-PE and late-PE. Performance of screening was examined by 




Multiple regression analysis in the control group demonstrated that for log10 PLGF 
significant independent contributions were provided by fetal CRL, maternal weight, 
cigarette smoking and ethnic origin: log10 expected PLGF = 1.150 + 0.008 x CRL in 
mm – 0.002 x weight in Kg + (0.199 if smoking, 0 if not) + (0.177 if Afro-Caribbean, 
0.100 if South Asian, 0 if other racial origin); R2=0.237, p<0.0001. In the control 





group, the median PLGF MoM was 0.99 (IQR 0.80-1.29) (Table 3.1, Figure 3.1). The 
median PAPP-A MoM was 1.07 (IQR 0.74-1.46) and uterine artery PI MoM was 1.03 
(IQR 0.84-1.24); (Table 3.1, Figure 3.1).  
 
There was a significant association between log10 PlGF MoM and log10 PAPP-A MoM 
(r=0.264, p<0.0001; Figure 3.2), log10 uterine artery PI MoM (r=0.102, p=0.012; 





In both the early-PE and late-PE groups, PlGF and PAPP-A were lower and uterine 




Figure 3.1 Box-whisker plot of placental growth factor (PlGF) multiple of median 
(MoM) in the pregnancy outcome groups: controls, early preeclampsia (PE), late PE, 
gestational hypertension (GH). 
 
 





Table 3.1 Median (interquartile range) of maternal serum placental growth factor 
(PLGF) multiple of the median (MoM), pregnancy associated plasma protein-A 
(PAPP-A) MoM and uterine artery pulsatility index (PI) MoM in the control, early- 
and late-preeclampsia groups. 
 
Outcome group PlGF MoM PAPP-A MoM Uterine artery PI MoM 
Control 0.99 (0.80-1.29) 1.07 (0.74-1.46) 1.03 (0.84-1.24) 
Early-PE 0.61 (0.48-0.84)‡ 0.54 (0.39-0.96)‡ 1.51 (1.20-1.65)‡ 
Late-PE 0.82 (0.55-1.06)‡ 0.93 (0.57-1.31)* 1.22 (0.93-1.45)‡ 
Mann-Whitney test: * P < 0.05, † P < 0.01, ‡ P < 0.0001 
 
There was a significant association between log10 PlGF MoM and log10 PAPP-A MoM 
(r=0.325, p<0.0001; Figure 3.2), log10 uterine artery PI MoM (r=-0.279, p=0.001; 






Figure 3.2. Relationship between placental growth factor (PLGF) multiple of the 
median (MoM) and pregnancy associated plasma protein-A (PAPP-A) MoM in the 
control group (left) and the preeclampsia group (right). 
 







Figure 3.3. Relationship between placental growth factor (PLGF) ) multiple of the 
median (MoM) and uterine artery pulsatility index (PI) MoM in the control group (left) 
and the preeclampsia group (right). 
 
Logistic regression analysis demonstrated that significant contributions for the 
detection of early-PE were provided from maternal factors, PLGF, PAPP-A and 
uterine artery PI (R2=0.500, p<0.0001; Table 3.2).  
 





Independent variable Early preeclampsia 
OR 95% CI p 
Log10 PLGF MoM 0.01 0.00 0.17 0.002 
Log10 uterine artery PI MoM 2020561 5358.56 7.6E
+08 <0.0001 
Log10 PAPP-A MoM 0.16 0.03 0.97 0.046 
Chronic hypertension 237.694 17.33 3260.52 <0.0001 
Afro-Caribbean race 3.17 1.17 8.56 0.023 





Logistic regression analysis demonstrated that significant contributions for the 
detection of late-PE were provided from maternal factors, PLGF and uterine artery PI 
(R2=0.290, p<0.0001; Table 3.3) but not PAPP-A (p=0.933). 
 
Table 3.3. Logistic regression analysis for prediction of late-preeclampsia. 
 
The performance of screening of different methods by comparison of the AUROC 
curves along with the DR of early-PE and late-PE for different FPR in screening by 
maternal factors, serum PlGF, serum PAPP-A, uterine artery PI and by their 
combinations are given in Tables 3.4 and 3.5.  
 
The AUROC for maternal factors in screening for early-PE was 0.762 with a DR of 
39% and 49% for a FPR of 5 and 10%, respectively. The performance of screening 
was significantly improved by the combination of maternal factors with PLGF, PAPP-
A and uterine artery PI with an AUROC of 0.936 and a corresponding DR of 76% and 
86% for a FPR of 5% and 10% respectively. Similarly, the AUROC for maternal 
factors in screening for late-PE was 0.788 with a DR of 39% and 49% for a FPR of 5 
and 10%, respectively. The performance of screening was significantly improved by 
the combination of maternal factors with PLGF and uterine artery PI with an AUROC 
of 0.817 and a corresponding DR of 30% and 49% for a FPR of 5 and 10% respectively 
(Table 3.4 and 3.5). 
 
Independent variable Late preeclampsia 
OR 95% CI p 
Log10 PLGF MoM 0.09 0.03 0.32 <0.0001 
Log10 uterine artery PI MoM 14.03 1.89 103.91 0.010 
Body mass index in Kg/m2 1.11 1.07 1.16 <0.0001 
Afro-Caribbean race 3.92 2.27 6.78 <0.0001 
South Asian race 2.95 1.16 7.55 0.024 
Mixed race 4.71 1.74 12.75 0.002 
Parous – no previous PE 0.28 0.16 0.48 <0.0001 
Family history of PE 4.22 1.71 10.41 0.002 





Table 3.4. Comparison of area under receiver operating characteristic curve 
(AUROCs) in screening for preeclampsia by maternal factors, placental growth factor 
(PLGF), pregnancy associated plasma protein-A (PAPP-A), uterine artery pulsatility 
index (PI) and by their combinations.. 
 
Screening test 
AUROC (95% CI) 
Early PE Late PE 
History 0.762 (0.654-0.870) 0.788 (0.742-0.834) 
PLGF 0.797 (0.705-0.888) 0.652 (0.589-0.714) 
PAPP-A 0.742 (0.639-0.846) 0.576 (0.513-0.639) 
Uterine artery PI 0.826 (0.740-0.912) 0.626 (0.560-0.692) 
History with PLGF 0.881(0.817-0.944) 0.817 (0.775-0.859) 
History with PAPP-A 0.842 (0.747-0.937) 0.788 (0.741-0.834) 
History with uterine artery PI 0.902 (0.833-0.971) 0.801 (0.753-0.849) 
History with PLGF and uterine artery PI 0.941 (0.889-0.994) 0.817 (0.773-0.861) 
History with PLGF, PAPP-A, uterine artery PI 0.936 (0.882-0.989) - 
 
 
Table 3.5. Comparison of detection rate (DR) for fixed false positive rates (FPRs) of 
5 and 10% in screening for preeclampsia by maternal factors, placental growth factor 
(PLGF), pregnancy associated plasma protein-A (PAPP-A), uterine artery pulsatility 
index (PI) and by their combinations. 
 
Screening test 
DR (%) for fixed FPR 
Early PE Late PE 
5% 10% 5% 10% 
History 39.0 49.0 29.6 43.9 
PLGF 27.6 51.7 19.4 32.7 
PAPP-A 24.1 41.4 8.2 18.4 
Uterine artery PI 37.9 65.5 16.3 27.6 
History with PLGF 55.2 62.1 28.6 52.0 
History with PAPP-A 51.7 69.0 29.6 46.9 
History with uterine artery PI 69.0 75.9 29.6 51.0 
History with PLGF and uterine artery PI 75.9 89.7 29.6 49.0 
History with PLGF, PAPP-A, uterine artery PI 75.9 86.2 - - 
 






3.3.2 Activin A 
 
Serum Activin A was measured in 126 cases and 214 controls. The measured values 
were converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between Activin A MoMs and serum PAPP-A MoM and uterine artery PI 
MoM in cases and controls were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 Activin-
A MoM with log10 PAPP-A MoM and log10 uterine artery PI MoM. Multivariate 
logistic regression analysis was used to determine factors providing a significant 
contribution in prediction of early-PE and late-PE. Performance of screening was 




Multiple regression analysis in the control group demonstrated that for log10 Activin 
A significant independent contributions were provided by maternal weight and racial 
origin: log10 expected activin A = 0.455 - 0.003 x maternal weight in Kg + (0.082 if 
Afro-Caribbean, 0 if other racial origin); R2=0.068, p=0.001.  
 
In the control group, the median activin A MoM was 1.00 (IQR 0.76-1.28) (Table 3.7). 
The median PAPP-A MoM was 1.03 (IQR 0.70-1.45) and uterine artery PI MoM was 
1.05 (IQR 0.84-1.30); (Table 3.6).  
 
In the control group, there was a significant association between serum activin A and 
PAPP-A (r=0.330, p<0.0001) but there was no significant association between activin 









Table 3.6. Median (interquartile range) of Activin A, pregnancy associated plasma 
protein-A (PAPP-A) multiple of the median (MoM) and uterine artery pulsatility index 
(PI) MoM in the outcome groups. 
 
Outcome group Activin A MoM PAPP-A MoM Uterine artery PI MoM 
Control 1.00 (0.76-1.28) 1.03 (0.70-1.45) 1.05 (0.84-1.30) 
PE 1.27 (0.96-1.68)* 0.81 (0.53-1.25)* 1.32 (0.99-1.56)* 




In PE, compared to controls, Activin A MoM and uterine artery PI MoM were higher 
and serum PAPP-A was lower (Table 3.7).  
 
There was a significant association between serum Activin A and PAPP-A (r=0.277, 
p=0.002) but there was no significant association between Activin A and uterine artery 




Figure 3.4. Relationship between maternal serum Activin A and pregnancy associated 
plasma protein-A (PAPP-A) in control group (left) and in those that developed 
preeclampsia (right). 





Logistic regression analysis demonstrated that in the prediction of early-PE there were 
significant contributions from log10 uterine artery PI MoM (OR 1.7E
5, 95% CI 247.8-
1.2E8; p<0.0001), log10 PAPP-A MoM (OR 0.050, 95% CI 0.006-0.426; p=0.006), 
and log10 Activin A MoM (OR 164.2, 95% CI 4.6-5833.8; p=0.005), history of chronic 
hypertension (OR 108.0, 95%CI 6.1-1900.6; p=0.001), Afro-Caribbean racial origin 
(OR 3.6, 95% CI 1.1-12.3; p=0.041) and parous with no previous PE (OR 0.182, 95% 
CI 0.049-0.677; p=0.011) but not BMI (p=0.782) or family history of PE (p=0.305); 
R2=0.569, p<0.0001.  
 
The estimated DR of screening for early-PE by Activin A was 11.1% and 25.9% at 
respective FPR of 5% and 10%. The performance of screening for early-PE by a 
combination of history, PAPP-A and uterine artery PI (AUROC 0.921, 95%CI 0.879-
0.952) was not significantly improved by the addition of Activin A (AUROC 0.927, 
95%CI 0.886-0.956, p=0.787). 
 
Logistic regression analysis demonstrated that in the detection of late-PE there were 
significant contributions from log10 uterine artery PI MoM (OR 36.0 95% CI 3.7-
346.7; p=002), log10 Activin A MoM (OR 32.1% CI 6.0-171.7; p<0.001), BMI (OR 
1.1, 95%CI 1.0-1.2; p=0.002), Afro-Caribbean ethnic origin (OR 3.4, 95% CI 1.8-6.4; 
p<0.001), parous with no previous PE (OR 0.171, 95% CI 0.09-0.324; p<0.001) and 
family history of PE (OR 4.5, 95%CI 1.4-14.7; p=0.014), but not log10 PAPP-A MoM 
(p=0.114) or history of chronic hypertension (p=0.215): R2=0.382, p<0.0001.  
 
The estimated DR of screening for late-PE by Activin A was 15.3% and 25.5% at 
respective FPR of 5% and 10%. The performance of screening for late-PE by a 
combination of history and uterine artery PI (AUROC 0.806, 95%CI 0.758-0.848) was 











Serum Inhibin-A was measured in 121 cases and 208 controls. The measured values 
were converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between Inhibin-A MoMs and uterine artery PI MoMs in cases and 
controls were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 Inhibin-
A MoM with log10 PAPP-A MoM and log10 uterine artery PI MoM. Multivariate 
logistic regression analysis was used to determine factors providing a significant 
contribution in prediction of early-PE and late-PE. Performance of screening was 




Multiple regression analysis in the control group demonstrated that for log10 inhibin 
A, significant independent contributions were provided by maternal weight and racial 
origin: log10 expected inhibin A = 2.596 - 0.003 x maternal weight in Kg + (0.127 if 
Afro-Caribbean, 0 if other racial origins); R2=0.078, p<0.0001 (Table 3.7).  
 
In the control group, the median Inhibin-A MoM was 0.98 (0.72-1.43) (Table 3.8, 
Figure 3.5). The median PAPP-A MoM was 1.00 (0.69-1.45) and uterine artery PI MoM 
was 1.05 (0.83-1.30) (Table 3.7, Figure 3.5).  
 
Table 3.7. Median (interquartile range) for Inhibin-A MoM, uterine artery pulsatility 
index (PI) multiple of the median (MoM) and pregnancy associated plasma protein-A 
(PAPP-A) MoM in the outcome groups.  
   Significance value * P < 0.05; PE: preeclampsia 
Outcome group Inhibin A MoM PAPP-A MoM Uterine artery PI MoM 
Control 0.98 (0.72-1.43) 1.00 (0.69-1.45) 1.05 (0.83-1.30) 
Early-PE 1.55 (0.95-2.05)* 0.62 (0.42-1.11)* 1.56 (1.20-1.69)* 
Late-PE 1.24 (0.89-1.65)* 0.95 (0.58-1.31) 1.26 (0.92-1.44)* 






There was no significant association between log10 Inhibin-A MoM and log10 uterine 









Maternal plasma inhibin A and uterine artery PI were significantly higher in early-PE 
and late-PE than in controls (Table 3.7, Figure 3.5). Serum PAPP-A was significantly 
lower in early-PE than in controls but not in late-PE compared to controls (Table 3.7). 
There was no significant association between plasma Inhibin-A and uterine artery PI 
in the PE group (early-PE p=0.568 and late-PE p=0.492). 
 
Logistic regression analysis demonstrated that in the prediction of early-PE there were 
significant contributions from log10 uterine artery PI MoM (OR 4.442E
5, 95% CI 





413.0-4.8E8; p<0.0001), log10 PAPP-A MoM (OR 0.099, 95% CI 0.011-0.929; 
p=0.043), and log10 Inhibin-A MoM (OR 249.6, 95% CI 9.3-6.688E
3; p=0.001), 
history of chronic hypertension (OR 143.3, 95%CI 8.3-2.463E3; p=0.001), Afro-
Caribbean racial origin (OR 5.5, 95% CI 1.4-21.8; p=0.016), mixed racial origin (OR 
16.3, 95% CI 1.3-198.1; p=0.029) and parous with no previous PE (OR 0.159, 95% CI 
0.039-0.651; p=0.011) but not BMI (p=0.190) or family history of PE (p=0.068); 
R2=0.608, p<0.0001.  
 
Logistic regression analysis demonstrated that in the detection of late-PE there were 
significant contributions from log10 uterine artery PI MoM (OR 32.0, 95% CI 3.4-
302.5; p=0.002), log10 Inhibin-A MoM (OR 21.0, 95% CI 4.6-96.1; p<0.0001), BMI 
(OR 1.1, 95%CI 1.1-1.2; p<0.001), Afro-Caribbean racial origin (OR 3.8, 95% CI 2.0-
7.3; p<0.0001) and parous with no previous PE (OR 0.123, 95% CI 0.062-0.243; 
p<0.0001) but not log10 PAPP-A MoM (p=0.283), history of chronic hypertension 
(p=0.266) and family history of PE (p=0.063) R2=0.377, p<0.0001. 
 
The estimated DRs of early-PE at fixed FPRs of 5% and 10% in screening by maternal 
obstetric history and characteristics, Inhibin-A, PAPP-A, uterine artery PI and by their 
combinations are shown in Table 3.8 and the areas under the receiver operating 
characteristic curves are shown in Table 3.9. The estimated DR of screening for early-
PE by Inhibin-A was 23.1% and 30.8% at respective FPR of 5% and 10% and the 
values increased to 84.6% and 88.5% in screening by a combination of maternal 
history and characteristics, Inhibin-A and uterine artery PI.  
 
The estimated DR of late-PE at fixed FPR of 5% and 10% in screening by maternal 
obstetric history and characteristics, Inhibin-A, PAPP-A, uterine artery PI and by their 
combinations are shown in Table 3.8 and the AUROC curves are shown in Table 3.9. 
The estimated DR of screening for late-PE by Inhibin-A was 13.7% and 16.8% at 
respective FPR of 5% and 10% and the values increased to 36.8% and 55.8% in 
screening by a combination of maternal obstetric history and characteristics and 
plasma Inhibin-A. 





Table 3.8 Detection rate (DR) of early- and late-preeclampsia at fixed false positive 
rate (FPR) of 5% and 10% in screening by maternal obstetric history and 
characteristics, Inhibin-A, pregnancy associated plasma protein-A (PAPP-A), uterine 
artery pulsatility index (PI) and by their combinations. 
 
Screening test 
Detection rate (%) 
Early-PE Late-PE 
FPR 5% FPR 10% FPR 5% FPR 10% 
History / characteristics 47.5  57.7 31.6 43.2 
Inhibin A 23.1 30.8 13.7 16.8 
PAPP-A 23.1 42.3 - - 
Uterine artery PI 50.0 73.1 19.0 22.1 
History with     
  Inhibin A 46.2 61.5 36.8 55.8 
  PAPP-A 69.2 69.2 - - 
  Inhibin A, PAPP-A 57.7 73.1 - - 
  Uterine artery PI 65.4 84.6 31.6 46.3 
  Uterine artery PI, PAPP-A 61.5 80.8 - - 
  Inhibin A, uterine artery PI 84.6 88.5 33.7 42.1 
  Inhibin A, PAPP-A, uterine artery 
PI 
80.8 88.5 - - 
 
Table 3.9 Comparison of the performance of screening for preeclampsia by maternal 
obstetric history and characteristics, Inhibin-A, pregnancy associated plasma protein-
A (PAPP-A), uterine artery pulsatility index (PI) and by their combinations by 
receiver-operating characteristics curve analysis. 
 
Screening test 
AUROC, mean (95 %CI) 
Early-PE Late-PE 
History / characteristics 0.806 (0.749-0.854) 0.783 (0.732-0.828) 
Inhibin A 0.679 (0.615-0.738) 0.625 (0.568-0.680) 
PAPP-A 0.705 (0.643-0.763) - 
Uterine artery PI 0.829 (0.774-0.875) 0.623 (0.566-0.678) 
History with    
     Inhibin A 0.876 (0.827-0.916) 0.815 (0.767-0.857) 
     PAPP-A 0.866 (0.815-0.907) - 
     Inhibin A and PAPP-A 0.896 (0.849-0.932) - 
     Uterine artery PI 0.899 (0.853-0.934) 0.799 (0.750-0.843) 
     Uterine artery PI and PAPP-A 0.919 (0.877-0.951) - 
     Inhibin A and uterine artery PI 0.938 (0.899-0.965) 0.823 (0.775-0.864) 
     Inhibin A, PAPP-A and uterine artery PI 0.938 (0.899-0.965) - 
 





3.3.4 Placental protein-13 
 
Serum PP13 was measured in 208 cases and 416 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between PP13 MoMs and serum PAPP-A and uterine artery PI MoMs in 
cases and controls were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 PP13 
MoM with log10 PAPP-A MoM and log10 uterine artery PI MoM. Multivariate logistic 
regression analysis was used to determine factors providing a significant contribution 
in prediction of early-PE and late-PE. Performance of screening was examined by 




Multiple regression analysis in the control group demonstrated that for log10 PP13 
significant independent contributions were provided by maternal weight and smoking 
but not by racial origin (p=0.594), parity (p=0.870) or fetal CRL (p=0.707): log 
expected PP13 = 2.089 - 0.004 x maternal weight in Kg + (- 0.214 if smoker, 0 if non-
smoker); R2=0.154, p<0.0001.  
 
In the control group, the median PP13 MoM was 1.02 (0.78-1.30) (Table 3.10, Figure 
3.6). The median PAPP-A MoM was 1.08 (0.75-1.48) and uterine artery PI MoM was 
0.97 (0.77-1.22). (Table 3.10, Figure 3.6). There was a significant association between 
log10 PP13 MoM and log10 PAPP-A MoM (r=0.269, p<0.0001) but not log10 uterine 




In those who subsequently developed early-PE, compared to controls, serum PP13 and 
PAPP-A were significantly decreased and uterine L-PI was increased (Table 3.10, 





Figure 3.6). In those who subsequently developed late-PE, compared to controls, 
PAPP-A was decreased and uterine L-PI was increased but serum PP13 was not 
significantly different.   
 
Table 3.10 Median (interquartile range) of maternal serum placental protein 13 (PP13) 
multiple of the median (MoM), pregnancy associated plasma protein-A (PAPP-A), 
uterine artery pulsatility index (PI) MoM in the control, early- and late- preeclampsia 
groups. 
 
Outcome group PP13 MoM PAPP-A MoM Uterine artery PI MoM 
Control 1.02 (0.78-1.30) 1.08 (0.75-1.48) 0.97 (0.77-1.22) 
Early-PE 0.83 (0.55-1.15)* 0.55 (0.37-0.94)* 1.61 (1.31-1.73)* 
Late-PE 0.96 (0.75-1.25) 0.84 (0.55-1.18)* 1.25 (0.88-1.52)* 






Figure 3.6. Box-and-whisker plot of placental protein-13 (PP13) multiple of the 
median (MoM) in outcome groups. 
 








Figure 3.7. Relationship between maternal serum placental protein-13 (PP13) with 
pregnancy associated plasma protein-A (PAPP-A) and uterine artery PI in those that 
developed preeclampsia.   
 
 
In the PE group there was a significant association between serum PP13 and both 
uterine artery L-PI (r=-0.342, p<0.0001) and serum PAPP-A (r=0.328, p<0.0001) 
(Figure 3.7).  
 
Logistic regression analysis demonstrated that in the prediction of early-PE there were 
significant contributions from log10 maternal factor-derived a priori risk (OR 15.9, 
95%CI 6.1-41.5), log10 uterine artery L-PI MoM (OR 5.1E4, 95% CI 1243.4-2.1E
6; 
p<0.0001) and log10 PAPP-A MoM (OR 0.07, 95% CI 0.02-0.27; p<0.0001).  
 
Although log10 PP13 MoM did provide significant contribution to prediction of early-
PE, it did not improve significantly the performance of screening for early-PE 
provided by the combination of the maternal factor-derived a priori risk, uterine artery 
L-PI and serum PAPP-A.  
 





Table 3.11 Detection rate (DR) of early-preeclampsia at fixed false positive rate (FPR) 
of 5% and 10% and comparison of screening performance by area under the receiver 
operating characteristic curves (AUROC) curve analysis in screening by maternal risk 
factor, placental protein 13 (PP13), pregnancy associated plasma protein-A (PAPP-A), 
uterine artery L-pulsatility index (PI) and by their combinations. 
 
Screening test FPR 5% FPR 10% AUROC (95 %CI) 
Maternal risk factor 39.0 49.0 0.785 (0.745-0.822) 
PP13 20.8 37.5 0.652 (0.606-0.695) 
PAPP-A 27.1 37.5 0.744 (0.701-0.783) 
Uterine artery L-PI 45.8 68.7 0.863 (0.829-0.893) 
Maternal risk factor plus    
     PP13 37.5 52.1 0.818 (0.779-0.852) 
     PAPP-A 47.9 54.2 0.872 (0.838-0.901) 
     PP13 and PAPP-A 52.1 60.4 0.878 (0.845-0.906) 
     Uterine artery L-PI 58.3 75.0 0.920 (0.891-0.943) 
     Uterine artery L-PI and PP13 66.7 77.1 0.924 (0.896-0.946) 
     Uterine artery L-PI and PAPP-A 64.6 81.2 0.936 (0.910-0.957) 
 
The estimated DR of early-PE at fixed FPR of 5% and 10% and their respective 
AUROC in screening by maternal factor-derived a priori risk, PP13, PAPP-A, uterine 
artery L-PI and by their combinations are shown in Table 3.11. The estimated DR of 
screening for early-PE by PP13 independently was 20.8% and 37.5% at respective 
FPR of 5% and 10%. The addition of PP13 did not improve the detection rate of early-
PE that was achieved by a combination of maternal factor-derived a priori risk, uterine 
artery PI and serum PAPP-A. The maternal serum PP13 in late-PE was not 





Serum P-Selectin was measured in 121 cases and 208 controls. The measured values 
were converted to MoMs. The MoMs in cases and controls were compared and the 





correlation between P-selectin MoMs and uterine artery PI MoMs in cases and controls 
were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 P-
selectin MoM with log10 uterine artery PI MoM. Multivariate logistic regression 
analysis was used to determine factors providing a significant contribution in 
prediction of early-PE and late-PE. Performance of screening was examined by 




Multiple regression analysis in the control group demonstrated that for log10 P-selectin 
significant independent contributions were provided by racial origin and method of 
conception but not CRL (p=0.180) or maternal weight (p=0.435) or smoking 
(p=0.224): log expected P-selectin = 1.482 + (- 0.050 if Afro-Caribbean, -0.251 if East 
Asian, 0 if other racial origins) + (-0.167 if conception with ovulation drugs, 0 if 
spontaneous or IVF conception); R2=0.075, p<0.0001.  
 
In the control group, the median P-selectin MoM was 1.01 (IQR 0.84-1.25) and the 
median uterine artery PI MoM was 1.04 (IQR 0.85-1.30). (Table 3.12). There were no 




Table 3.12. Median (interquartile range) for P-selectin and uterine artery PI in the 
outcome groups. 
 
Significance level p<0.05 
Outcome group Plasma P-selectin MoM 
(median, IQR) 
Uterine artery PI MoM 
(median, IQR) 














Figure 3.8. Relationship between maternal serum P-selectin (left) and uterine artery 





Plasma P-selectin and uterine artery PI were higher in PE than in controls (Table 3.13). 
There were no significant associations between plasma P-selectin and uterine artery PI 
in the PE group (p=0.072). In the PE group, there was a significant association of 
uterine artery PI with gestation at delivery (r=-0.384, p<0.0001; Figure 3.8) but no 
significant association with P-selectin (p=0.579; Figure 3.8). 
 
Multiple logistic regression analysis demonstrated that for prediction of early-PE, 
significant contributions were provided by maternal factors and uterine artery PI but 
not by maternal plasma P-selectin: Y= -3.470 +14.13 x log10 uterine artery PI MoM + 





(1.083 if Afro-Caribbean, 0 if other racial origins) + (0 if nulliparous or parous with 
previous PE, -1.30 if parous without previous PE) + 4.875 if history of chronic 
hypertension; R2=0.470, p<0.001. 
 
In screening for early-PE by a combination of maternal factors and uterine artery PI 
the area under the ROC curve was 0.903 (95% CI 0.836-0.971) and at FPR of 5% and 
10% the DR were 63.0% and 85.2%, respectively.  
 
Multiple logistic regression analysis demonstrated that for prediction of late-PE 
significant contributions were provided by maternal factors, uterine artery PI and 
plasma P-selectin: Y = -3.678 + 4.926 x log10 P-selectin MoM + 3.345 x log10 uterine 
artery PI MoM + 0.105 x BMI in Kg/m2 + (1.326 if Afro-Caribbean, 0 if other racial 
origins) + (0 if nulliparous or parous with previous PE, - 1.979 if parous without 
previous PE) + 1.251 if family history of PE; R2=0.397, P<0.0001.  
 
In screening for late-PE by a combination of maternal factors and uterine artery PI the 
area under the ROC curve was 0.797 (95% CI 0.745-0.849) and at FPR of 5% and 10% 
the DR were 31.9% and 42.6%, respectively. In screening by a combination of 
maternal factors, uterine artery PI and plasma P-selectin the area under the ROC curve 






Serum PTX3 was measured in 120 cases and 207 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between PTX3 MoMs and uterine artery PI MoMs in cases and controls 
were investigated. Linear regression analysis was used to examine the relationship 
between log10 PTX3 MoM with log10 uterine artery PI MoM.  
 
 







Multiple regression analysis in the control group demonstrated that for log10 PTX3 
significant independent contributions were provided by racial origin and maternal 
weight but not fetal CRL (p=0.658), smoking (p=0.089), parity (p=0.923) or method 
of conception (p=0.170): log10 expected PTX3 = -0.078 + (- 0.003 X maternal weight 
in kg) + (-0.122 if South Asian, 0 if other racial origins); R2=0.042, p=0.004.  
 
In the control group, the median PTX3 MoM was 0.99 (IQR 0.80-1.29) and uterine 
artery PI MoM was 1.03 (IQR 0.84-1.24). (Table 3.14). There was no significant 




Plasma PTX3 MoM was significantly higher in early-PE compared to controls but not 
in late-PE (Table 3.14). Uterine artery PI MoM was significantly increased in both 
early-PE and late-PE than in controls (Table 3.13).  
 
 
Table 3.13. Median (interquartile range) for plasma pentraxin 3 multiple of the median 
(MoM) and uterine artery pulsatility index (PI) MoM in the outcome groups. 
 
Adjusted significance level * P<0.01 
 
There were no significant associations between plasma PTX3 and uterine artery PI in 
the PE group (p=0.693) (Figure 3.9). 
 
 
Outcome group Plasma pentraxin MoM Uterine artery PI MoM 
Control 0.97 (0.74-1.22) 1.05 (0.84-1.31) 
Early preeclampsia 1.44 (0.83-2.00)* 1.54 (1.20-1.68)* 
Late preeclampsia 1.11 (0.78-1.63) 1.26 (0.94-1.45)* 









Figure 3.9. Association between pentraxin-3 (PTX3) uterine artery pulsatility index 
(PI) multiple of the median (MoM) in the preeclampsia group. 
 
3.3.7 Soluble Endoglin 
 
Serum sEng was measured in 90 cases and 180 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between sEng MoMs and serum PAPP-A, PLGF and uterine artery PI 
MoMs in cases and controls were investigated.  
 
Linear regression analysis was used to examine the relationship between log10 sEng 
MoM with log10 PAPP-A MoM, log10 PLGF MoM and log10 uterine artery PI MoM. 
Multivariate logistic regression analysis was used to determine factors providing a 
significant contribution in prediction of early-PE and late-PE. Performance of 
screening was examined by AUROC curves analysis.  








Multiple regression analysis in the control group demonstrated that for log10 sEng 
significant independent contributions were provided by maternal weight but not by 
racial origin (p=0.602), parity (p=0.757), smoking (p=0.365) or fetal CRL (p=0.675): 
Log10 expected sEng = 4.313 - 0.002 x maternal weight in kg; R
2=0.154, p=0.013.  
 
In the control group, the median sEng MoM was 0.98 (0.78-1.30) (Table 3.15, Figure 
3.10). The median PAPP-A MoM was 1.01 (0.77-1.32), PLGF MoM was 1.01 (0.83-
1.33) and uterine artery L-PI MoM was 1.00 (0.80-1.23). (Table 3.14, Figure 3.10).  
 
There was a significant association between plasma sEng and serum PAPP-A 




In early-PE, compared to controls, plasma sEng and uterine L-PI were significantly 
increased and serum PAPP-A and PlGF were decreased (Table 3.15, Figure 3.10). In 
late-PE, compared to controls, serum PlGF was decreased and uterine L-PI was 
increased but plasma sEng and serum PAPP-A were not significantly different.  
 
In the PE group there was a significant association between plasma sEng and both 
uterine artery L-PI (r=0.212, p=0.045) and serum PlGF (r=-0.434, p<0.0001) but not 
serum PAPP-A (p=0.253). 
 
Logistic regression analysis demonstrated that in the prediction of early-PE there were 
significant contributions from log10 maternal factor-derived a priori risk [odds ratio 
(OR) 9.5, 95%CI 2.6-34.6; p=0.001], log10 uterine artery L-PI MoM (OR 1.6E+05, 
95% CI 353.0-8.1E+07; p<0.0001), log10 PlGF MoM (OR 0.002, 95% CI 0.0-0.10; 
p=0.001) and log10 sEng MoM (OR 465.2, 95%CI 5.2-4.1E+04; p=0.007), but not 
from log10 PAPP-A MoM (p=0.240). 
 
 





Table 3.14 Median (interquartile range) of maternal serum soluble endoglin (sEng) 
multiple of the median (MoM), placental growth factor (PLGF) MoM, pregnancy 
associated plasma protein-A (PAPP-A) MoM and uterine artery L-pulsatility index 











Control 0.98 (0.78-1.30) 1.01 (0.83-1.33) 1.01 (0.77-1.32) 1.00 (0.80-1.23) 
Early-PE 1.38 (1.06-1.87)* 0.61 (0.46-0.84)* 0.56 (0.47-0.90)* 1.65 (1.31-1.85)* 
Late-PE 0.90 (0.73-1.21) 0.82 (0.53-1.03)* 0.93 (0.57-1.18) 1.31 (1.13-1.55)* 




Figure 3.10 Box-whisker plot of soluble endoglin (sEng) multiple of the median 
(MoM) in controls, early- and late- preeclampsia. 
 
The patient-specific risk for early-PE was calculated from the formula: odds / 
(1+odds), where odds=eY and Y was derived from multivariate logistic regression 
analysis of the log10 transformed maternal factor-derived a priori risk, log10 uterine 
artery L-PI MoM, log10 PlGF MoM and log10 sEng MoM: Y= 0.991+ 2.249 X log10 





maternal factor-derived a priori risk + 12.039 X log10 uterine artery L-PI MoM – 6.032 




Table 3.15. Detection rate (DR) of early-preeclampsia at fixed false positive rate 
(FPR) of 5% and 10% and comparison of screening performance by ROC curve 
analysis in screening by maternal risk factor, soluble endoglin (sEng), placental growth 
factor (PLGF), uterine artery L- pulsatility index (PI) and by their combinations. 
 
 DR for Early preeclampsia 
Screening test FPR 5% FPR 10% 
AUROC 
(95 %CI) 
Maternal factors 29.6 40.0 0.751 (0.686-0.808) 
sEng 30.0 46.7 0.742 (0.677-0.800) 
PlGF 25.9 59.3 0.831 (0.772-0.880) 
PAPP-A 20.0 43.4 0.741 (0.676-0.799) 
Uterine artery L-PI 60.0 73.3 0.870 (0.817-0.913) 
Maternal factors plus    
  sEng 33.3 56.7 0.865 (0.811-0.908) 
  PlGF 48.1 66.7 0.902 (0.852-0.939) 
  PAPP-A 46.7 53.3 0.839 (0.782-0.886) 
  sEng and PlGF 55.6 74.1 0.923 (0.877-0.955) 
  sEng and PAPP-A 63.3 73.3 0.905 (0.857-0.941) 
  Uterine artery L-PI 63.3 76.7 0.908 (0.860-0.943) 
  Uterine artery L-PI and PAPP-A 60.0 83.3 0.923 (0.878-0.955) 
  Uterine artery L-PI and sEng 66.7 80.0 0.937 (0.895-0.966) 
  Uterine artery L-PI and PlGF 77.8 85.2 0.945 (0.904-0.972) 
  Uterine artery L-PI, PAPP-A and sEng 63.3 83.3 0.943 (0.903-0.971) 
  Uterine artery-L-PI, PlGF and sEng 77.8 96.3 0.949 (0.909-0.975) 
 
 
The estimated DR of early-PE at fixed FPR of 5% and 10% and their respective 
AUROC curves in screening by maternal factor-derived a priori risk, sEng, PAPP-A, 
PLGF, uterine artery L-PI and by their combinations are shown in Table 3.15. The 
estimated DR of screening for early-PE by sEng independently was 30.0% and 46.7% 
at respective FPR of 5% and 10%.  





The combination of maternal factor-derived a priori risk, uterine artery L-PI, PLGF 
and sEng achieved a DR of 77.8% and 96.3% for FPR of 5% and 10% respectively. 
The maternal plasma sEng in late-PE was not significantly different from controls and 
therefore did not add value in screening for late-PE. 
 
 
3.3.8 Plasminogen activator inhibitor-2 
 
 
Serum PAI-2 was measured in 119 cases and 204 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between PAI-2 MoMs and uterine artery PI MoMs in cases and controls 
were investigated. Linear regression analysis was used to examine the relationship 




Multiple regression analysis in the control group demonstrated that for log10 PAI-2 
significant independent contribution was provided by maternal BMI but not by fetal 
CRL (p=0.365), smoking (p=0.800), parity (p=0.824) or racial origin (p=0.239): Log10 
expected PAI-2 = 1.895 + (- 0.006 X BMI in kg/m2); R2=0.032, p=0.006.  
 
In the control group, the median PAI-2 MoM was 0.96 (0.77-1.28). The median uterine 
artery PI MoM was 1.05 (0.83-1.29). (Table 3.16). There were no significant 




There was no significant difference in maternal plasma PAI-2 MoM in patients with 
PE compared to controls whereas the uterine artery PI was significantly increased in 
PE compared to the controls (Table 3.16). There were no significant associations 
between plasma PAI-2 and uterine artery PI in the PE group (p=0.70).  







Table 3.16 Median (interquartile range) for maternal plasma plasminogen activator 












Serum Ang-2 was measured in 126 cases and 214 controls. The measured values were 





Multiple regression analysis in the control group demonstrated that for log10 Ang-2 
significant independent contributions were provided by maternal weight but not fetal 
CRL (p=0.877), smoking (p=0.863), parity (p=0.797) or Afro-Caribbean racial origin 





There was no significant difference in maternal serum Ang-2 levels in PE compared 
to controls. In contrast, uterine artery PI was significantly increased in PE compared 




Outcome group PAI-2 MoM Uterine artery PI MoM 
Control 0.96 (0.77-1.28) 1.05 (0.83-1.29) 
Preeclampsia 1.07 (0.86-1.33) 1.32 (0.98-1.56)* 





Table 3.17 Median (interquartile range) for maternal serum angiopoetin-2 (Ang-2) and 
uterine artery pulsatility index (PI) in the outcome groups. 
 
 
Significance level * P<0.01. 
 
 
3.3.10 Soluble fms-like tyrosine kinase-1 
 
Serum s-Flt-1 was measured in 90 cases and 180 controls. The measured values were 
converted to MoMs. The MoMs in cases and controls were compared and the 
correlations between sFlt-1 MoMs and serum PLGF and uterine artery PI MoMs in 
cases and controls were investigated. Linear regression analysis was used to examine 
the relationship between log10 sFlt-1 MoM with log10 PLGF MoM and log10 uterine 




Multiple regression analysis in the control group demonstrated that log10 sFlt-1 did not 
change with fetal CRL (p=0.227), maternal age (p=0.874), racial origin (p=0.963), 
parity (p=0.524), maternal weight (p=0.987), method of conception (p=0.531) or 
smoking status (p=0.672).  
 
In the control group, the median sFlt-1 was 6349 (IQR 3697-10153) (Table 3.18, 
Figure 3.11). The median PLGF MoM was 1.03 (IQR 0.83-1.33) and uterine artery PI 
MoM was 0.99 (IQR 0.80-1.23). (Table 3.18). There was no significant association 
between plasma sFlt-1 and serum PlGF (p=0.299), gestation at delivery (p=0.264) or 
birth weight centile (p=0.729) but there was a significant association between plasma 
sFlt-1 and uterine artery L-PI (r=-0.166, p=0.026).  
 
Outcome group Ang-2 MoM Uterine artery PI MoM 
Control 1.07 (0.70-1.45) 1.05 (0.83-1.29) 
Preeclampsia 0.96 (0.62-1.48) 1.32 (0.99-1.56)* 







In the pregnancies that subsequently developed early-PE and late-PE, the median 
plasma sFlt-1 concentration was not significantly different from that in the control 
group (Figure 3.11), whereas in both early-PE and late-PE the uterine artery L-PI was 
significantly increased and serum PlGF was significantly decreased (Table 3.18). 
 
Table 3.18 Median (interquartile range) of maternal serum placental growth factor 
(PLGF) multiple of the median (MoM), pregnancy associated plasma protein-A 
(PAPP-A) MoM and uterine artery pulsatility index (PI) MoM in the control, early- 
and late-preeclampsia groups. 
 
Outcome group sFlt-1 pg/mL PLGF MoM Uterine artery PI MoM 
Control 6349 (3697-10153) 1.03 (0.83-1.33) 0.99 (0.80-1.23) 
Early-PE 7099 (4769-58270) 0.61 (0.46-0.84)* 1.65 (1.31-1.85)* 
Late-PE 6840 (4200-11381) 0.82 (0.53-1.03)* 1.31 (1.13-1.55)* 




Figure 3.11 Box-whisker plot of soluble fms-like tyrosine kinase-1 (sFlt-1) multiple 
of the median (MoM) in controls, early- and late- preeclampsia. 
 





In the PE group there was no significant association between plasma sFlt-1 and uterine 
artery L-PI (p=0.736), serum PlGF (p=0.676), gestation at delivery (p=0.102) or birth 




The results of this study demonstrates that the maternal serum or plasma levels of 
PlGF, Activin A, Inhibin A, PP13, sEng, PTX-3 and P-selectin are significantly altered 
at 11-13 weeks’ gestation in pregnancies that subsequently develop PE whereas there 
is no significant difference in the levels of PAI-2, Ang-2 and sFlt-1 in women who 
develop PE compared to controls. There is a significant reduction in levels of PlGF 
and PP-13 whereas the levels of Activin A, Inhibin A, sEng, PTX-3 and P-selection 
are increased in pregnancies destined to develop PE. The levels of PlGF, Inhibin A, 
PP-13 were significantly different in both early and late-PE but the levels of Activin 
A and P-Selectin were only altered in late-PE whereas PTX-3 was different from 
controls only in early-PE but not in late-PE.  
 
There is a significant effect of maternal characteristics on the maternal serum or 
plasma concentration of these biochemical markers in unaffected pregnancies and 
consequently, the measured concentration of these markers must be adjusted for these 
maternal and pregnancy characteristics before comparison with pathological 
pregnancies (Kagan et al., 2008a). The maternal characteristics affecting the serum or 
plasma levels include gestational age, maternal weight, racial origin, method of 
conception and smoking. There was an inverse relationship with maternal weight in 
case of almost all biochemical markers including PlGF, Activin A, Inhibin A, PP13, 
PTX-3, sEng, PAI-2 and Ang-2 except in case of P-selectin and sFlt-1. The association 
of maternal serum concentration with maternal weight reflects the effect of dilution of 
the levels of biomarker in plasma volume, which increases with maternal weight. The 
levels are also affected by racial origin and the concentration of PlGF, Activin A and 
inhibin A is higher in women of Afro-Caribbean origin compared to Caucasian 
women. The other factor affecting concentration is maternal smoking status and the 





levels of PP-13 and P-selectin are lower in cigarette smokers compared to non-smokers 
whereas the levels of PlGF are higher in smokers.  
 
The biochemical markers also demonstrate a relationship with established markers of 
placentation reflected in uterine artery Doppler and maternal serum PAPP-A. In the 
case of serum PlGF, Activin-A and PP-13, there was a significant linear relationship 
with maternal serum PAPP-A whereas there was a significant relationship between 
PlGF, PP-13 and sEng with uterine artery PI suggesting a common pathogenesis of 
impaired trophoblastic relationship. In the case of biochemical markers such as inhibin 
A, PTX-3 and P-selectin there was no association with either serum PAPP-A or uterine 
artery Doppler suggesting that the increased levels of this biomarker are secondary to 
a mechanism that is likely to be different than placental dysfunction. There was no 
association of Ang-2, PAI-2, sFlt-1 with neither serum PAPP-A nor uterine artery PI 
and the levels of these biomarkers are not altered in PE suggesting that they are not 
involved in the pathogenesis of PE at least in the first trimester of pregnancy. In the 
PE group, there was a significant association of PlGF and PP-13 with gestational age 
delivery which supports the hypothesis that these biochemical markers are associated 
with impaired trophoblastic proliferation which is reflected in their inverse 
relationship with gestational age at delivery and therefore severity of disease.  
 
The biochemical markers providing a significant contribution to early screening for 
PE either alone or in combination with maternal factor derived a priori risk, uterine 
artery PI and serum PAPP-A were PlGF, Activin A, Inhibin-A, sEng, PP-13 and P-
selectin. The DR of early-PE from maternal serum PlGF alone at a FPR of 10% was 
about 50% which improved to 90% when PlGF was added to the combination of 
maternal factors and uterine artery PI. Similarly, the estimated DR of screening for 
early-PE by Inhibin-A was 30.8% at FPR of 10% and this increased to 88.5% in 
screening by a combination of maternal factors, Inhibin-A and uterine artery PI. 
Although, Activin A was higher in women with PE but when added to the combination 
of maternal factors and uterine artery PI, the contribution was not significant. The 
estimated DR of screening for early-PE by sEng independently was 46.7% at FPR of 





10%. The combination of maternal factor-derived a priori risk, uterine artery L-PI, 
PLGF and sEng achieved a DR of 96.3% for FPR of 10%. The estimated DR of 
screening for early-PE by PP13 independently was 37.5% at respective FPR of 10%. 
The addition of PP13 did not improve the detection rate of early-PE that was achieved 
by a combination of maternal factor-derived a priori risk, uterine artery PI and serum 
PAPP-A. 
 
Similarly, in screening for late-PE, the DR of PlGF and inhibin-A for a FPR of 10% 
was 32 and 17%, respectively, which improved to 49 and 42 % when PlGF was added 
to the combination of maternal factors and uterine artery PI. Although the levels were 
increased in late-PE compared to controls but the addition of Activin-A to the 
combination of maternal factors and uterine artery PI did not provide a significant 
contribution. In case of P-selectin, addition to P-selectin to the combination of 
maternal factors and uterine artery PI increased the DR of late-PE from 53 to 50%. 
 
These findings demonstrate that there are a series of biochemical markers which are 
placental products involved either in placentation or in the cascade of events leading 
from impaired placentation to placental ischemia and damage with release of 
inflammatory factors which cause platelet activation and endothelial dysfunction and 
consequent development of the clinical symptoms of the disease. These biochemical 
markers are altered in pregnancies from as early as 11-13 weeks’ of gestation. It is also 
evident that there is a relation of these biochemical markers with established markers 
of placentation and the combination of these biochemical markers with maternal factor 
derived a priori risk and markers of placentation such as uterine artery Doppler 
significantly improves the performance of screening for PE. Such early screening 
would allow identification of women at high-risk and this could potentially improve 
pregnancy outcome because not only that these women would benefit from intensive 
maternal and fetal monitoring but they could be administered treatments that could 
potentially lead to prevention and reducing the prevalence of the disease. The findings 
from these case-control studies need to be validated in further larger prospective 
studies.  














PREDICTION OF PREECLAMPSIA FROM 
MATERNAL FACTORS, BIOPHYSICAL AND 















The traditional approach to screening for PE is based on risk factors identified from 
maternal characteristics and medical history (NICE 2008). An alternative approach is 
to combine maternal factors into an algorithm derived by multivariate analysis to 
estimate the individual patient-specific risk for PE. Such prior risk can then be 
combined with a series of biophysical and biochemical markers. Useful biophysical 
markers are uterine artery PI and MAP (Placensia et al., 2007 and Poon et al., 2008) 
and potentially useful biochemical markers are PLGF, PAPP-A, PP13, sEng, inhibin-
A, activin-A, PTX3 and P-selectin (Chapter 3). 
 
There is evolving evidence that both the degree of impaired placentation and the 
incidence of adverse fetal and maternal short-term and long-term consequences of PE 
are inversely related to the gestational age at onset of the disease (Chapter 1.3.3). 
Consequently, the end-point in screening for PE by first-trimester biophysical and 
biochemical markers should not be total PE but the condition should be subdivided 
according to gestational age at delivery.  
 
This subdivision has so far been limited to early-PE, requiring delivery before 34 
weeks and late PE. In our ongoing studies there are now sufficient data to allow further 
subdivision of the cases delivering at or after 34 weeks into intermediate PE and late 




The objectives of this chapter are to develop algorithms based a combination of 
maternal factors, uterine artery PI, MAP and serum biomarkers to estimate patient-
specific risks for early-, intermediate- and late-PE and to evaluate the screening 
performance of such algorithms. 








4.2.1 Study population 
 
The study comprised of two components. The first population included 36,743 
pregnancies undergoing routine screening for pregnancy complications at 11-13 
weeks. In all cases we recorded maternal factors and serum PAPP-A. Additionally, in 
21,693 cases we measured uterine artery PI and in 13,946 we measured MAP. The 
measurements of uterine artery PI and MAP were not based on any pre-selection of 
the patients but were introduced into routine practice sequentially in time. 
 
The second component of the study comprised of case-control studies, arising from 
the screened population, in which measurements of biochemical markers were carried 
out. 
 
4.2.2 Statistical analysis 
 
In this study we developed a model for predicting PE based on maternal characteristics 
in the whole screened population. We then expanded this model for prediction of PE 
to include the addition of firstly, uterine artery PI, MAP and serum PAPP-A derived 
from the screened population and secondly, serum or plasma PLGF, PP13, sEng, 
inhibin-A, activin-A, PTX3 and P-selectin derived from case-control studies. A 
detailed description of study population (Section 2.1) and statistical analyses (Section 




The maternal characteristics and history in each PE group and the controls in the 
screening population and in the subgroups with measurements of uterine artery PI, 
MAP and serum PLGF are shown in Chapter 2 (Tables 2.1 to 2.4). 






4.3.1 Biophysical and biochemical markers in unaffected pregnancies 
 
Multiple regression analyses in the unaffected pregnancies demonstrated that for each 
marker significant independent contributions were provided by certain maternal 
characteristics. Expected Log10 values for sEng, inhibin-A, activin-A, PTX3 and P-
selectin are given in Chapter 3. Values for uterine artery PI, MAP, PLGF and PP13 
are given below. 
 
Log10 uterine artery PI expected = 0.438 (SE 0.017) - 0.001 (SE 0.0001) x maternal 
age in years - 0.002 (SE 0.0004) x maternal weight in kg + 5.96e-06 (SE 2.55e-06) x 
(maternal weight in kg) 2 + [0.009 (SE 0.003) if cigarette smoker, 0 if not] - 0.002 (SE 
0.0001) x fetal CRL in mm + [0.028 (SE 0.002) if Afro-Caribbean, 0.016 (SE 0.005) 
if Mixed, 0 if any other racial origin]; R2=0.034, p<0.0001. 
 
Log10 MAP expected = 1.797 (SE 0.007) + 0.001 (SE 6.06 e
-05) x maternal age in years 
+ 0.003 (SE 1.57e-04) x maternal weight in kg – 1.0e-04 (SE 1.01e-06) x (maternal weight 
in kg)2 + [0.006 (SE 6.8e-04) if nulliparous, 0 if parous] – [0.008 (SE 0.001) if cigarette 
smoker, 0 in non-smoker] + [(0.066 (SE 0.003) if chronic hypertension, 0 if not] - 
1.68e-04 (SE 4.25e-05) x fetal CRL in mm + [0.011 (SE 0.005) if diabetes mellitus type 
1, 0 if not] – [0.002 (SE 0.001) if Afro-Caribbean, -0.004 (SE 0.002) if Mixed, 0 if any 
other racial origin]; R2=0.161, p<0.0001. 
 
Log10 PlGF expected = 0.932 (SE 0.042) + 0.002 (SE 0.001) x maternal age in years -  
0.002 (SE 3.0e-04) x maternal weight in kg + [0.174 (SE 0.015) if cigarette smoker, 0 
if non-smoker] + 0.009 (SE 5.1e-04) x fetal CRL in mm + [0.177 (SE 0.010) if Afro-
Caribbean, 0.0871 (SE 0.020) if South Asian, 0.045 (SE 0.022) if Mixed, 0 if any other 
racial origin]; R2=0.289, p<0.0001. 
 
Log10 PP13 expected = 1.982 (SE 0.040) + 0.003 (SE 0.001) x maternal age in years – 
0.004 (SE 3.9e-04) x maternal weight in kg – [0.214 (SE 0.019) if cigarette smoker, 0 





if non-smoker] + [0.030 (SE 0.014) if Afro-Caribbean, 0 if any other racial origin]; 
R2=0.174, p<0.0001. 
 
4.3.2 Patient-specific risks for early, intermediate and late PE 
 
The patient-specific a priori risk for early, intermediate and late PE based on maternal 
characteristics was calculated from the formula: odds / (1+odds), where odds= eY. The 
Y for each type of PE was derived from backward stepwise multivariate regression 
analysis.  
 
The results of this analysis are summarized in Tables 4.1 to 4.3. The shrinkage 
coefficient for early, intermediate and late PE models were 0.95, 0.96 and 0.99 
respectively, and all parameters in the model were adjusted accordingly. 
 
The biophysical and biochemical results of each PE group and the unaffected 
pregnancies are compared in Table 4.4. The differences between the PE groups and 
unaffected pregnancies were sequentially greater in the early than intermediate or late 
disease, except for activin-A where the differences were greater for late than early 
disease. 
 
The inter-correlations between biophysical and biochemical markers in PE and 
unaffected pregnancies are shown in Tables 4.5 to 4.8. 
 
4.3.3 Performance of screening for preeclampsia 
 
The estimated detection rates of early, intermediate and late PE at fixed FPRs of 5% 
and 10% in screening by maternal factors only and by combinations of maternal factors 
with biophysical and biochemical markers are given in Table 4.9. Receiver operating 
characteristic curves are shown in Figure 4.1. 
   
 
 
   
 
Table 4.1. Logistic regression analysis to determine factors defining the a priori risk for the prediction of early preeclampsia by maternal 
history and characteristics. 
 
 
OR=odds ratio; CI=confidence interval; p=significance value 
 
Independent variable 
Univariate analysis Multivariate analysis 
OR 95% CI p OR 95% CI P 
Age (per year) 0.761 0.608-0.953 0.017 - - - 
(Age)2 1.004 1.001-1.008 0.024 - - - 
Weight (per kg) 1.026 1.016-1.037 <0.0001 1.021 1.009-1.033 0.001 
Height (per cm) 0.958 0.932-0.985 0.002 0.949 0.921-0.978 0.001 
Race origin       
   Caucasian (reference) 1.000   - - - 
   Afro-Caribbean 4.429 2.987-6.566 <0.0001 3.644 2.431-5.463 <0.0001 
   South Asian 2.829 1.334-5.997 0.007 2.575 1.192-5.560 0.016 
   East Asian 0.000 0.000- 0.992 - - - 
   Mixed 2.122 0.763-5.903 0.149 - - - 
Smoking 0.203 0.050-0.824 0.026 - - - 
Assisted conception 1.974 0.960-4.061 0.065 2.225 1.061-4.670 0.034 
History of diabetes 3.663 1.155-11.613 0.017 - - - 
History of chronic hypertension 15.621 8.970-27.205 <0.0001 5.622 2.988-10.578 <0.0001 
Family history of preeclampsia 2.783 1.558-4.974 0.001 1.910 1.031-3.538 0.040 
Parity       
   Nulliparous (reference) 1.000   1.000   
   Parous with previous preeclampsia 5.052 3.048-8.375 <0.0001 2.235 1.259-3.966 0.006 
   Parous without previous preeclampsia 0.403 0.257-0.631 <0.0001 0.333 0.211-0.525 <0.0001 
























   
 
 
   
 
Table 4.2. Logistic regression analysis to determine factors defining the a priori risk for the prediction of intermediate preeclampsia by 
maternal history and characteristics. 
 
OR=odds ratio; CI=confidence interval; p=significance value 
 
Independent variable 
Univariate analysis Multivariate analysis 
OR 95% CI p OR 95% CI p 
Age (per year) 1.010 0.985-1.035 0.431 - - - 
Weight (per kg) 1.026 1.018-1.034 <0.0001 1.022 1.012-1.031 <0.0001 
Height (per cm) 0.967 0.947-0.988 0.002 0.957 0.936-0.980 <0.0001 
Race origin       
   Caucasian (reference) 1.000   - - - 
   Afro-Caribbean 3.273 2.406-4.452 <0.0001 2.662 1.938-3.657 <0.0001 
   South Asian 2.585 1.468-4.551 0.001 2.411 1.349-4.309 0.003 
   East Asian 0.811 0.199-3.301 0.770 - - - 
   Mixed 1.662 0.726-3.808 0.229 - - - 
Smoking 0.767 0.427-1.379 0.376 - - - 
Assisted conception 1.917 1.088-3.378 0.024 2.131 1.198-3.790 0.010 
History of diabetes 5.948 2.897-12.211 <0.0001 3.376 1.568-7.270 0.002 
History of chronic hypertension 10.759 6.538-17.707 <0.0001 4.198 2.408-7.319 <0.0001 
Family history of preeclampsia 2.120 1.284-3.499 0.003 - - - 
Parity       
   Nulliparous (reference) 1.000   1.000   
   Parous with previous preeclampsia 4.421 2.898-6.744 <0.0001 2.411 1.521-3.823 <0.0001 
   Parous without previous preeclampsia 0.513 0.369-0.711 <0.0001 0.432 0.309-0.603 <0.0001 
























   
 
 
   
 
Table 4.3. Logistic regression analysis to determine factors defining the a priori risk for the prediction of late preeclampsia by maternal 
history and characteristics. 
 
OR=odds ratio; CI=confidence interval; p=significance value 
 
Independent variable 
Univariate analysis Multivariate analysis 
OR 95% CI p OR 95% CI p 
Age (per year) 0.840 0.745-0.948 0.005 - - - 
(Age)2 1.003 1.001-1.005 0.007 - - - 
Weight (per kg) 1.029 1.024-1.034 <0.0001 1.028 1.022-1.034 <0.0001 
Height (per cm) 0.983 0.970-0.997 0.015 0.964 0.950-0.978 <0.0001 
Race origin       
   Caucasian (reference) 1.000   - - - 
   Afro-Caribbean 2.624 2.150-3.202 <0.0001 2.123 1.735-2.598 <0.0001 
   South Asian 1.346 0.851-2.129 0.205 - - - 
   East Asian 1.478 0.782-2.794 0.229 - - - 
   Mixed 1.111 0.605-2.309 0.735 - - - 
Smoking 0.765 0.524-1.117 0.166 - - - 
Assisted conception 1.062 0.661-1.707 0.804 - - - 
History of diabetes 0.590 0.146-2.380 0.459 - - - 
History of chronic hypertension 6.909 4.699-10.224 <0.0001 3.019 1.967-4.632 <0.0001 
Family history of preeclampsia 1.720 1.208-2.449 0.003 - - - 
Parity       
   Nulliparous (reference) 1.000   1.000   
   Parous with previous preeclampsia 3.216 2.404-4.304 <0.0001 1.815 1.325-2.485 <0.0001 
   Parous without previous preeclampsia 0.350 0.279-0.438 <0.0001 0.289 0.230-0.362 <0.0001 





















   
 
 
   
 
Table 4.4. Median and interquartile range (IQR) of pregnancy associated plasma protein-A (PAPP-A), free β-human chorionic 
gonadotropin (hCG), uterine artery pulsatility index (PI), mean arterial pressure (MAP), placenal growth factor (PlGF), placental protein 
13 (PP13), soluble endoglin (sEng), inhibin-A, activin-A, pentraxin-3 (PTX-3) and P-selectin in the control group and in those 
subsequently developing early, intermediate and late- preeclampsia. 
 
Variables 
Control Early PE Intermediate PE Late PE 
n MoM n MoM n MoM n MoM 
PAPP-A, median (IQR) 32,850 1.02 (0.70-1.45) 112 0.63 (0.40-1.14)* 187 0.79 (0.53-1.11)* 453 0.90 (0.62-1.29)* 
Uterine artery PI, median (IQR) 21,090 1.02 (0.84-1.23) 86 1.47 (1.11-1.72)* 143 1.28 (1.06-1.51)* 354 1.11 (0.88-1.36)* 
MAP, median (IQR) 13,515 1.00 (0.95-1.06) 69 1.10 (1.04-1.17)* 111 1.08 (1.03-1.13)* 251 1.06 (1.00-1.13)* 
PlGF, median (IQR) 2,143 0.99 (0.77-1.27) 56 0.64 (0.46-0.82)* 104 0.72 (0.55-0.91)* 186 0.85 (0.68-1.12)* 
PP13, median (IQR) 1,210 1.00 (0.76-1.33) 48 0.88 (0.57-1.23) 70 0.93 (0.70-1.30) 103 1.11 (0.89-1.49) 
sEndoglin, median (IQR) 181 0.99 (0.78-1.31) 29 1.44 (1.03-1.92)* 28 0.89 (0.70-1.21) 32 0.99 (0.74-1.23) 
Inhibin-A, median (IQR) 403 0.98 (0.75-1.33) 25 1.61 (0.90-1.94)† 37 1.13 (0.83-1.70) 62 1.32 (0.91-1.70)* 
Activin-A, median (IQR) 398 1.00 (0.76-1.30) 26 1.25 (1.00-1.72)† 41 1.22 (0.97-1.74)† 61 1.36 (1.01-1.70)* 
Pentraxin 3, median (IQR) 291 0.99 (0.76-1.31) 26 1.40 (0.82-2.04) 37 1.40 (0.93-1.89)† 60 1.02 (0.78-1.40) 
P-Selectin, median (IQR) 294 1.01 (0.84-1.24) 26 1.21 (0.83-1.35) 36 1.18 (0.90-1.43) 62 1.16 (0.96-1.37)† 
 
MoM=multiple of the unaffected median. Comparisons between the outcome groups by Mann Whitney-U test with post hoc Bonferroni 
correction. Critical significance level p=0.0167; * p<0.0001; †p<0.01. 
  
























   
 
 
   
 
Table 4.5. Intercorrelations between pregnancy associated plasma protein-A (PAPP-A) multiple of the median (MoM), uterine artery 
pulsatility index (PI) MoM, mean arterial pressure (MAP) MoM, placental growth factor (PlGF) MoM, placental protein 13 (PP13) MoM, 
soluble endoglin (sEng) MoM, inhibin-A MoM, activin-A MoM, pentraxin-3 (PTX-3) MoM and P-selectin MoM in unaffected 
pregnancies. 
 
Variable PAPP-A Uterine artery PI MAP PlGF PP13 sEndoglin Inhibin-A Activin-A Pentraxin 3 P-Selectin 
PAPP-A  
  Pearson correlation (r) 1.000 -0.154 -0.016 0.350 0.334 0.240 0.208 0.310 0.107 -0.033 
  Significance value (p) - <0.0001 0.064 <0.0001 <0.0001 0.001 <0.0001 <0.0001 0.068 0.572 
Uterine artery PI  
  Pearson correlation (r) -0.154 1.000 -0.047 -0.149 -0.113 -0.078 -0.043 -0.010 -0.073 -0.044 
  Significance value (p) <0.0001 - <0.0001 <0.0001 <0.0001 0.295 0.387 0.850 0.214 0.452 
MAP  
  Pearson correlation (r) -0.016 -0.047 1.000 0.002 0.026 0.033 0.113 0.037 0.068 0.187 
  Significance value (p) 0.064 <0.0001 - 0.943 0.375 0.674 0.030 0.483 0.263 0.002 
PlGF  
  Pearson correlation (r) 0.350 -0.149 0.002 1.000 0.066 -0.090 0.092 0.132 0.001 -0.016 
  Significance value (p) <0.0001 <0.0001 0.943 - 0.036 0.231 0.106 0.020 0.988 0.781 
PP13  
  Pearson correlation (r) 0.334 -0.113 0.026 0.066 1.000 0.029 0.400 0.393 0.113 0.059 
  Significance value (p) <0.0001 <0.0001 0.375 0.036 - 0.701 <0.0001 <0.0001 0.055 0.310 
sEndoglin  
  Pearson correlation (r) 0.240 -0.078 0.033 -0.090 0.029 1.000 0.158 0.098 0.194 0.045 
  Significance value (p) 0.001 0.295 0.674 0.231 0.701 - 0.117 0.340 0.059 0.666 
Inhibin-A  
  Pearson correlation (r) 0.208 -0.043 0.113 0.092 0.400 0.158 1.000 0.224 0.113 0.157 
  Significance value (p) <0.0001 0.387 0.030 0.106 <0.0001 0.117 - <0.0001 0.055 0.007 
Activin-A  
  Pearson correlation (r) 0.310 -0.010 0.037 0.132 0.393 0.098 0.224 1.000 0.052 0.060 
  Significance value (p) <0.0001 0.850 0.483 0.020 <0.0001 0.340 <0.0001 - 0.383 0.308 
Pentraxin 3  
  Pearson correlation (r) 0.107 -0.073 0.068 0.001 0.113 0.194 0.113 0.052 1.000 0.087 
  Significance value (p) 0.068 0.214 0.263 0.988 0.055 0.059 0.055 0.383 - 0146 
P-Selectin  
  Pearson correlation (r) -0.033 -0.044 0.187 -0.016 0.059 0.045 0.157 0.060 0.087 1.000 
  Significance value (p) 0.572 0.452 0.002 0.781 0.310 0.666 0.007 0.308 0.146 - 
  
























   
 
 
   
 
Table 4.6. Intercorrelations between pregnancy associated plasma protein-A (PAPP-A) multiple of the median (MoM), uterine artery 
pulsatility index (PI) MoM, mean arterial pressure (MAP) MoM, placental growth factor (PlGF) MoM, placental protein 13 (PP13) MoM, 
soluble endoglin (sEng) MoM, inhibin-A MoM, activin-A MoM, pentraxin-3 (PTX-3) MoM and P-selectin MoM in pregnancies destined 
to develop early-preeclampsia. 
 
Variable PAPP-A Uterine artery PI MAP PlGF PP13 sEndoglin Inhibin-A Activin-A Pentraxin 3 P-Selectin 
PAPP-A           
  Pearson correlation (r) 1.000 -0.094 0.210 0.399 0.213 -0.068 -0.348 -0.001 0.169 -0.164 
  Significance value (p) - 0.389 0.083 0.002 0.154 0.726 0.088 0.995 0.409 0.424 
Uterine artery PI           
  Pearson correlation (r) -0.094 1.000 -0.153 0.074 -0.053 0.096 -0.014 0.267 -0.182 0.292 
  Significance value (p) 0.389 - 0.218 0.594 0.727 0.622 0.947 0.188 0.373 0.148 
MAP           
  Pearson correlation (r) 0.210 -0.153 1.000 -0.067 -0.050 0.086 0.338 0.202 0.320 0.065 
  Significance value (p) 0.083 0.218 - 0.660 0.759 0.677 0.124 0.367 0.137 0.769 
PlGF           
  Pearson correlation (r) 0.399 0.074 -0.067 1.000 0.159 -0.269 -0.412 -0.276 -0.335 -0.115 
  Significance value (p) 0.002 0.594 0.660 - 0.394 0.183 0.040 0.172 0.094 0.577 
PP13           
  Pearson correlation (r) 0.213 -0.053 -0.050 0.159 1.000 -0.312 -0.117 -0.155 -0.111 -0.228 
  Significance value (p) 0.154 0.727 0.759 0.394 - 0.099 0.578 0.449 0.591 0.263 
sEndoglin           
  Pearson correlation (r) -0.068 0.096 0.086 -0.269 -0.312 1.000 -0.148 0.313 -0.001 0.183 
  Significance value (p) 0.726 0.622 0.677 0.183 0.099 - 0.481 0.137 0.994 0.370 
Inhibin-A           
  Pearson correlation (r) -0.348 -0.014 0.338 -0.412 -0.117 -0.148 1.000 0.169 0.362 -0.040 
  Significance value (p) 0.088 0.947 0.124 0.040 0.578 0.481 - 0.430 0.075 0.851 
Activin-A           
  Pearson correlation (r) -0.001 0.267 0.202 -0.276 -0.155 0.313 0.169 1.000 0.361 0.085 
  Significance value (p) 0.995 0.188 0.367 0.172 0.449 0.137 0.430 - 0.083 0.692 
Pentraxin 3           
  Pearson correlation (r) 0.169 -0.182 0.320 -0.335 -0.111 -0.001 0.362 0.361 1.000 -0.052 
  Significance value (p) 0.409 0.373 0.137 0.094 0.591 0.994 0.075 0.083 - 0.800 
P-Selectin           
  Pearson correlation (r) -0.164 0.292 0.065 -0.115 -0.228 0.183 -0.040 0.085 -0.052 1.000 
  Significance value (p) 0.424 0.148 0.769 0.577 0.263 0.370 0.851 0.692 0.800 - 
























   
 
 
   
 
Table 4.7. Intercorrelations between pregnancy associated plasma protein-A (PAPP-A) multiple of the median (MoM), uterine artery 
pulsatility index (PI) MoM, mean arterial pressure (MAP) MoM, placental growth factor (PlGF) MoM, placental protein 13 (PP13) MoM, 
soluble endoglin (sEng) MoM, inhibin-A MoM, activin-A MoM, pentraxin-3 (PTX-3) MoM and P-selectin MoM in pregnancies destined 
to develop intermediate-preeclampsia. 
 
Variable PAPP-A Uterine artery PI MAP PlGF PP13 sEndoglin Inhibin-A Activin-A Pentraxin 3 P-Selectin 
PAPP-A           
  Pearson correlation (r) 1.000 -0.047 -0.020 0.071 0.198 0.228 0.140 0.352 0.264 0.294 
  Significance value (p) - 0.581 0.837 0.476 0.095 0.243 0.407 0.024 0.115 0.081 
Uterine artery PI           
  Pearson correlation (r) -0.047 1.000 -0.029 -0.193 -0.225 0.370 0.100 0.086 -0.286 -0.241 
  Significance value (p) 0.581 - 0.770 0.049 0.060 0.053 0.558 0.594 0.086 0.157 
MAP           
  Pearson correlation (r) -0.020 -0.029 1.000 0.048 0.085 -0.013 0.048 -0.013 -0.121 0.229 
  Significance value (p) 0.837 0.770 - 0.660 0.490 0.950 0.782 0.936 0.480 0.187 
PlGF           
  Pearson correlation (r) 0.071 -0.193 0.048 1.000 0.146 -0.488 -0.173 -0.186 -0.262 0.225 
  Significance value (p) 0.476 0.049 0.660 - 0.254 0.008 0.307 0.244 0.118 0.187 
PP13           
  Pearson correlation (r) 0.198 -0.225 0.085 0.146 1.000 0.030 0.212 0.234 0.143 0.235 
  Significance value (p) 0.095 0.060 0.490 0.254 - 0.878 0.209 0.141 0.397 0.168 
sEndoglin           
  Pearson correlation (r) 0.228 0.370 -0.013 -0.488 0.030 1.000 0.064 0.134 0.235 0.204 
  Significance value (p) 0.243 0.053 0.950 0.008 0.878 - 0.747 0.497 0.228 0.307 
Inhibin-A           
  Pearson correlation (r) 0.140 0.100 0.048 -0.173 0.212 0.064 1.000 0.517 0.190 -0.157 
  Significance value (p) 0.407 0.558 0.782 0.307 0.209 0.747 - 0.001 0.260 0.361 
Activin-A           
  Pearson correlation (r) 0.352 0.086 -0.013 -0.186 0.234 0.134 0.517 1.000 0.280 -0.046 
  Significance value (p) 0.024 0.594 0.936 0.244 0.141 0.497 0.001 - 0.093 0.790 
Pentraxin 3           
  Pearson correlation (r) 0.264 -0.286 -0.121 -0.262 0.143 0.235 0.190 0.280 1.000 0.076 
  Significance value (p) 0.115 0.086 0.480 0.118 0.397 0.228 0.260 0.093 - 0.658 
P-Selectin           
  Pearson correlation (r) 0.294 -0.241 0.229 0.225 0.235 0.204 -0.157 -0.046 0.076 1.000 
  Significance value (p) 0.081 0.157 0.187 0.187 0.168 0.307 0.361 0.790 0.658 - 
 
























   
 
 
   
 
Table 4.8. Intercorrelations between pregnancy associated plasma protein-A (PAPP-A) multiple of the median (MoM), uterine artery 
pulsatility index (PI) MoM, mean arterial pressure (MAP) MoM, placental growth factor (PlGF) MoM, placental protein 13 (PP13) MoM, 
soluble endoglin (sEng) MoM, inhibin-A MoM, activin-A MoM, pentraxin-3 (PTX-3) MoM and P-selectin MoM in pregnancies destined 
to develop late- preeclampsia. 
 
Variable PAPP-A Uterine artery PI MAP PlGF PP13 sEndoglin Inhibin-A Activin-A Pentraxin 3 P-Selectin 
PAPP-A           
  Pearson correlation (r) 1.000 -0.123 0.125 0.254 0.346 -0.047 0.435 0.352 0.106 -0.006 
  Significance value (p) - 0.020 0.048 <0.0001 <0.0001 0.799 <0.0001 0.005 0.420 0.962 
Uterine artery PI           
  Pearson correlation (r) -0.123 1.000 -0.114 -0.032 -0.215 -0.042 -0.168 -0.159 0.084 -0.316 
  Significance value (p) 0.020 - 0.074 0.661 0.029 0.820 0.191 0.221 0.526 0.012 
MAP           
  Pearson correlation (r) 0.125 -0.114 1.000 0.060 -0.058 -0.149 0.006 0.054 -0.199 0.047 
  Significance value (p) 0.048 0.074 - 0.477 0.572 0.416 0.962 0.682 0.134 0.719 
PlGF           
  Pearson correlation (r) 0.254 -0.032 0.060 1.000 0.161 -0.360 -0.019 0.009 -0.144 0.006 
  Significance value (p) <0.0001 0.661 0.477 - 0.130 0.043 0.885 0.947 0.276 0.963 
PP13           
  Pearson correlation (r) 0.346 -0.215 -0.058 0.161 1.000 0.109 0.410 0.364 0.299 0.118 
  Significance value (p) <0.0001 0.029 0.572 0.130 - 0.551 0.001 0.004 0.020 0.359 
sEndoglin           
  Pearson correlation (r) -0.047 -0.042 -0.149 -0.360 0.109 1.000 0.128 0.171 0.010 0.089 
  Significance value (p) 0.799 0.820 0.416 0.043 0.551 - 0.484 0.349 0.955 0.628 
Inhibin-A           
  Pearson correlation (r) 0.435 -0.168 0.006 -0.019 0.410 0.128 1.000 0.286 0.212 0.206 
  Significance value (p) <0.0001 0.191 0.962 0.885 0.001 0.484 - 0.028 0.105 0.109 
Activin-A           
  Pearson correlation (r) 0.352 -0.159 0.054 0.009 0.364 0.171 0.286 1.000 0.325 0.037 
  Significance value (p) 0.005 0.221 0.682 0.947 0.004 0.349 0.028 - 0.013 0.780 
Pentraxin 3           
  Pearson correlation (r) 0.106 0.084 -0.199 -0.144 0.299 0.010 0.212 0.325 1.000 -0.082 
  Significance value (p) 0.420 0.526 0.134 0.276 0.020 0.955 0.105 0.013 - 0.536 
P-Selectin           
  Pearson correlation (r) -0.006 -0.316 0.047 0.006 0.118 0.089 0.206 0.037 -0.082 1.000 
  Significance value (p) 0.962 0.012 0.719 0.963 0.359 0.628 0.109 0.780 0.536 - 
 
























   
 
 
   
 
Table 4.9. Performance of screening for early, intermediate and late-PE by maternal factors only and maternal factors with pregnancy 
associated plasma protein-A (PAPP-A), uterine artery pulsatility index (PI), mean arterial pressure (MAP), placental growth factor (PlGF), 




Detection rate (95% confidence interval) for fixed false positive rate 
Early PE Intermediate PE Late PE 
5% 10% 5% 10% 5% 10% 
Maternal factors 33.0 (24.6-42.7) 46.4 (36.9-56.1) 27.8 (20.0-37.2) 37.4 (28.6-47.2) 24.5 (17.1-33.8) 34.7 (26.1-44.4) 
Maternal factors plus       
   Pregnancy associated plasma protein-A 47.0 (37.5-56.7) 58.3 (49.5-67.5) 31.4 (23.1-41.0) 43.2 (33.2-53.0) 25.8 (17.7-34.5) 37.2 (28.4-47.0) 
   Uterine artery pulsatility index 54.1 (44.4-63.5) 66.1 (56.4-74.6) 36.9 (28.1-46.7) 48.9 (39.3-58.6) 27.1 (19.4-36.5) 38.6 (29.7-48.4) 
   Mean arterial pressure 49.7 (40.1-59.3) 62.6 (52.8-71.5) 41.1 (32.0-50.9) 53.7 (44.0-63.2) 33.1 (24.7-42.8) 44.6 (35.2-54.4) 
   Placental growth factor 53.5 (43.8-63.0) 65.0 (55.3-73.6) 40.3 (31.2-40.1) 52.7 (43.0-62.2) 27.0 (19.3-36.4) 38.7 (29.7-48.5) 
   Placental protein 13 39.8 (30.8-49.6) 51.9 (42.2-61.4) 30.2 (22.1-39.8) 41.4 (32.2-51.2) 26.2 (18.6-35.6) 37.8 (28.9-47.6) 
   sEndoglin 46.2 (36.8-55.9) 58.8 (49.0-68.0) 31.0 (22.8-40.6) 42.2 (33.0-52.0) 25.7 (18.2-35.1) 37.1 (28.3-46.9) 
   Inhibin-A 44.4 (35.1-54.2) 56.7 (46.9-66.0) 32.6 (24.2-42.3) 44.2 (34.9-54.0) 30.8 (22.6-40.4) 42.5 (33.3-52.3) 
   Activin-A 40.4 (31.3-50.2) 53.1 (43.4-62.6) 33.7 (25.2-43.4) 46.0 (36.6-55.7) 34.1 (25.6-43.8) 47.0 (37.5-56.7) 
   Pentraxin 3 37.8 (28.9-47.6) 50.1 (40.5-59.7) 31.2 (23.0-40.8) 43.2 (33.9-53.0) 25.6 (18.1-35.0) 36.8 (28.0-46.6) 
   P-Selectin 38.5 (29.6-48.3) 50.5 (40.9-60.1) 31.1 (22.9-40.7) 42.6 (36.8-55.9) 28.5 (20.6-38.0) 40.5 (31.4-50.3) 
Maternal factors plus biophysical markers 66.5 (56.8-75.0) 77.8 (68.7-84.8) 48.7 (39.1-58.4) 61.2 (51.4-70.2) 34.3 (25.7-44.0) 46.6 (37.1-56.3) 
   plus PAPP-A and PLGF 77.8 (68.7-84.8) 86.7 (78.7-92.0) 56.6 (46.8-65.9) 68.9 (59.3-77.1) 35.2 (26.6-45.0) 48.5 (38.9-58.2) 
   plus PAPP-A , PLGF, Inhibin-A and Activin-A 83.4 (74.9-89.4) 90.0 (82.6-94.5) 63.6 (53.8-72.4) 74.8 (65.5-82.3) 47.9 (38.4-57.6) 61.4 (51.6-70.4) 
   plus PAPP-A , PLGF, Inhibin-A , Activin-A, sEndoglin 86.7 (78.7-92.1) 92.1 (85.1-96.0) 68.6 (59.0-76.9) 79.5 (70.6-86.3) 50.5 (40.9-60.1) 64.2 (54.4-72.9) 
Maternal factors plus all markers 91.0 (83.8-95.2) 95.2 (89.1-98.0) 79.4 (70.5-86.2) 88.3 (80.5-93.2) 60.9 (51.1-69.9) 71.1 (61.6-79.1) 
































Figure 4.1. Receiver operating characteristics curves in the prediction of early (left), 
intermediate (middle) and late preeclampsia (right) by maternal factors only (   ) and 






The results of this study demonstrate that the risk for PE is associated with maternal 
characteristics; it increases with maternal weight and decreases with height, it is higher 
in women of Afro-Caribbean and South Asian racial origin than in Caucasians, and it is 
increased in women conceiving after the use of ovulation induction drugs, in those 
with a personal or family history of PE and in those with pre-existing chronic 
hypertension or diabetes mellitus. In parous women with no previous PE the risk of 
developing PE in the current pregnancy was reduced by 60-70%. In general, the odds 
ratios for the factors in maternal history which defined the a priori risk for PE were 
inversely proportional to the gestation at delivery, with higher ratios for early disease 
compared to intermediate and late PE.  





Algorithms that combine the various maternal characteristics at 11-13 weeks could 
potentially identify 33%, 28% and 25% of pregnancies that subsequently develop 
early, intermediate and late PE, at the FPR of 5%.  
 
The patient-specific a posteriori risk for early, intermediate and late PE were 
calculated by multiplying the a priori patient characteristics-derived risk with the 
likelihood ratio of a series of biophysical and biochemical markers after appropriate 
adjustments for the inter-correlations between these markers. As in the cases of 
maternal factors the differences in biophysical and biochemical markers of impaired 
placentation between the PE and unaffected groups were in general more pronounced 
in those developing early disease compared to intermediate or late-PE. Algorithms 
which combine maternal characteristics and biophysical and biochemical tests at 11-
13 weeks could potentially identify about 90%, 80% and 60% of pregnancies that 
subsequently develop early, intermediate and late PE, at the FPR of 5%.  
 
An integrated first hospital visit at 11-13 weeks combining data from maternal 
characteristics and history with findings of biophysical and biochemical tests can 
define the patient-specific risk for a wide spectrum of pregnancy complications, 
including aneuploidies, fetal defects, miscarriage and fetal death, preterm delivery, 
fetal growth restriction and macrosomia, gestational diabetes, hypothyroidism and PE 
(Akolekar et al., 2011a; Ashoor et al., 2010; Beta et al., 2011; Greco et al., 2011; 
Karagiannis et al., 2011; Nanda et al., 2011; Nicolaides, 2011; Syngelaki et al., 2011; 
Poon et al, 2011a and 2011b). Early estimation of patient-specific risks for these 
pregnancy complications would improve pregnancy outcome by shifting antenatal care 
from a series of routine visits to a more individualized patient and disease-specific 
approach both in terms of the schedule and content of such visits. In the case of PE 
effective early identification of the high-risk group could potentially improve outcome 
by directing such patients to specialist clinics for close surveillance and would be the 
basis for future studies investigating the potential role of pharmacological 
interventions, such as aspirin, starting from the first-trimester to improve placentation 














COMPETING RISKS MODEL IN EARLY 
SCREENING FOR PREECLAMPSIA BY 





  CHAPTER 5 
 
 








PE has been defined as early or late on the basis of whether or not delivery occurs 
before 34 weeks’ gestation. In general, the deviations from normal for the various 
proposed biomarkers have been greater in early-PE than in late-PE (Poon et al., 2009a; 
Akolekar et al., 2011b). In our previous study (Chapter 4), we demonstrated this 
approach to screening by expressing the effects of variables from maternal 
characteristics and history as odds ratios and the effect of biomarkers MoMs as 
likelihood ratios for early, intermediate or late PE. This has led to the view that early 
and late-PE may be different diseases with different biomarker profiles. An alternative 
view is that PE is a spectrum disorder the degree of which is reflected in both gestation 




The objectives of this chapter are to investigate the performance of screening for PE 
based on a survival time model which treats gestation at delivery as a continuous 
variable and using Bayes theorem to combine information from maternal 




The data for this study were derived from our prospective study for pregnancy 
complications in women attending for their routine first hospital visit in pregnancy at 
11-13 weeks’ gestation. We developed a model for predicting PE based on maternal 
characteristics in the whole screened population. We then expanded this model for 
prediction of PE to include the addition of uterine artery PI, MAP, PAPP-A and PLGF. 
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The approach for early screening for PE proposed in this chapter was based on a 





5.3.1  Gestational age at delivery with preeclampsia given maternal 
characteristics 
 
A standard Gaussian regression model for the gestation at delivery was fitted by 
treating deliveries for which PE did not occur as censored observations (Table 5.1). 
This specified the mean gestational age at delivery with PE for given variables from 
maternal demographic characteristics, medical and obstetric history; the smaller the 
mean gestational age the higher the risk for PE (Figure 5.1).  
 
 
Table 5.1. Fitted regression model for posited gestational age in weeks at delivery 
with preeclampsia (PE). In this model the mean gestational age for delivery with PE 
is 55 weeks with a residual standard deviation of 7.11 weeks. 
 
 
 Coefficient SE 95% CI p 
Intercept 55.0081 0.3465 54.3289 to 55.6873 0.00000 
Age above 30 years -0.10367 0.02319 -0.14912 to -0.05822  0.00001 
Weight in kg  - 69  -0.07259 0.00551 -0.08339 to -0.06180  0.00000 
Height in m - 1.64 12.4007 1.3263 9.801129 to 15.0003 0.00000 
Ethnicity      
    Afro-Caribbean -3.0357 0.2040 -3.4355 to -2.6360  0.00000 
    South Asian -1.7709 0.3737 -2.5034 to -1.0384  0.00000 
Previous History      
   Parous with PE -3.0333 0.3174 -3.6554 to-2.4112  0.00000 
   Parous with no PE 3.1440 0.2033 2.7455 to 3.5424 0.00000 
Mother had PE -1.8841 0.3262 -2.5234 to -1.2448  0.00000 
Conception by IVF -1.7895 0.4782 -2.7268 to -0.8523  0.00018 
SLE or APS -4.0613 1.3186 -6.6459 to -1.4768  0.00207 
Chronic hypertension -6.2415 0.4179 -7.0606 to -5.4223  0.00000 
Type 1 DM -3.8525 0.9732 -5.7600 to -1.9450  0.00008 
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In this model the mean gestational age for delivery with PE was 55 weeks with 
estimated standard deviation (SD) of 7.11 weeks (Table 5.1). Certain variables, 
including advancing maternal age over 30 years, increasing weight, Afro-Caribbean 
and South Asian racial origin, previous pregnancy with PE, conception by in vitro 
fertilization and a medical history of chronic hypertension, type 2 diabetes mellitus 
and systemic lupus erythematosus or antiphospholipid syndrome increase the risk for 
development of PE. The consequence of this increased risk is a shift to the left of the 





Figure 5.1. Effects of maternal characteristics (with 95% confidence intervals) on the 
gestational age at delivery for preeclampsia. This effect is expressed as gestational 
weeks by which the expected gestational age at delivery for preeclampsia is altered.  
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Figure 5.2. Distribution of gestational age at delivery for preeclampsia (PE). In 
pregnancies at low-risk for PE the gestational age distribution is shifted to the right 
and in most pregnancies delivery will occur before the development of PE. In 
pregnancies at high-risk for PE the distribution is shifted to the left. The risk of PE 
occurring at or before a specified gestational age is given by the area under the 
distribution curve (black). In the low-risk group the risk of PE at or before 34 weeks’ 
gestation is 0.01 or 1% and in the high-risk group the risk is 0.6 or 60%.    
 
 
5.3.2 Distribution of biomarkers in pregnancies with preeclampsia 
 
Multiple regression analyses in the unaffected pregnancies demonstrated the 
significant independent contributions for the prediction of log10 uterine artery PI 
(Table 5.2; R2=0.034, p<0.0001) and log10 MAP (Table 5.3; R
2=0.127, p<0.0001). 
 
Log10 uterine artery PI expected = 0.2638615843586 – [0.0008928915003 x (maternal 
weight – 69 kg)] + [0.0000089122525 x (maternal weight – 69 kg)2] – 
[0.0046798061340 x (gestational age – 77 days)] + (0.0232056722206 if Afro-
Caribbean racial origin, 0 if any other race); R2=0.034, p<0.0001. 
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Log10 MAP expected = 1.9299538440779 + [0.0011415204801 x (maternal weight – 
69 kg)] – [0.0000080469298 x (maternal weight – 69 kg)2]; R2=0.127, p<0.0001. 
 
 











In pregnancies with PE there was an inverse correlation between MoM values of 
biophysical and biochemical markers with gestational age at delivery (Figures 5.3 and 
5.4).  
 



























Variable Coefficient 95% CI p 
Intercept 1.9299538440779 
1.9294356282676 
to  1.9304720598883 
<0.0001 
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Figure 5.3. Scatter diagram and regression line with 95% confidence limits for the 
relationship between uterine artery pulsatility index (PI) multiple of the median 
(MoM) and mean arterial pressure (MAP) MoM and gestational age at delivery in 
pregnancies with preeclampsia. 
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Figure 5.4. Scatter diagram and regression line with 95% confidence limits for the 
relationship between pregnancy associated plasma protein-A (PAPP-A) multiple of 
the median (MoM) and placental growth factor (PLGF) MoM and gestational age at 
delivery in pregnancies with preeclampsia. 
 
The fitted regression models for log10 MoM values on gestational age at delivery are 
presented in Table 5.4 and the estimated parameters for the assumed bivariate 
Gaussian distributions for log MoM values are given in Table 5.5.   
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Table 5.4. Fitted regression model for marker log10 multiple of the median (MoM) 
values on gestation at time of delivery for pregnancies with preeclampsia. 
 
Marker Intercept SE Slope P 
Uterine artery PI 0.642102 0.038479 -0.015173 <0.0001 
Mean arterial pressure 0.114859 0.014798 -0.002115 <0.0001 
Pregnancy associated plasma protein-A -0.656448 0.078707 0.015555 <0.0001 
Placental growth factor 0.861296 0.089182 0.020221 <0.0001 
 
 
Table 5.5.  Standard deviations (SD) and correlations, with 95% confidence limits, 
for log10 multiples of the median (MoM) biomarker values. 
 
 No preeclampsia Preeclampsia 
SD Uterine artery PI 0.1242215  
(0.122254 to 0.127840) 
0.1409539  
(0.122250 to 0.158148) 
SD MAP 0.0386549  
(0.037002 to 0.040257) 
0.0426263  
(0.032693 to 0.053506) 
SD PAPP-A 0.2368016  
(0.229462 to 0.237103) 
0.2679589  
(0.252859 to 0.285103) 
SD PLGF 0.1764965  
(0.173864 to 0.179168) 
0.2165872  
(0.202972 to 0.229780) 
Correlation Uterine PI and MAP -0.0724816  
(-0.075278 to -0.070882) 
0.0093204  
(-0.004507 to 0.014433) 
Correlation Uterine PI and PAPP-A -0.156970  
(-0.177317 to -0.145472) 
-0.1766223  
(-0.256403 to -0.099764) 
Correlation Uterine PI and PLGF -0.1322802  
(-0.144440 to -0.111484) 
-0.2113414  
(-0.303681 to -0.154827) 
Correlation MAP and PAPP-A -0.0069674  
(-0.020433 to 0.011444) 
0.0354576  
(-0.091128 to 0.066178) 
Correlation MAP and PLGF -0.0346327  
(-0.052455 to -0.018998) 
0.0128895  
(-0.070326 to 0.091987) 
Correlation PAPP-A and PLGF 0.3009237  
(0.293361 to 0.328260) 
0.3543634  
(0.271487 to 0.421228) 
 
 
5.3.3 Performance of screening for preeclampsia 
 
Estimated detection rates of PE requiring delivery before 34, 37 and 42 weeks’ 
gestation, at false positive rates of 5% and 10% in screening by maternal factors, 
uterine artery PI, MAP, serum PAPP-A, PLGF and their combination are given in 
Table 5.6. 





Table 5.6. Estimated detection rates of preeclampsia requiring delivery before 34, 37 and 42 weeks’ gestation, at false positive rate (FPR) 
of 5% and 10%. 
 
Screening test FPR (%) 
PE <34 wks 
N=214 
PE <37 wks 
N=568 
PE <42 wks 
N=1,426 
Risk cut-off Detection Risk cut-off Detection Risk cut-off Detection 
Maternal characteristics 
5.0 1:93 78 (35.5) 1:35 186 (32.7) 1:9 419 (29.4) 
10.0 1:143 108 (50.5) 1:51 246 (43.3) 1:12 574 (40.3) 
  Uterine artery PI 
5.0 1:88 127 (59.3) 1:31 227 (40.0) 1:9 445 (31.2) 
10.0 1:164 161 (75.2) 1:52 313 (55.1) 1:12 602 (42.2) 
  MAP 
5.0 1:88 125 (58.4) 1:31 250 (44.0) 1:8 532 (37.3) 
10.0 1:159 156 (72.9) 1:52 337 (59.3) 1:12 763 (53.5) 
  PAPP-A 
5.0 1:88 93 (43.6) 1:33 212 (37.3) 1:9 449 (31.5) 
10.0 1:151 117 (54.7) 1:52 274 (48.2) 1:12 601 (42.1) 
  PLGF 
5.0 1:95 127 (59.3) 1:33 232 (40.8) 1:9 415 (29.1) 
10.0 1:170 155 (72.4) 1:55 309 (54.4) 1:12 572 (40.1) 
  Uterine PI and MAP 
5.0 1:96 171 (79.9) 1:31 310 (54.6) 1:7 498 (34.9) 
10.0 1:197 192 (89.7) 1:57 406 (71.5) 1:12 807 (56.6) 
  PAPP-A and PLGF 
5.0 1:101 129 (60.3) 1:34 243 (42.8) 1:9 433 (30.4) 
10.0 1:181 159 (74.3) 1:56 317 (55.8) 1:12 582 (40.8) 
  Uterine PI, MAP and PAPP-A 
5.0 1:105 175 (81.8) 1:26 298 (52.5) 1:7 514 (36.0) 
10.0 1:216 198 (92.5) 1:65 424 (74.6) 1:12 811 (59.9) 
  Uterine PI, MAP and PLGF 
5.0 1:126 187(87.4) 1:36 344 (60.6) 1:8 536 (37.6) 
10.0 1:261 205 (95.8) 1:67 439 (77.3) 1:12 755 (52.9) 
  Uterine PI, MAP, PAPP-A and PLGF 
5.0 1:128 200 (93.4) 1:36 347 (61.1) 1:8 539 (37.8) 
10.0 1:269 206 (96.3) 1:67 435 (76.6) 1:12 764 (53.6) 
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The comparison of the expected and observed number of cases with according to the 
estimated risk range is presented in Table 5.7.  
 
Table 5.7. Accuracy of estimated risk for preeclampsia by a combination of maternal 
characteristics, uterine artery pulsatility index (PI), mean arterial pressure (MAP), 
serum pregnancy associated plasma protein-A (PAPP-A) and serum placental growth 
factor (PLGF). 
 
Estimated risk Observed 
Range Median (95% CI) Incidence Risk 
    
PE <34 weeks    
1 in 2 to 1 in 50 1 in 29 (6-48) 157 of 1,170 1 in 7.5 
1 in 51 to 1 in 100 1 in 76 (53-98) 22 of 1,241 1 in 56.4 
1 in 101 to 1 in 300 1 in 197 (109-290) 29 of 4,140 1 in 142.8 
Less than 1 in 300 1 in 3724 (452-41,342) 6 of 51,121 1 in 8520.2 
    
PE <37 weeks    
1 in 2 to 1 in 50 1 in 27 (5-48) 399 of 4,582 1 in 11.5 
1 in 51 to 1 in 100 1 in 74 (53-98) 96 of 4,492 1 in 46.8 
1 in 101 to 1 in 300 1 in 188 (108-288) 63 of 12,518 1 in 198.7 
Less than 1 in 300 1 in 978 (340-5362) 10 of 36,434 1 in 3643.4 
    
PE <42 weeks    
1 in 2 to 1 in 10 1 in 7 (2-10) 673 of 5,414 1 in 8.0 
1 in 11 to 1 in 20 1 in 16 (11-20) 364 of 7,283 1 in 20.0 
1 in 21 to 1 in 50 1 in 34 (22-49) 
330 of 
17,327 1 in 52.5 
Less than 1 in 50 1 in 99 (54-302) 59 of 28,860 1 in 489.2 
 
Table 5.8 shows the performance of screening for PE requiring delivery before 37 
weeks’ gestation by maternal factors, uterine artery PI, MAP, serum PAPP-A and 
serum PLGF at risk cut-off of 1:65 in women of Caucasian and Afro-Caribbean racial 
origin and according to obstetric history. In women of Afro-Caribbean racial origin, 
compared to Caucasians, and in nulliparous, compared to parous women, both the FPR 
and detection rates for PE are higher. 





Table 5.8. Estimated detection rate (DR) of preeclampsia requiring delivery before 37 
weeks’ gestation and FPR, at risk cut-off of 1:65 in screening by maternal factors, 
uterine artery pulsatility index (PI), mean arterial pressure (MAP), serum pregnancy 
associated plasma protein-A (PAPP-A) and serum placental growth factor (PLGF) 
according to Caucasian and Afro-Caribbean racial origin and obstetric history. 
 
Study population False positive rate (%) Detection rate (%) 
Total 5,572 / 57,458 (9.7) 432 / 568 (76.1) 
Caucasian all 3,012 / 42,514 (7.1) 181 / 281 (64.4) 
Caucasian nulliparous 2,077 / 21,785 (9.5) 130 / 187 (69.5) 
Caucasian parous 935 / 20,729 (4.5) 51 / 94 (54.3) 
Afro-Caribbean all 2,007 / 9,268 (21.7) 200 / 224 (89.3) 
Afro-Caribbean nulliparous 1,061 / 3,638 (29.2) 93 / 96 (96.9) 





This study has established a new approach for early screening for PE by a combination 
of maternal characteristics and history with biophysical and biochemical markers. In 
this approach, which is based on a survival time model, the gestation at the time of 
delivery for PE is treated as a continuous rather than a categorical variable. As 
demonstrated by the MoM values of uterine artery PI, MAP and serum PAPP-A and 
PLGF in pregnancies with PE the distribution with gestational age is linear. 
Consequently, PE could be considered as a single pathophysiological entity with a 
wide spectrum of severity manifested in gestational age at which delivery becomes 
necessary for maternal and or fetal indications.  
 
The major advantage of the new, compared to our previous models (Chapter 4), is that 
it offers the option to clinicians and researchers to select their own gestational age cut-
off to define the high-risk group that could potentially benefit from therapeutic 
interventions starting from the first trimester of pregnancy. 
 
In early biochemical screening for PE several biochemical markers have been 
proposed, including maternal serum or plasma levels of soluble endoglin, inhibin-A, 





activin-A, pentraxin-3 and P-selectin, which are increased and PAPP-A, PLGF and 
placental protein-13, which are decreased (Chapter 3). These markers are thought to 
be involved in placentation or in the cascade of events leading from impaired 
placentation to development of clinical symptoms of PE. In this study we examined 
only PAPP-A and PLGF because these are the only two that have been investigated 
extensively in screening for PE, they have both been shown to be useful in screening 
for aneuploidies (Wright et al., 2010; Pandya et al., 2012) and they are now part of the 
platform of automated machines that provide reproducible results within 30-40 
minutes of sampling.  
 
The findings demonstrate that in first-trimester screening for PE the performance of 
the test is better for early rather than late onset disease. This is particularly important 
because the objective of early screening is to identify the high-risk group that may 
benefit from therapeutic interventions that reduce the prevalence of PE. The 
prophylactic use of low-dose aspirin starting before 16 weeks’ gestation is particularly 
effective in the prevention of preterm rather than term-PE (Roberge et al., 2012a and 
2012b). In screening for PE requiring delivery before 34 weeks the detection rate, at 
10% FPR, was about 50% by maternal characteristics and this was improved to about 
90% by the addition of biophysical markers and to about 75% by the addition of 
biochemical markers. The detection rate improved to more than 95% in screening by 
an algorithm combining maternal factors, biophysical markers and biochemical 
markers. 
 
The new algorithm provides accurate patient-specific risks and in each range of 
estimated risks for PE by combined screening there was in general good agreement 
between the expected and observed number of affected pregnancies. The FPR and DRs 
of PE are influenced by the characteristics of the study population and for a given risk 
cut-off they are both higher in nulliparous than in parous women and in those of Afro-
Caribbean than Caucasian racial origin. Consequently, comparison of the performance 
of screening using these algorithms between studies requires the appropriate 
























6.1    CONCLUSIONS 
 
6.1.1 Biochemical markers of preeclampsia 
 
The results of the studies in Chapter 3 demonstrate that a series of biochemical 
markers, which are placental products involved either in placentation or in the cascade 
of events leading from impaired placentation to placental ischemia with release of 
inflammatory factors which cause endothelial dysfunction and consequent 
development of the clinical symptoms of the disease, are altered in pregnancies that 
subsequently develop PE from as early as 11-13 weeks’ gestation. In pregnancies that 
subsequently develop PE there are altered maternal serum or plasma levels of PlGF, 
Activin A, Inhibin A, PP13, sEng, PTX-3 and P-selectin, but not PAI-2, Ang-2 or sFlt-
1. The levels of PlGF, Inhibin A, PP-13 were significantly different in both early and 
late-PE but the levels of Activin A and P-Selectin were only altered in late-PE, whereas 
PTX-3 was different from controls only in early-PE but not in late-PE. The study also 
demonstrates that the level of these biochemical markers in maternal blood in 
unaffected pregnancies is affected by maternal demographic characteristics and 
consequently the measured concentration of these markers must be adjusted for these 
maternal and pregnancy characteristics before comparison with pathological 
pregnancies.  
 
The biochemical markers also demonstrate a relationship with established markers of 
placentation reflected in uterine artery Doppler and maternal serum PAPP-A. In the 
case of serum PlGF, Activin-A and PP-13, there was a significant linear relationship 
with maternal serum PAPP-A whereas there was a significant relationship between 
PlGF, PP-13 and sEng with uterine artery PI suggesting a common pathogenesis of 
impaired trophoblastic relationship. These case-control studies demonstrate that the 
biochemical markers which provide a significant independent contribution to 
prediction of early-PE in addition to maternal factor derived a priori risk and uterine 





artery PI and serum PAPP-A include PlGF, inhibin A and sEng. In case of late-PE, 
only PlGF and P-selectin provided significant contributions.  
 
6.1.2 Multivariate model for early prediction of preeclampsia 
 
The study in Chapter 4 demonstrates that effective screening for PE based on maternal 
characteristics and history necessitates the use of specific algorithms derived from 
multivariate logistic regression analysis. The study demonstrates that factors such as 
maternal weight and height, racial origin, method of conception, family history of PE 
and pre-existing chronic hypertension or diabetes mellitus define the a priori risk for 
early, intermediate and late-PE.  
 
In general, the odds ratios for the factors in maternal history which defined the a priori 
risk for PE were inversely proportional to the gestation at delivery, with higher ratios 
for early disease compared to intermediate and late PE. Algorithms that combine the 
various maternal characteristics at 11-13 weeks could potentially identify 33%, 28% 
and 25% of pregnancies that subsequently develop early, intermediate and late PE, at 
the FPR of 5%.  
 
The patient-specific a posteriori risk for early, intermediate and late PE were 
calculated by multiplying the a priori patient characteristics-derived risk with the 
likelihood ratio of a series of biophysical and biochemical markers after appropriate 
adjustments for the inter-correlations between these markers.  
 
As in the case of maternal factors the differences in biophysical and biochemical 
markers of impaired placentation between the PE and unaffected groups were in 
general more pronounced in those developing early disease compared to intermediate 
or late-PE. Algorithms which combine maternal characteristics and biophysical and 
biochemical tests at 11-13 weeks could potentially identify about 90%, 80% and 60% 
of pregnancies that subsequently develop early, intermediate and late PE, at the FPR 
of 5%.  






6.1.3 Competing risk model for early prediction of preeclampsia 
 
This study in Chapter 5 establishes a new approach for early screening for PE by a 
combination of maternal characteristics and history with biophysical and biochemical 
markers. The specific advantages of this new approach are the use of Bayes theorem 
which combines prior information from maternal characteristics and the posterior risk 
is estimated by multiplying it with likelihoods associated with biomarker MoMs. In 
our previous approach to screening, we expressed the effects of variables as odds ratios 
for early, intermediate or late-PE. This led to arbitrary categorisation of the PE as two 
or three different diseases with different models for each. This alternative view 
assumes that PE is a spectrum disorder, the severity of which is reflected in gestational 
age at the time of delivery.  
 
The competing risk approach takes into account the gestation at the time of delivery 
for PE and treats it as a continuous rather than a categorical variable. The effect of 
various risk factors is to modify the mean of the distribution of gestational age at 
delivery with PE. In pregnancies at low-risk for PE the distribution is shifted to the 
right with the implication that in most pregnancies delivery will actually occur before 
the development of PE. In high-risk pregnancies the distribution is shifted to the left 
and the smaller the mean gestational age, the higher the risk for PE. It is also important 
to recognize that there are significant associations between all biophysical and 
biochemical markers in PE and unaffected pregnancies and therefore when combining 
the four biomarkers in calculating the patient-specific risk for PE the correlation 
factors are taken into account to provide accurate risk assessment for PE.  
 
The findings demonstrate that in first-trimester screening for PE the performance of 
the test is better for early rather than late onset disease. In screening for PE requiring 
delivery before 34 weeks the DR, at 10% FPR, was about 50% by maternal 
characteristics and this was improved to about 90% by the addition of biophysical 
markers and to about 75% by the addition of biochemical markers. The detection rate 





improved to more than 95% in screening by an algorithm combining maternal factors, 
biophysical markers and biochemical markers. Estimated DR of PE requiring delivery 
before 34, 37, and 42 weeks' gestation in screening by maternal factors are 93%, 61%, 
and 38%, respectively, at FPR of 5% and 96%, 77%, and 54%, respectively, at FPR of 
10%.  
 
In summary, this study demonstrates that effective screening for PE can be achieved 
in the first trimester of pregnancy. The value of this early screening is to identify 
pregnancies at high-risk which would benefit from pharmacological prevention or 
from close monitoring in specialist dedicated clinics to individualise management and 
select the ideal time for delivery.  
 
 
6.2 FUTURE STUDIES 
 
This thesis demonstrates that similar to first-trimester combined screening for fetal 
aneuploidies, effective screening for PE can also be achieved at 11-13 weeks’ gestation 
by a combination of maternal factors and biochemical and biophysical markers. The 
major advantage of the proposed model is that not only it achieves an improved 
performance of screening compared to the model based on a series of maternal 
characteristics alone but it offers the option to clinicians and researchers to select their 
own gestational age cut-off to define the high-risk group that could potentially benefit 
from therapeutic interventions starting from the first-trimester of pregnancy. 
 
The competing risk model for early prediction of PE requires prospective validation in 
multicentre studies which would also compare the performance of screening with the 
current method recommended by NICE. Such a multicentre study involving the use of 
the algorithm developed in this thesis will undertake screening at 11-13 weeks’ 
gestation in 16,500 singleton pregnancies (SPREE - Screening programme for pre-
eclampsia); this study has already received funding from the National Institute of 
Health Research in the UK and will be start in early in 2016. 






The rationale for early prediction of PE is that pharmacological interventions in the 
high-risk groups, starting from the 12th week of pregnancy, could potentially reduce 
the prevalence of the disease. It is therefore necessary to investigate through 
randomised studies the value of drugs vs placebo in the high-risk groups identified by 
our method of screening in early pregnancy. One such study (ASPRE - Combined 
multi-marker screening and randomised patient treatment with aspirin for evidence-
based pre-eclampsia prevention) involving several European centres aims to screen 
33,680 singleton pregnancies at 11-13 weeks and randomise the high-risk group into 
either Aspirin 150 mg/day vs placebo. It is anticipated that aspirin will reduce the rate 
of preterm-PE and associated complications by 50%. The study is ongoing and 
recruitment will be completed by April 2016 with expected results by December 2016. 
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